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Summary 
 
A disproportion between oxygen delivery and consumption leads to a restricted 
oxygenation of tissues. In a variety of pathologies like ischemia, stroke, inflammation 
and cancer this shortage of oxygen is a key feature. It enrolls a unique response that 
is based on the transcriptional regulation of hundreds of downstream target genes 
that promote eventually the adaption of cell metabolism. The maintenance of the 
oxygen homeostasis is centrally governed by hypoxia-inducible transcription factors 
(HIFs). Direct target genes of these transcription factors are increasingly expressed 
by binding of the HIF-complex to the cis-acting highly conserved consensus 
sequence 5‘-RCGTG-3’; also referred to as hypoxia response elements (HRE). 
Heterodimeric HIFs consist of a tightly O2-regulated α-subunit (in humans HIF-1α, 
HIF-2α or HIF-3α) and a constitutively expressed β-subunit (HIF-1β). In oxygenated 
conditions HIF α-subunits are continuously marked for proteasomal degradation 
through hydroxylation of two key prolyl-residues by prolyl-4-hydroxylase domain 
(PHD) oxygen sensor proteins. In hypoxic conditions the HIF-α subunit is stabilized 
and translocates to the nucleus where it forms the heterodimer HIF. Biochemically, 
the stabilization of the HIF-α subunit is explained by a reduced hydroxylation that is 
required for the interaction with the ubiquitin-ligase von-Hippel-Lindau protein 
(pVHL).  
Two of three PHDs are transcriptionally regulated by HIFs. As a consequence HIF 
causes increased expression of PHD2/3 that compensates for their decreased 
enzymatic activity in hypoxia. In this negative HIF-PHD2/3 feedback loop we decided 
to focus on the oxygen sensor PHD2. PHD2 is widely considered as the main cellular 
oxygen sensor since, amongst other evidences, only the knockout of the PHD2 
(EGLN1) gene shows prenatal lethality in mice. 
We regard the transcriptional regulation of the PHD2 gene as important since the 
abundance of the PHD2 enzyme determines the above mentioned negative feedback 
loop. Therefore, we aimed to profoundly understand the transcriptional regulation by 
studying the PHD2 promoter architecture and to elucidate further regulatory 
mechanisms of its activity.  
We carried out consecutive truncations of the PHD2 promoter and defined the 
minimal promoter region. By chromosome immunoprecipitation we could confirm on 
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an endogenous level that hypoxic PHD2 expression is predominantly mediated 
through HIF-1α rather than HIF-2α. Additionally we identified and cloned a 95 and 55 
nucleotide PHD2 promoter region encompassing a single HBS as highly conserved 
in several organisms and demonstrated high hypoxia-inducibility. To date, HIF is the 
only known transcription factor influencing PHD2 gene transcription. However, 
various putative transcription factor binding sites were predicted in this conserved 
PHD2 promoter region. By a mutation approach we could exclude the ubiquitous 
transcription factor Sp1 to be involved in basal or hypoxia-induced regulation of the 
PHD2 gene although numerous predicted Sp1-consensus motifs suggested so. 
When motifs located 5' or 3' to the HBS were mutated, total abrogation of the hypoxic 
response was observed, but binding of the HIF-1 complex remained unaffected. This 
suggests that other transcription factors might contribute to hypoxic activation of the 
PHD2 promoter.  
In order to find out which other (co-) transcription factors might influence the PHD2 
promoter activity we established a synthetic transactivation screening where 704 
arrayed transcription factors were analyzed for their influence on the PHD2 HBS 
(Wollenick et al., Nucleic Acid Res., in press). We found several family members of 
the activator protein-1 (AP-1) transcription factors, such as JUN and FOSB, and 
three ETS-transcription factors to be involved in the activation of the PHD2 promoter. 
Most strikingly, the ETS-transcription factor ETS variant 4 (ETV4) showed, when 
overexpressed, not only impact on hypoxic PHD2 expression but also on other well-
known hypoxic target genes such as PHD3 (EGLN3) and carbonic anhydrase 9 
(CA9). We hypothesize that ETV4 potentially increases the hypoxic activation of 
those promoters or elements that contain a distinct sequence architecture 
surrounding the HBS. HBSs that are similar to the PHD2 HBS seem to be 
preferentially super-induced by ETV4. 
By mammalian two-hybrid and fluorescence resonance energy transfer (FRET) 
analysis we found evidence for formation of a complex between ETV4 and HIF-1/2α. 
Chromatin immunoprecipitation confirmed the recruitment of HIF-1α and ETV4 to the 
PHD2 locus. Additionally, we could provide evidence that the co-activation of hypoxic 
target genes by ETV4 also has relevance for clinical data. In vivo data underlined 
that ETV4 expression strongly correlates with PHD2, HIF-1/2α and other hypoxic 
marker genes in 282 human tissues of breast cancer patients.  
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Although FRET data suggest a direct interaction, we hypothesize a trimeric complex 
composed of HIF:p300/CBP:ETV4. We carried out a thorough HIF-1α domain 
mapping and found that during the hypoxically induced HIF-1α:ETV4 interaction 
mainly the C-terminal activation domain is involved. Additionally, overexpression of 
CBP/p300-interacting transactivator 2 (CITED2), a competitor of HIF for the 
p300/CBP interaction, disrupted the ETV4:HIF complex pointing towards the 
involvement of p300/CBP. Factor inhibiting HIF (FIH) depletion provoked unregulated 
binding of HIF to p300/CBP and as a result the loss of oxygen-dependent 
suppression of the interaction between HIF and ETV4. Taken together, these 
experiments provided evidence for the cooperation between HIF-1α and p300/CBP in 
ETV4 binding. 
Recent data provide indications that ETV4 protein is more abundant in hypoxic and in 
PHD2 knockdown cells while ETV4 mRNA levels remain unaffected. ETV4 protein 
levels were also increased when cells were treated with a PHD inhibitor. That might 
hint to a hydroxylation-dependent regulation of ETV4 through PHDs that is inhibited 
when the O2-concentration is low or when PHDs are silenced.  
In conclusion, this work demonstrated that a synthetic transactivation screening can 
unravel so far unrecognized transcriptional pathway interactions that also have 
implications on clinical data of different cancer specimen. 
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Zusammenfassung 
 
Ein Ungleichgewicht in der Sauerstoffzufuhr und dem Sauerstoffverbrauch führt zu 
einer limitierten Oxygenierung des Gewebes. Eine Reihe von Erkrankungen wie z.B. 
Ischämien, Hirnschläge, Entzündungen oder Krebserkrankungen haben 
Sauerstoffmangel als Schlüsseleigenschaft. Bei der Sauerstoffunterversorgung wird 
zellulär eine evolutionär-konservierte Antwort ausgelöst, die die transkriptionelle 
Regulierung von mehreren 100 Genen zur Folge hat. Letztlich wird somit der 
Zellstoffwechsel an die veränderten Bedingungen angepasst und sichert das 
Überleben des Gewebes. Die Sauerstoffhomöostase wird hauptsächlich durch die 
hypoxieinduzierten Faktoren (HIFs) gesteuert. Direkte Zielgene dieser 
Transkriptionsfaktoren werden verstärkt exprimiert, indem der HIF-Komplex an cis-
Elemente mit der hochkonservierten Konsensussequenz 5‘-RCGTG-3‘ - auch 
Hypoxie-Response-Element (HRE) genannt - bindet. Die heterodimeren HIFs 
bestehen aus einer stark sauerstoffregulierten α-Untereinheit (im Menschen: HIF-1α, 
HIF-2α, HIF-3α) und einer kontinuierlich exprimierten β-Untereinheit (HIF-1β). Unter 
sauerstoffreichen Bedingungen werden die HIF-α-Untereinheiten stetig für den 
proteasomalen Abbau markiert. Dies geschieht durch die Hydroxylierung zweier 
Proline durch HIF-Prolyl-Hydroxylasen (PHDs), die als Sauerstoffsensoren fungieren. 
Unter hypoxischen Bedingungen dagegen stabilisiert sich die HIF-α Untereinheit und 
transloziert in den Zellkern, wo schliesslich das Heterodimer HIF gebildet wird. 
Biochemisch ist die Stabilisierung der HIF-α Untereinheit mit einer reduzierten 
Hydroxylierung zu erklären. Die Interaktion mit der Ubiquitin-Ligase von-Hippel-
Lindau Protein (pVHL) benötigt jedoch die vorgängige Hydroxylierung der α-Einheit. 
Interessanterweise sind zwei der drei PHDs selbst durch HIFs transkriptioniell 
reguliert. Daraus resultiert eine durch HIF ausgelöste vermehrte PHD2/3 Expression, 
die die erniedrigte Enzymaktivität in der Hypoxie kompensiert.  
In der beschriebenen HIF-PHD2/3-Rückkopplungsschleife haben wir uns auf den 
Sauerstoffsensor PHD2 fokussiert, da PHD2 als wichtigster zellulärer 
Sauerstoffsensor betrachtet wird. Das Primat von PHD2 als Hauptsauerstoffsensor 
wurde unter anderem durch einen Knockout in Mäusen bewiesen, der pränatal zum 
Tod der Embryonen führt.  
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Wir erachten die transkriptionelle Kontrolle des PHD2 Genes als wichtig, da die 
Menge an PHD2-Enzym im entscheidenden Maße die zuvor genannte negative 
Rückkopplungsschleife beeinflusst. Eine tiefgehende Strukturanalyse des PHD2 
Promoters sollte dazu beitragen, seine Regulationsmechanismen besser zu 
verstehen.  
Dazu führten wir eine Abfolge von Deletionen am PHD2 Promoter durch und 
definierten so den Minimalpromoter. Mit Hilfe der Chromatin-Immunopräzipitation 
konnten wir auf endogenem Level zeigen, dass hauptsächlich HIF-1 die hypoxische 
Expression des PHD2 Gens dominiert.  
Darüber hinaus identifizierten und klonierten wir ein 95 und 55-Nukleotid langes 
PHD2 Promoterstück, welches die alleinige HIF-Bindungsstelle (HBS) umspannt und 
in mehreren Organismen stark konserviert ist. Diese Promoterregion zeigte sich 
hochgradig hypoxieinduziert. 
HIF ist bis dato der einzig bekannte Transkriptionsfaktor, der das PHD2 Gen in 
seiner Transkription beeinflusst. Dennoch wurden in diesem konservierten PHD2 
Promoterelement mehrere mögliche Bindungsstellen für andere 
Transkriptionsfaktoren vorhergesagt. Durch einen Mutationsansatz konnten wir den 
ubiquitären Transkriptionsfaktor SP1 von der basalen oder hypoxieinduzierten 
Regulation ausschliessen, obwohl mehrere in silico vorhergesagte SP1-
Konsensusmotive eine Regulation nahegelegt haben. Mit Hilfe von Mutationen der 
HBS flankierenden 5’- und 3’-Regionen wurde der Hypoxie-verursachte Anstieg der 
PHD2 Promoteraktivität komplett unterdrückt, wenngleich die Bindung des HIF-1 
Komplex an die HBS nicht betroffen war. Dies ist ein erneuter Hinweis auf die 
Existenz weiterer Transkriptionsfaktoren, die in der hypoxischen Aktivierung des 
PHD2 Promoters involviert sein könnten. 
Aus diesem Grunde entwarfen wir einen synthetischen Transaktivierungsansatz, in 
dem 704 Transkriptionsfaktoren auf ihren Einfluss auf die PHD2 HBS untersucht 
wurden (Wollenick et al., Nucleic Acid Res., im Druck). Bei der Analyse fanden wir 
einige Aktivatorprotein-1 (AP-1) Familienmitglieder, sowie drei ETS-
Transkriptionsfaktoren, die in der Aktivierung des PHD2 Promoters eine Rolle 
spielen. Ein besonders starker Effekt wurde mit der Überexpression des ETS-
Transkriptionsfaktors ETS Variante 4 (ETV4) erreicht. ETV4 erhöhte nicht nur die 
hypoxische PHD2 Expression, sondern auch andere bekannte hypoxieinduzierte 
Zielgene. So zeigten sich z.B. PHD3 (EGLN3) und die Carboanhydrase 9 (CA9) als 
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stark ETV4-abhängig. Wir vermuten, dass ETV4 die hypoxische Aktivität solcher 
Promotoren oder Elemente steigert, die eine distinkte Sequenzarchitektur in der 
HBS-Umgebung aufweisen. Anscheinend werden jene HBSen, die der PHD2 HBS 
ähneln, bevorzugt von ETV4 superinduziert.  
Ein mechanistischer Beleg der Komplexbildung von ETV4 und HIF-1/2α fanden wir in 
Mammalian-Zwei-Hybrid-Systemen und Fluoreszenz-Resonanzenergietransfer 
(FRET)-Experimenten. Chromatin-Immunopräzipitation bestätigte zusätzlich die 
Rekrutierung von HIF-1α und ETV4 an den PHD2 Locus. Ferner konnten wir 
beweisen, dass die Ko-Aktivierung von hypoxischen Zielgenen auch medizinische 
Bedeutung hat. In vivo Daten bestätigten eine stark positive Korrelation zwischen der 
Expression von ETV4 und PHD2, HIF-1/2α und anderen Hypoxie-Markergenen in 
282 menschlichen Geweben von Brustkrebspatientinnen. 
Obwohl unsere FRET-Daten eine direkte Interaktion von HIF-α und ETV4 nahelegen, 
schlagen wir eher den Ansatz eines trimeren Komplexes bestehend aus 
HIF:p300/CBP:ETV4 vor. Bei einer tiefgehenden HIF-1α Domänenkartierung fanden 
wir heraus, dass die hypoxieinduzierte HIF-1α:ETV4 Interaktion hauptsächlich über 
die C-terminale Aktivierungsdomäne stattfindet. Darüber hinaus wurde durch die 
Überexpression von CBP/p300-interagierenem Transaktivator 2 (CITED2), ein 
Konkurrent von HIF um die p300/CBP-Interaktionsstelle, der ETV4:HIF Komplex 
zerstört. Dieses Resultat unterstreicht die Bedeutung von p300/CBP in der 
Komplexbildung. Durch die Verarmung des „HIF-inhibierenden Faktors“ (FIH) wurde 
eine deregulierte Bindung von HIF an p300/CBP provoziert, die den Verlust der 
sauerstoffabhängigen Interaktion von HIF und ETV4 zur Folge hatte. 
Zusammengefasst beweisen diese Experimente die Zusammenarbeit von HIF-1α 
und p300/CBP bei der ETV4 Bindung. 
Neuste Daten weisen darauf hin, dass ETV4-Proteinlevel unter hypoxischen 
Bedingungen und bei PHD2-Knockdown in der Normoxie erhöht sind, während 
mRNA-Level sich unverändert zeigten. ETV4 Proteinlevel waren ebenfalls erhöht, 
wenn Zellen mit einem PHD-Inhibitor behandelt wurden.  
Zusammenfassend demonstrierte diese Arbeit, dass ein synthetischer 
Transaktivierungsansatz unbekannte Wechselwirkungen von transkriptionellen 
Pfaden aufdecken kann, die zudem klinische Bedeutung bei unterschiedlichen 
Krebsarten haben. 
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1  Introduction 
1.1  Hypoxia 
 
One can survive without food for 3 weeks, without water 3 days, without warmth 3 
hours, but only 3 minutes without oxygen1. Although these values are not exact, 
oxygen is unquestionably essential for mammals. Hypoxia, the undersupply of 
oxygen, occurs on different levels. An adaptation to hypoxia is already provoked by 
exposing the body to altitudes higher than 3000 m2,3. Physiological processes like an 
increased ventilation and cardiac output compensate for the decreased partial 
inspiratory oxygen pressure (pO2). Later during acclimatization, oxygen 
transportation capacity is increased through the hormone erythropoietin (EPO), by 
stimulating the erythroid progenitor cells in the bone marrow.  
Most of Bolivian, Tibetian and Ethiopian subjects living in high altitude and thus, 
constantly exposed to low pO2 show chronically elevated hematocrit (about 10%)4. 
The undersupply of oxygen also happens within a human body. Without exposing to 
high altitude certain tissues can become hypoxic. This might happen when the lung 
function is impaired or the circulation is blocked during asthma, embolism or 
ischemia, respectively. Another pathophysiologic hypoxic environment is a solid 
tumor. Common for all solide tumors is a switch in cellular metabolism to prevent the 
tissue from death.  
 
1.1.1  The hypoxia-inducible factor (HIF) 
 
It took long to link EPO to the hypoxia-inducible factor (HIF). EPO is expressed in the 
fetal liver and later shifts its expression to the adult kidney. HIF was only identified in 
1991 when Semenza et al. found a 50 nucleotide long cis-acting element in the EPO 
gene5,6. It was shown that hypoxia triggers an activation of the EPO gene in the 
hepatoma cell line Hep3B6. Also, a binding activity to the EPO-enhancer region could 
be revealed, which was enhanced when cells were exposed to hypoxia and was 
reduced when treated with the translational inhibitor cycloheximide (CHX)7. Four 
years later, in 1995, Wang and Semenza purified and identified this hypoxic DNA 
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binding activity8. It was found to be a heterodimeric protein complex of two subunits: 
An α-subunit (HIF-α) and a β-subunit (HIF-β). They named this transcriptional 
complex “HIF-1”. HIF-1β is also known as aryl hydrocarbon receptor nuclear 
translocator (ARNT) and was previously described to heterodimerize with the aryl 
hydrocarbon receptor (AhR) to mediate xenobiotic responses9.Both 
heterodimerization partners of HIF-1β - HIF-1α and AhR - are basic helix-loop-helix 
(bHLH) transcription factors belonging to the PAS subfamily (period circadian protein 
(PER), ARNT and single-minded protein (SIM)). Three paralogues of the HIF-α 
subunit are known: HIF-1α encoded by the HIF1A gene; HIF-2α by endothelial PAS 
domain 1 (EPAS1); and HIF-3α by HIF3A. Furthermore, different β-subunits are 
discussed. Besides the well-studied HIF-1β (ARNT)9 subunit, there are also few 
studies available concerning the potential interaction with HIF-2β (ARNT2)10,11 or 
HIF-3β (ARNT3)12 as well as ARNT Like (ARNTL)13 and ARNT Like 2 (ARNTL2)14,15 
subunits. 
 
1.1.2  Genetic ablation of HIF 
 
Hif1a-deficient mice show a lethal phenotype by embryonic day (E) 11. This is 
caused by a developmental arrest of Hif1a-/- embryos that results in a defective 
neural tube, cardiac and vascular malformations, hypoplastic pharyngeal arches and 
cell death within the cephalic mesenchyme16–18. 
In contrary, Hif2a-knockout results in a set of different phenotypes that are eventually 
fatal. Prenatal death (E12.5-16.5) is probably due to vascular disorganization and an 
impaired catecholamine production leading to bradycardia, an improper cardiac 
function and circulatory failure19,20. Neonatal death, however, is probably caused by 
an insufficient production of surfactant provoking the neonatal respiratory distress 
syndrome21. Conversely, viable Hif2a-deficient mice have been reported by 
Scortegagna et al. using 129S6/SvEvTac mice to have a multitude of impairments 
such as syndromes of multiple-organ pathology (retinopathy, hepatic steatosis, 
cardiac hypertrophy, skeletal myopathy, etc.), biochemical abnormalities 
(hypoglycemia, lactic acidosis, etc.) and altered gene expression patterns22.  
So far, a Hif3a-deficient mouse model has not been reported yet. Also Hif1b-
knockout mice show embryonic lethality in utero between E9.5-10.523. 
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Developmental abnormalities include amongst others, neural tube closure defects 
and forebrain hypoplasia. Prenatal lethality appears to be due to a defective 
composition of the placenta23. 
 
1.1.3  Expression pattern of HIF-α subunits 
 
Amongst the HIF-α subunits, HIF-1α is the most ubiquitously expressed isoform. HIF-
1α is expressed in different tissues and organs, whereas HIF-2α and HIF-3α are 
more restrictively expressed. Although HIF-1α and HIF-2α share 48% of sequence 
similarity, HIF-2α is mainly found in embryonic and adult endothelium. This is already 
suggested by HIF-2α's synonymous name EPAS-124.  
The human HIF3A gene expresses 6 alternative splicing variants (HIF-3α1-6) and the 
full length mRNA expressed in the kidney is suggested to be HIF-3α125. The splice 
variant HIF-3α4, also known as inhibitory PAS domain protein (IPAS), was shown to 
be expressed predominantly in the eye and at lower levels in the cerebellum and the 
cerebrum, indicating a tissue-restricted expression pattern of IPAS mRNA26. It was 
reported that IPAS might inhibit VEGF expression in murine cornea by HIF-1α 
binding and thus prevents a HIF-1 formation and activation of target genes that lead 
to a negative regulation of angiogenesis and maintenance of an avascular 
phenotype27. Complex formation of IPAS with HIF-2α was demonstrated to interfere 
with the expression of HIF-2α downstream targets and tumor formation28. 
 
1.1.4  Composition of the HIF complex 
 
The heterodimeric transcription factor HIF contains a highly regulated α-subunit. The 
N-terminus of the α-subunit shows two important domains (fig. 1). First, a basic helix-
loop-helix (bHLH) domain that is responsible for the specific binding to a core DNA-
consensus sequence and heterodimer formation. In this work, following 
nomenclature is used: the HIF DNA binding site (HBS) (5’-RCGTG-3’) lies inside the 
hypoxia response element (HRE) and represents the core region of the HRE being 
situated in HIF target genes9,29,30. The HRE describes here the minimal cis-regulatory 
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element needed for hypoxic induction of gene transcription. The HBS is necessary 
but does not guarantee full hypoxic gene activation. Consequently, the HBS 
represents the minimal DNA sequence for HIF interaction, but a fully functional HRE 
typically includes also neighboring DNA binding sites for additional (co-)transcription 
factors31–33. The second domain, called PAS, is subdivided into PAS A and PAS B 
and mediates HIF-1β dimer formation.  
Interestingly, HIF-α subunits have two transactivation domains (TAD): a carboxy-
terminal TAD (CTAD) and an amino-terminal TAD (NTAD). The latter overlaps with 
the oxygen-dependent degradation domain (ODDD) that is required for the stability 
regulation of the HIF-α subunits34. Importantly, an active nuclear localization signal 
can be found in the carboxy -terminal end of HIF-1α and HIF-2α35. The suggested 
amino-terminal NLS was shown not to be effective35. In contrast to HIF-1α and HIF-
2α, HIF-3α1 although full length protein, does not contain a CTAD.  
 
Figure 1. Domain structure of HIF-α subunits and HIF-1β 
bHLH - basic helix-loop-helix; PAS - PER-ARNT-SIM (A and B), ODDD - oxygen dependent 
degradation domain, NTAD - Amino-terminus transactivation domain; CTAD - carboxy-terminus 
transactivation domain; NLS - nuclear localization sequence, LZIP - leucine zipper  
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1.1.5  O2-dependent regulation of HIF-α protein stability and transactivation 
activity 
 
HIF-α protein levels are firmly regulated by oxygen, whereas HIF-α mRNA levels 
remain unaffected. The rapid degradation of the HIF-α subunits via the ubiquitin- 26S 
proteasome pathway in normoxic conditions results in a half-life of less than 5 
minutes. This fast degradation of the HIF-α subunit is independent of its sub-cellular 
localization. Therefore, the HIF-1α entry into the nucleus is not a key event that 
controls its stability36. Instead, the degradation process under normoxic conditions is 
mediated through the hydroxylation of distinct prolines in the ODD by prolyl-4-
hydroxylase-domain containing proteins (PHDs) (fig. 2). The oxygen-dependent 
hydroxylation by PHDs leads to the subsequent binding of the von Hippel-Lindau 
protein (pVHL) tumor suppressor37–40. 
 
Figure 2. Scheme of oxygen sensing by PHDs41 
Under high pO2, HIF hydroxylases are active and destabilize the HIF-α subunits through the 
hydroxylation of distinct prolines by PHDs and of asparagines by factor inhibiting HIF (FIH). The prolyl-
hydroxylation mediates the proteolysis via pVHL. The asparagine hydroxylation inhibits the recruitment 
of the co-activator p300. Both hydroxylation reactions lead to the inactivation of HIF transcriptional 
activity. Under low pO2, the hydroxylation reactions are inhibited. The HIF-α subunits are no longer 
degraded and recruit the transcriptional co-activator p300. This leads to a powerful transcriptional 
activation of HIF.  
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VHL is one component in the complex with elongin B, elongin C, cullin-2 and its main 
function is suggested to be the E3 ubiquitin ligase activity for specific degradation 
labeling. The loss of pVHL leads to a rare inherited cancer syndrome known as VHL 
disease. This condition predestinates to a variety of malignant and benign tumors of 
the eye, brain and spinal cord (hemangioblastoma); kidney (clear cell carcinoma), 
pancreas, and adrenal glands (pheochromocytoma), caused by an abnormal 
accumulation of HIF-α subunits in normoxia39. 
Another regulation of the HIF-α subunit protein stability might be the acetylation of 
the amino acid (aa) 532 by the murine acetyltransferase arrest-defective-1 (ARD1) 
protein. The mARD1-mediated acetylation might enhance an interaction of HIF-1α 
with pVHL and HIF-1α ubiquitination. This suggests that the acetylation of HIF-1α by 
mARD1 and the support of the complex formation of HIF-1α with pVHL is critical for 
accelerated proteasomal degradation42. 
In contrast to this report, data were published showing no evidence for a HIF-1α 
destabilization through acetylation, leading to an ongoing debate on the role of 
acetylation-mediated destabilization of HIF-α43–45. 
 
These findings led to a model that is now widely accepted for regulation of HIF-α 
subunits: in decreased O2 levels the substrate for the hydroxylation reaction by the 
PHDs, namely oxygen, is missing. The hydroxylation reaction is inhibited and the 
HIF-α subunits are no longer marked for their degradation. This leads to an 
accumulation of HIF-α subunits in the cytoplasm. They translocate into the nucleus, 
where they heterodimerize with the constitutively expressed HIF-β subunit and form 
the transcription factor HIF. HIF binds to the conserved DNA consensus sequence 5’-
G/ACGTG-3’ (HREs) situated mostly in promoter sites30. With its transcriptional 
activation HIF induces the gene expression of target genes promoting the adaptation 
to low oxygen concentrations on cellular and systemic levels. The adaptation is 
mediated by changes in gene expression that lead to an enhancement of oxygen 
delivery and / or promote survival in low oxygen conditions. The list of roughly 100 
known HIF target genes comprises angiogenesis, erythropoiesis and ventilation 
supporting gene products, i.e. vascular endothelial growth factor (VEGF), transferrin 
(TF) and heme oxygenase-1 (HO-1); as well as glycolysis and autophagy supporting 
mechanisms as glycolytic enzymes (aldolase A, enolase 1, lactate dehydrogenase A) 
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and glucose transporters (i.e. Glut-1)46–52. Interestingly, PHD2 and PHD3 are HIF 
target genes as well. Thus, PHD2 and PHD3 expression is increased and 
consequently compensate for the decreased enzyme activity. This limits the HIF 
response under hypoxic conditions and leads to a rapid degradation of HIF-α 
subunits following reoxygenation53–55. 
 
Additionally, the transcriptional activity of HIF is tuned by the factor inhibiting HIF 
(FIH)56. FIH was reported to hydroxylate an asparagine (N) residue and subsequently 
hinder the association with p300/CBP via the cysteine/histidine rich (CH)-1 domain. 
Eventually, this results in the prevention of the formation a transcriptional active HIF 
complex57. The location of the essential asparagine residue hydroxylated by FIH in 
the CTAD differ inbetween the HIF-α isoforms. In the HIF-1α subunit the distinct 
amino acid N803 is hydroxylated, whereas in HIF-2α it is the asparagines residue 
847. 
 
In summary, it could be shown that an intracellular O2-sensor system exists and that 
the O2 tension is connected with HIF-α protein stability and hence the transcriptional 
activity of genes. The system can be tuned by a further decrease of pO2 that leads to 
an inactivation of FIH and the disinhibition of the recruitment of co-activators such as 
p300/CBP, steroid receptor coactivator 1 (SRC-1), transcription intermidiary factor 2 
(TIF2) and Redox factor-1 (Ref-1)58–61. 
 
1.1.6  O2-independent regulation of HIF transactivation 
 
The HIF activation and stabilization can also be regulated by oxygen-independent 
HIF-α protein synthesis or posttranslational modifications other than the previously 
described oxygen-dependent hydroxylation of proline and asparagine residues of the 
HIF-α subunit. Many interplaying processes are discussed in the field. For example, 
the S-nitrosylation of the cysteine residue 800 (C800) has been reported to activate 
the interaction between stabilized HIF-1α and the co-activator CBP/p300, eventually 
stimulating transactivation of the HIF-complex62.  
Another mechanism shown to increase the transcriptional activity of HIF is the 
phosphorylation of threonine 796 (T796) and of the serine residues 641 and 643 
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(S641, S643) by the mitogen-activated protein kinases (MAPKs)63–65. The latter 
seems to control HIF-1α mediated translocation to the nucleus and as a 
consequence the transcriptional activity of the HIF complex66. 
Lately, also SUMOylation, meaning the attachment or detachment of small ubiquitin-
related modifier (SUMO) is discussed. However, conflicting results have been 
reported leading to an increase or a decrease of HIF-α stability67–69. SUMOylated 
HIF-α is reported to be recognized by VHL and additionally, mice lacking the SUMO-
specific protease 1 (SENP1) develop fetal anemia, insufficient EPO production and 
undergo prenatal death (E13-E15)67. Conversely, SUMO1 was reported to be itself 
hypoxia inducible suggesting that HIF is stabilized in hypoxic conditions and thus, 
influences HIF protein stability and transcriptional activity68–70.  
Along with the aforementioned modifications heat shock protein 90 (Hsp90) has been 
implicated to promote HIF stability in a VHL-dependent manner, since Hsp90-
inhibitors apparently promote HIF-α degradation71,72.  
Recent studies suggest that also the transcript levels of HIF-1α are increased by 
NFκB upon stimulation through reactive oxygen species (ROS) and 
lipopolysaccharide (LPS), probably via a conserved κB site in the human and murine 
HIF1a gene73–78. 
Together with the mentioned modifications, HIF has been shown to be influenced in 
its protein synthesis rate by growth factors (IGF-1, IGF-2), cytokines (TNFα, IL-1β) 
and Insulin79–86. Often those stimuli are interlinked with cell growth that is in turned 
associated with an increased oxygen demand. The cells adjust to the expected rise 
in oxygen consumption by inducing cellular signaling pathways (often kinase-related) 
and ROS (partially in combination). For example, stimulation of the PI3K pathway by 
insulin-like growth factor 1 (IGF-1) leads to an overall increase in protein translation, 
a saturation of the degradation machinery and eventually in an oxygen-independent 
accumulation of HIF-α83,87.  
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1.2  Prolyl-4-hydroxylase domain containing proteins (PHDs) 
1.2.1  Discovery and characterization of PHDs 
 
It needed about a decade after the discovery of HIF to find a protein that is capable 
to sense changes in oxygen availability and converting this signal to a shift in HIF-α 
stability. It was known that in the presence of oxygen HIF-α subunit is recognized by 
an E3 ubiquitin ligase containing the pVHL tumor suppressor protein and is targeted 
for proteasomal degradation37. In 2001, a conserved family of HIF prolyl-4-
hydoxylase (PHD or alternatively HIF prolyl hydroxylase (HPH)) enzymes was 
identified which was responsible for this posttranslational modification of HIF-α37,88–92. 
The first identification of a unique PHD was in Caenorhabditis elegans and named 
egg-laying abnormal-9 (EGL-9)89. In mammals three different isoforms were 
discovered: PHD1 (HPH3, EGLN2), PHD2 (HPH2, EGLN1) and PHD3 (HPH1, 
EGLN3). Alternative splicing forms have been reported for PHD2 and PHD3, but not 
for PHD193,94. The proteins differ in size, intracellular localization and tissue 
distribution95. In contrast to PHD2 and PHD3, PHD1 also exists in a shorter fully 
functional isoform generated from alternative translational initiation96. The two critical 
prolines of the ODD are both independent and non-redundant hydroxylation targets 
and interact therefore separately with the pVHL complex97. Interestingly, under in 
vitro conditions the different PHD isoforms also have distinguishable preferences to 
hydroxylate the two target prolines in the HIF-ODD98,99. In conclusion, PHDs are 
considered to be cellular oxygen sensors since they were demonstrated to modulate 
the HIF-α stability in an oxygen-dependent mode through proline hydroxylation88,92. 
 
Lately, a fourth PHD-related protein (PH-4) was discovered100,101. PH-4 was reported 
to be able to hydroxylate the two critical prolyl residues of the HIF-1α subunit, but 
unlike PHDs which localize to the cytoplasm and nucleus - was associated with the 
endoplasmic reticulum (ER). However, the functional relevance of PH-4 for the 
hypoxia-induced pathway is still elusive. 
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1.2.2  The enzymatic reaction 
 
HIF-prolyl-hydroxylases are members of the iron (Fe2+) and 2-oxoglutarate (2-OG)-
dependent family of dioxygenases, similar to collagen prolyl-hydroxylases. Members 
of this family need molecular oxygen, Fe2+ and 2-OG for their enzymatic reaction. 
During the catalyzed reaction one oxygen atom is used in a decarboxylation reaction 
converting 2-OG to succinate and providing the second oxygen atom for the 
hydroxylation of the prolyl residue (fig. 3)102. Proline hydroxylation is an irreversible 
reaction. 
 
 
Figure 3. The enzymatic reaction of proline hydroxylation catalyzed by HIF-prolyl-4-
hydroxylases102.  
Essential co-factors of the reaction are ferrous iron (Fe2+) and ascorbate, whereas hypoxia, iron 
chelators, transition metals (Co2+, Ni2+, Cu2+), dimethyloxalylglycine (DMOG) and N-oxalylglycine (N-
OG) are inhibiting the reaction. 
 
Essential co-factors in this reaction are Fe2+ (ferrous iron) and ascorbate (vitamin C). 
It is speculated that ascorbate might have a protective role against oxidation of the 
Fe2+ incorporated in the active center of the PHD or for the enzyme itself103,104. 
However, very recently ascorbate was found to be not required for oxygen sensing in 
ascorbate-deprived Gulo(-/-) knockout mice since they responded normal to 
inspiratory hypoxia105. Also, hypoxic HIF induction was essentially normal under 
serum- and ascorbate-free cell culture conditions and glutathione was demonstrated 
to be able to fully substitute for the vitamin C requirement of all three PHD isoforms in 
vitro105. 
2-oxoglutarate  proline 4-hydroxyproline  succinate  
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Two distinct prolines located in the HIF-1α ODDD are hydroxylated by PHDs, namely 
Pro402 and Pro564. The PHDs seem to have a preferential ranking for hydroxylating 
those prolines. The proline residue 564 seems to be hydroxylated by all PHD 
isoforms, whereas Pro402 is only hydroxylated by PHD1 and PHD2 in vitro89. 
Nevertheless, by overexpressing PHDs in cells, all PHD isoforms could hydroxylate 
both proline residues99. 
It could be shown that the two prolines have independent yet interactive roles in the 
regulation of HIF-1α protein turnover and that under normoxic conditions proline (P) 
564 is hydroxylated prior to P402. With decreasing pO2, the hydroxylation of P402 
stops earlier then the hydroxylation of P564 and the inhibition of P402 hydroxylation 
is sufficient to induce HIF-α stabilization in hypoxia, while hydroxylation of P564 was 
still observed99. So far the “motif” for proline residues that are considered as targets 
for hydroxylation is L-X-X-L-A-P (X stands for any amino acid)106. However, only the 
proline in this motif is indispensable for recognition, which makes the relevance of the 
defined pattern questionable106–108. 
 
1.2.3  Modulation of PHD activity and co-factors 
 
The hydroxylation capacity of PHDs is influenced by many factors. The availability of 
oxygen, 2-oxoglutarate, Fe2+ and ascorbate together with the interplay of small 
molecules regulate the activity of PHDs and consequently the abundance of HIF and 
its transcriptional activity.  
 
Oxygen 
Oxygen is the most important factor for the hydroxylation reaction. In an in vitro 
hydroxylation-coupled decarboxylation assay the Michaelis-Menten (Km) constant of 
PHDs for O2 was determined to be in the range of 230-250 µM109. However, these Km 
values are still above the tissue O2 concentration of 10-30 µM delivering the oxygen 
necessary for the hydroxylation reaction110. This is a cornerstone feature of the PHDs 
because the uneffective hydroxylation reaction permits a fine-tuned response to 
small oxygen changes that “translate” later into different degrees of HIF-α 
stabilization. Intriguingly, the Km for oxygen of FIH was determined to be even lower, 
namely 90 µM, meaning that FIH activity is maintained under hypoxic conditions 
INTRODUCTION 
 
12 
limiting the transcriptional power of the accumulated HIF111. This decreased Km with 
respect to the PHD enzymes suggests that FIH is still functional at reduced O2 
concentrations where HIF-α protein is already accumulating.  
In spite of this, more recent studies employing longer and thus also more 
physiological HIF-α peptides indicate that the oxygen Km of PHDs are rather in the 
range of 100 µM112,113. It was demonstrated that the determination of Km values is 
influenced by the purity and origin (insect cells, bacteria) of the enzymes as well as 
dependent on the length of the substrate (the longer, the more physiological e.g. HIF-
fragment) used for oxygen consumption assays or in vitro hydroxylation studies112–
114
.  
 
Tricarboxylic acid cycle and metabolic intermediates 
Another cosubstrate for PHDs is 2-OG (2-oxoglutarate) coming from the tricarboxylic 
acid cycle (TCA). The Km constant of PHDs for 2-OG was determined to be around 
60 µM115. Binding of 2-OG to the enzyme is required for normal turnover of the 
enzyme, so that 2-OG analogs inhibiting enzyme activity by binding to the 2-OG 
pocket. PHDs were also reported to be reduced by glucose metabolites such as 
pyruvate, citrate, iso-citrate, succinate, fumarate, malate and oxaloacetate supporting 
HIF-α accumulation104,116–120.  
 
Iron and divalent metals 
The cofactor Fe2+ is tightly bound by PHDs. The Km values for PHD1 and PHD2 were 
suggested to be around 30 nM, whereas PHD3 shows a Km of about 100 nM121. As a 
consequence, iron chelators have impact on the HIF pathway. Hirslä et al. further 
demonstrated that PHDs are affected in their activity by divalent metals, such as 
Cd2+, Ni2+, Mg2+, Mn2+ and Co2+, which converts to the activation of the HIF 
system121. Mechanistically, divalent metals are suggested to operate either by 
replacement or oxidation of PHD bound Fe2+. Cu2+ was shown to cause HIF-1α 
accumulation and reporter gene activation in normoxia122,123. Nytko et al. explain that 
this occurs in the presence of oxygen through a strong Cu2+-catalysed oxidation of 
ascorbate104. The strong inhibitory effects of Co2+ were suggested to originate from 
direct binding of Co2+ to HIF-1α causing an inhibition of HIF-1α protein degradation 
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by the VHL ubiquitin E3 ligase complex124. Additionally, Ca2+ interferes with the 
PHD2 activity and Ca2+ chelation lead to PHD2 inhibition125. 
Nitric oxide 
Nitric oxide (NO) showed modulating effects on PHD activities. NO derived from NO 
donors or inducible NO synthase (iNOS) directly inhibits PHD function and thus leads 
to HIF-α stabilization126–128. The inhibition of PHD might be derived from iron 
oxidation in the catalytic center. Interestingly, endothelial NOS (eNOS) is a HIF target 
gene that could provide an additional layer of feedback regulation to the system114.  
On the other hand, NO has shown opposing effects by decreasing hypoxia induced 
HIF-1α levels. This ambivalent response to NO treatment could also be explained by 
a chronological order of the events: in the early phase, when NO is present, PHD 
activity is inhibited and thus HIF stabilized. In a later phase HIF-dependent de novo 
PHD2 synthesis is increased. Additionally, mitochondrial oxygen consumption is 
inhibited which results in increased intracellular oxygen availability. The rise of both 
PHD2 and oxygen availability leads to a decreased NO-dependent HIF-1α 
stabilization129–131. 
 
Reactive oxygen species and antioxidants 
Production of reactive oxygen species (ROS) were shown to be increased in hypoxia 
presumably due to an inhibition of the respiratory chain132–134. Additionally, cells 
deficient in mitochondrial DNA have been demonstrated not to activate HIF-target gene 
expression132,135. That implies again an involvement of mitochondria in the oxygen 
sensing pathway. Of note, this finding could not be confirmed by other groups, 
especially in respect to the controversially discussed questions if ROS are able to be 
generated during hypoxia, before reoxygenation and if ROS really are implied in the 
regulation of HIF-α stability136–139. ROS inhibit the hydroxylation capacity of PHDs by 
oxidizing either directly amino acid residues of the enzyme or indirectly oxidizing 
cofactors (Fe2+, ascorbate) resulting in an inactivation or cellular depletion. The 
antioxidant ascorbate as has been shown to prevent Fe2+ oxidation in the catalytic 
center of PHDs or for the enzyme itself and thus support in vitro hydroxylation of HIF-
α ODD fusion protein constructs103,104,126,140. The Km values of PHDs for ascorbate is 
between 140-180 µM and Nytko et al. showed that ascorbate affects oxygen sensing 
neither in vitro nor in an ascorbate-deprived Gulo(-/-) mouse model in vivo105,115,141. 
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However, cells deleted for the transcription factor JunD, belonging to the AP1-family 
members and involved in the oxidative stress defense, have been shown to inhibit 
prolyl hydroxylation by enhancing the hydrogen peroxide (H2O2) metabolism, 
followed by iron oxidation and HIF-α accumulation, eventually resulting in the 
activation of HIF-target genes142. Further, the oncoprotein mucin 1 (MUC1) was 
reported - lacking detailed mechanistic understanding - to be able to suppress 
hypoxia-induced ROS accumulation and to induce PHD3 expression which results in 
an attenuated HIF transcriptional activity143–145. 
 
1.2.4  Subcellular and tissue distribution of PHDs 
 
In cells, PHDs contribute differentially to the regulation of HIF based on their 
abundance98. PHDs are differently expressed on both cellular and systemic levels. 
On the cellular level fluorescent fusion proteins revealed that PHD1 was exclusively 
detected in the nucleus, PHD2 was located in the cytoplasm, and PHD3 was 
homogeneously distributed in cytoplasm and nucleus106,146. On the other hand, 
endogenous PHD2 and PHD3 were found in cytoplasm and nucleus in rat 
hepatocytes147. Interestingly, in this approach PHD1 was found in the nucleus during 
normoxic conditions, but shuttled to the cytoplasm in hypoxia and back to the nucleus 
following reoxygenation. 
On the tissue level, PHD2 is the most abundant one, ubiquitously expressed in most 
tissues, whereas PHD1 is strongly expressed in testis and PHD3 shows highest 
expression in the heart100,148,149.  
 
1.2.5  Genetic ablation of PHDs 
 
The knockout of PHD2, but not PHD1 or PHD3, in mice leads to embryonic lethality 
in E12.5-14.5 due to placental and heart defects150. Conditional PHD2 knockout mice 
show an increased erythropoiesis and angiogenesis through HIF stabilization and the 
downstream targets EPO and serum VEGF-a151. Eventually, mice with conditional 
PHD2-inactivation (mated with beta-actin-Cre-ER mice) die from venous congestion 
and dilated cardiomyopathy152. Interestingly, a study in human subjects confirmed the 
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critical role of PHD2 in human physiology. Mutations in the human PHD2 gene have 
been demonstrated to cause erythrocytosis, a familial hereditary disease 
characterized by the excessive production of erythrocytes153,154.  
The genetic ablation of PHD3 results in an abnormal sympathoadrenal development 
and systemic hypotension155. The authors of the above mentioned study suggest that 
functional PHD3 is essential for the correct anatomical and physiological status of the 
organisms and the PHD3-HIF-2α pathway is not redundant155. A combined knockout 
of PHD3 and PHD2 aggravate HIF activation (compared to mice lacking PHD2 
alone). These mice have shown symptoms such as hepatic steatosis, dilated 
cardiomyopathy and premature mortality156. The phenotype resembles more pVHL-
deficient mice156,157. 
PHD1-deficient mice show a shift in glucose metabolism from aerobic oxidation to 
anaerobic glycolysis and render the muscle fibers tolerant to hypoxia through 
lowered oxygen consumption158. As a consequence, the mice have been 
demonstrated to be protected against ischemic injury in heart and liver, as well as 
colitis158–160. 
A combined PHD1 and PHD3 knockout led to moderate erythrocytosis and HIF-2α 
accumulated in the liver resulting in an increased EPO expression in adult livers and 
as a consequence a slight increase of the hematocrit, hemoglobin concentration and 
red blood cell amount161.  
 
1.2.6  Regulation of PHD expression  
 
PHD1 gene expression is induced by estradiol162. PHD2 expression has been shown 
to be regulated by TGF-β by decreasing PHD2 mRNA and protein levels and 
consequently inducing HIF-1 accumulation and transcriptional activity163. 
Interestingly, PHD2 and PHD3, but not PHD1, are direct HIF target genes, resulting 
in up-regulated mRNA expression levels under hypoxic conditions30. The increased 
abundance of the two oxygen-dependent regulated PHDs partially compensates for 
the decreased activity of the hydroxylases in hypoxia. As a consequence HIF-α 
accumulation is restricted and the hypoxic response is limited164. Further, in case of 
reoxygenation after long-term hypoxia, this negative regulatory mechanism causes 
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an accumulation of PHD2 and PHD3 leading to an accelerated degradation of HIF-
α (fig. 4)165–168.  
 
Figure 4. Illustration of HIF-PHD2/3 negative feedback loop.  
The interplay of the HIF-α subunit and the PHDs can be regarded as a classical negative feedback 
loop. HIF-1α takes the role of the main effector and PHD2/PHD3 of O2-sensors, initiating HIF-α 
degradation. If high levels of the constitutively expressed HIF-1α accumulate, HIF will bind to the 
promoter of PHD2 and PHD3. This results in an increased expression of PHDs, which subsequently 
mark the HIF-1α subunit for degradation and eventually suppresses the PHD2/3 expression. This 
effect allows a stabilization of HIF-1α again. The feedback loop limits hypoxic signaling and 
accelerates HIF degradation after reoxygenation (modified; figure kindly provided by DP Stiehl). 
 
The regulation of EGLN1 (PHD2) and EGLN3 (PHD3) gene is based on a functional 
HBS located in the corresponding genes. The regulatory HBS of PHD2 is located in a 
CpG island situated in the PHD2 promoter immediately upstream of the translational 
start site (fig. 5)169. In contrast, an HBS was reported to be located in a conserved 
region of the first intron of the EGLN3 gene 12 kb downstream of the transcription 
initiation site55. However, the hypoxic regulation of PHDs transcription, other than 
through the transcription factor HIF, is not yet fully understood. 
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Figure 5. The EGLN1 / Egln1 (PHD2) gene in the human and murine genome. 
The human PHD2 promoter region was predicted based on the location of a CpG-island approximately 
0.5 kb upstream of the translational start site and had been proven experimentally to be functional170. 
The murine and human EGLN1 (PHD2) gene sequences were aligned. However, expressed 
sequence tag (EST) alignments did not lead to a precise mapping of the transcriptional start site. 
Prediction analysis of potential transcription factor binding sites for the human and murine PHD2 gene 
was performed and the HBS was found to be conserved between these species (modified from E 
Metzen et al.169). 
 
1.2.7  Other regulatory mechanisms of PHD expression and degradation  
 
PHDs are not only differently expressed but also degraded via different pathways. 
PHD1 and PHD3 have been reported to be Siah1/2 targets, an E3 ubiquitin ligase, 
and consequently degraded via the proteasome. In contrast, PHD2 protein stability is 
regulated by an ubiquitin-independent proteasomal pathway involving the interaction 
with the peptidyl prolyl cis/trans isomerase FK506-binding protein (FKBP38) as 
adaptor protein. Furthermore, FKBP38 mediates proteasomal interaction leading to 
degradation of FKBP38-bound PHD2 whereas cytosolic PHD2 is stable and able to 
function as an active prolyl-4-hydroxylase171,172. 
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1.2.8  Interactors and putative HIF-α hydroxylation substrates of PHDs 
 
PHDs are not only regulated by their expression levels and activity, but their function 
might also be influenced through the interaction with different proteins. Characterized 
PHD interactors are listed in table 195. Some of these interactors are potentially 
hydroxylated by PHDs. 
 
interactor action PHD 
Siah2173 inhibits PHD1/3 
FKBP38171 inhibits PHD2 
TriC174 activates PHD3 
OS-9175 activates PHD2/3 
AKAP176 activates PHD2 
Morg1177 activates PHD3 
ING4178 inhibits PHD2 
IOP1179 activates PHD2 
MAGE180 inhibits PHD1/3 
Cdr2181 activates PHD1 
ATF4182 is inhibited PHD3 
IKKβ183 is inhibited PHD1 
Myogenin184 Is activated PHD3 
KIFBβ185 is activated PHD3 
Rbp1186 is inhibited PHD1 
PKM2187 is activated PHD3 
 
Table 1. Characterized interactors of PHD1-3.  
Shading indicates putative hydroxylation through PHDs (modified from RH Wenger et al.95). 
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1.2.9  Relevance of PHDs in physiology and pathophysiology 
 
Numerous diseases like anemia, ischemia and stroke, but also solid cancer 
development are associated with inadequate tissue oxygenation. As PHDs play an 
important role in HIF-α-destabilization, they are interesting targets for inhibitor 
treatment of different diseases.  
It is known that HIFα-stabilization has a positive influence on anemia, ischemia and 
stroke since erythrocyte production, angiogenesis and tissue survival is supported188. 
However, a prolonged PHD-inhibitor administration might have severe side effects by 
promoting angiogenesis, cancer cell invasion of healthy surrounding tissue and 
tumorigenesis189. PHD inhibition was shown to be beneficial for neuronal survival and 
reduced brain infarct volume after transient ischemia through carotid artery 
occlusion190,191. Further, transient RNAi-mediated PHD2 knockdown showed to 
attenuate ischemia reperfusion injury and decreased the infarct size in the 
myocardial tissue192.  
Another field of PHD inhibitor application is the treatment of inflammatory bowel 
disease, an inflammatory condition of the gastrointestinal tract. In mouse models the 
progression of colitis and inflammatory markers, such as IL-1β, TNF-α and IL-12 
could be attenuated by the administration of the PHD inhibitor dimethyloxalylglycine 
(DMOG)193.  
On the other hand the activation of PHDs may also comprise options in cancer 
treatments. Already at the size of a few millimeters solid tumors are insufficiently 
penetrated by nutrients and oxygen. Consequently, hypoxic regions develop where 
HIF-α is stabilized and induces the transcription of HIF downstream targets beneficial 
for tumor survival and growth194. The role of PHD2, the main cellular oxygen sensor, 
is controversially discussed. On the one hand, decreased PHD2 levels were shown 
to promote breast cancer progression together with an increase in mature blood 
vessels in the tumor195,196. On the other hand, tumors injected into PHD2 
haplodeficient mice were reported to show an enhanced tumor perfusion and 
oxygenation by vessel normalization and inhibited tumor cell invasion197. This 
apparent divergence in the role of PHD2 in angiogenesis was attempted to be 
elucidated by distinguishing the origin of PHD2 deficiency: if the tumor cells 
themselves are deficient in PHD2 an increased angiogenic response is triggered, 
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whereas if the host endothelium is lacking PHD2, the blood vessels structure is 
normalized198.  
In conclusion, the modulation of PHD activity to eventually influence HIF-α stability 
seems to be an attractive option of treating various conditions. However, the precise 
biochemical mechanisms of HIF-α hydroxylation by PHDs as well as possible other, 
yet unknown, hydroxylation targets may cause severe side effects in patients.  
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1.3  ETS factors 
 
Several lines of evidence point to an involvement of the E-twenty six (ETS) 
transcription factor family in regulating different hypoxia-inducible genes199–202. For 
example, ETS1 has been shown to up-regulate hypoxia-inducible genes such as 
carbonic anhydrase 9 (CA9), lysyloxidase like 2 (LOXL2) and n-myc-down regulated 
1 (NDRG1) / calcium activated protein (Cap43) in a HIF-independent manner199. 
Additionally, promoter analysis revealed putative binding sites for members of the 
ETS transcription factor family in all target genes that were exclusively HIF-2α 
dependent. These potential ETS-binding sites were in proximity to putative HREs in 
90% of the cases200.  
 
The ETS gene family is a transcription factor family that can be found in all 
metazoans203. The oncogene v-ets was at first discovered as part of a fusion protein 
of a transforming retrovirus (avian erythroblastosis virus E26) and later also found as 
cellular gene, termed ETS-1204–206. Two years later the most similar ets-protein in 
comparison to ETS-1, named ETS-2, was identified207. Subsequently, the family of 
ETS genes enlarged enormously. Up-to-date there are at least 29 members of the 
ETS transcription factor family known, characterized by a conserved 85-amino acids 
DNA-binding domain, termed the ETS-domain. According to the sequence similarity 
in this ETS-domain, the position of the domain and additional conserved domains 
amongst the family members the ETS proteins are subdivided into approximately 12 
subfamilies (ETS, ERG, ELG, ELF, ESE, ERF, PEA3, Er71, TEL, SPI, TCF and 
PDEF)208,209 (fig. 6). The ETS domain has been shown to interact specifically with a 9 
to 15 nucleotide DNA sequence in the consensus core sequence 5’-GGAA/T-3’, 
termed ETS binding site (EBS)210,211. The EBS is found in promoters of diverse 
genes involved in development, proliferation, differentiation and in pathologies such 
as cancer212. However, the ETS-domain can be also involved in protein-protein 
interactions especially with transcriptional cofactors that guide the transcriptional 
activity213,214. 
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Figure 6. The 12 subfamilies of the ETS family of transcription factors and their members.  
The main functional domains characteristic of members of each ETS subfamily are depicted; 
alternative names for each member are given (separated by a slash). Domains: AD, transcriptional 
activation domain; ETS, DNA binding domain; Pointed, basic helix–loop–helix pointed domain; RD, 
transcriptional repressor domain. Protein abbreviations: E1AF, E1A enhancer binding protein; EHF, 
ETS homologous factor; ELF, E74-like factor; ELG, ETS like gene; ER81, ETS related protein 81; 
ERF, ETS repressor factor; ERG, v-ets avian erythroblastosis virus E26 oncogene related; ERM, ETS 
related molecule; ESE, epithelial specific ETS; ETS, v-ets erythroblastosis virus E26 oncogene 
homolog; ETV, ETS variant gene; FLI1, Friend leukemia virus integration 1; FEV, fifth Ewing variant; 
GABP, GA repeat binding protein; LIN, abnormal cell lineage; MEF, myeloid ELF1-like factor; NERF, 
new ETS-related factor; PEA3, polyomavirus enhancer activator-3; PDEF, prostate derived ETS 
transcription factor; PSE, prostate epithelium-specific ETS; SAP, serum response factor accessory 
protein; SPDEF, SAM pointed domain containing ETS transcription factor; SPI, spleen focus forming 
virus proviral integration oncogene; TEL, translocation, Ets, leukemia; TCF, Ternary complex factor 
(modified from A Gutierrez-Hartmann)215. 
 
ETS transcription factors are usually activators of transcription, with some 
exceptions. For example, in humans ETS-2 repressor factor (ERF)216and in 
Drosophila Yan, an isoform of E74 are transcriptional repressors217,218. 
Transcriptional activation is realized by either the interaction with coactivators 
ER71 
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through the transactivation domains, the synergy on other transcription factors, or 
through the direct influence with the general transcription machinery212.  
Apart from the ETS-domain the primary structure amongst the ETS transcription 
factors is variable. First structural studies of an ETS-DNA-binding domain of Friend 
leukemia virus integration 1 (FLI-1) provided insights that the ETS-domain is a 
variant of the winged helix-turn-helix motif219. Later studies with other ETS factors 
showed a high degree of secondary structure conservation, each containing three α-
helices and four β-sheets (fig. 7)220,221. 
 
 
 
Figure 7. The location of helices (H) and β-strands (β) within the structures of the pointed 
domain95 (blue) and ETS domain18 (red) of ETS-1 are shown220. 
 
Additionally, another motif termed Pointed domain (PNT) was found in several ETS 
proteins220,222. The PNT domain contains a helix-loop-helix (HLH) domain that may 
support dimerization with ETS proteins223. Conversely the PNT domain was found to 
consist of 4 to 5 helices, but does not show any characteristics of a HLH motif220,222. 
However, it was found that the PNT domain of the ETS protein translocation (TEL) is 
able to support the formation of chimaeric kinase domain fusion proteins and thereby 
deregulates kinase activity and oncogenic progression in human leukemia 
pathologies224,225. Nevertheless, almost all ETS transcription factors, apart from GA 
repeat binding protein α (GABPα), act as monomers when they bind to DNA226. 
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1.3.1  The ETS translocation variant 4 (ETV4) subfamily of ETS proteins 
 
As described above, the family of ETS transcription factor comprises 12 subgroups. 
One of those subgroups is the polyomavirus enhancer activator-3 (PEA3), named 
after the group founding member PEA3 (also known as and later referred to as ETS 
translocation variant 4 (ETV4) or E1A enhancer binding protein (E1AF)). Additionally 
to ETV4 the subgroup consists of two other members: Er81 (ETS related protein 81, 
aka and from here on referred to as ETV1)227,228 and ERM (ETS related molecule, 
alias and from here on referred to as ETV5)229,230. 
 
1.3.1.1  ETV4 subfamily protein structure and function 
 
The three ETV4 family members share a ≥95% sequence similarity in their ETS 
domain. Further they show an approximately 80% similarity in their acidic domains 
and about 50% of the overall primary structure is similar (fig. 8)231.  
 
 
Figure 8. Domain structure of the ETV4 subfamily proteins (ETV1, ETV4, ETV5) 
AD - transactivation domain; NRR - negative regulatory region (of transactivation or DNA-binding); 
ETS - ETS domain (adapted from Y de Launoit et al.232,233) 
 
In view of the fact that the ETV4 family members show ≥95% sequence similarity in 
their ETS domain that is responsible for DNA-binding, it is speculated that the ETV4 
subgroup of transcription factors bind similar promoter regions with identical binding 
affinities.  
The three ETV4 subfamily members act as transcriptional activators. Their 
transactivation domain is an about 40 amino acid long region of acidic residues that 
is suggested to be able to form α-helices that may interact directly with the general 
transcription factor TAFII60234. 
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However, DNA-binding and transactivation capacities of ETV4 subfamily proteins 
were shown also to be negatively influenced by domains surrounding the ETS DNA-
binding and acidic transactivation domains, respectively235–237. It has been suggested 
that this could involve conformational changes in the N- and C-terminal helices 
flanking the ETS DNA-binding domain222. However, the mechanism of this 
transactivational repression by the ETV4 subfamily proteins still needs to be 
elucidated. Of note, ETV4 family members do not contain a PNT domain.  
 
Further ETS transcription factors show cooperation with other transcription factors or 
directly synergize with general transcription factors212,222,238,239.  
Especially the common feature that ETV4 binding sites and AP-1 transcription factor 
binding sites are situated in close vicinity in several promoters leads to cooperativity 
in DNA-binding and transactivation238,240 
 
In addition, the genomic structure of the ETV4 subfamily genes is very similar, 
suggesting that they originate from a common ancestor but diverged throughout 
evolution and are to-date located on different chromosomes in humans (fig. 9)241. 
The genes were mapped for ETV1 to chromosome 7 (7q22)242, ETV4 is found on 
chromosome 17 (17q12)243 and ETV5 is located on chromosome 3 (3q27)244. 
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Figure 9. The genomic structure and evolution of the ETV4 subfamily genes. 
(A) All three ETV4 subfamily genes have equivalently-sized exons encoding similar regions of their 
respective proteins. Introns are represented by a horizontal line, and exons are illustrated by 
rectangles. The cross-hatched areas represent non-coding, untranslated sequences embodied in the 
mRNAs of each gene. The sequence (ATG) encoding the translation initiation codon is present in 
exon 2 of each gene. The ETS domain is encoded by exons 11, 12, and 13. The acidic transactivation 
domain is encoded by exons 3, 4, and 5. The divergence in structure amongst these three genes 
occurs primarily in the untranslated regions as well as in the size of several introns (adapted from T 
Shepherd and AD Hassell245). (B) Phylogenetic tree of the ETV4 subfamily genes. The genes of the 
ETV4 group probably appear after two duplications of a common ancestor (adapted from Y de Launoit 
et al.232). 
 
1.3.1.2  Discovery and characterization of ETV4 
 
ETV4 was originally discovered as polyomavirus enhancer binding activity246. Four 
years later JH Xin and colleagues successfully cloned cDNAs that encode ETV4 from 
a mouse FM3A cell cDNA library through its ability to bind to the polyomavirus 
ETV4 
ETV5 
ETV1 
B 
A 
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enhancer element 5’-AGGAAG-3’247. ETV4 showed to be able to transactivate a 
minimal promoter containing several ETV4 binding sites235,248. ETV4 binding sites 
have been found in promoter regions of several genes of growth factors and growth 
factor receptors (Her2/neu) as well as proteases and their inhibitors (MMP-7, TIMP-
1)249–251. 
 
1.3.1.3  Regulation of the ETV4 subfamily members 
 
The regulation of the ETV4 subfamily members is suggested - like many transcription 
factors - to be governed by posttranslational modification, such as phosphorylation. 
ETV4 is mainly phosphorylated on serine residues by the MAPK pathway including 
RAS, RAF-1, MEK, ERK-1, and ERK-2252,253. The ETV4 subgroup members become 
phosphorylated on specific serine and threonine residues that usually results in an 
increase of transcriptional activity252,237,254,255. Additionally, ETV1 and ETV5 were 
shown not only to be phosphorylated by MAPK, but also by protein kinase A 
(PKA)237,256–258. The phosphorylation by PKA was shown to increase the 
transcriptional activity of ETV5237,256. 
 
Posttranslational modification at lysines has been reported to effect the regulation of 
transcription factors. It has been demonstrated that activation of p300 via the 
Ras/MAPK pathway can lead to ETV1 lysine acetylation that eventually results in an 
enhanced transcriptional capacity259,260. 
 
Another lysine modification, namely SUMOylation, was reported for the ETV4 
subfamily261–266. SUMOlyation of ETV5 results in inhibition of transactivation, 
whereas SUMOylation of ETV4 is required for maximal activation of target gene 
promoters, including MMP-1 and COX-2, through the synergistic activation with the 
coactivator CBP. Furthermore, SUMOylation of ETV4 is required for ubiquitination of 
ETV4 and promotes its degradation, suggesting that SUMO-mediated recycling of 
ETV4 plays a role in ETV4-mediated promoter activation264. 
 
The ETV4 subfamily of transcription factors is also known to be ubiquitinated and 
finally degraded via the ubiquitin-proteasome pathway267–270. Recently, in particular 
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ETV1, but also ETV4 and ETV5, has been shown to be degraded by the ubiquitin E3 
ligase COP1269,270. This degradation process seems to have an important influence 
on the tumor suppressing function of COP1 through the inhibition of ETV1 protein 
accumulation in prostate adenocarcinomas269. 
 
1.3.1.4  ETV4 subfamily tissue distribution 
 
ETV5 is the most ubiquitously expressed ETV4 subfamily member. ETV5 mRNA was 
shown to be highly expressed in human and murine brain and placenta and, to a 
lesser extent, in lung, pancreas, and heart. Recently it was shown that ETV5 is 
expressed exclusively within Sertoli cells in the testis and is required for 
spermatogonial stem cell self-renewal271. Moreover, almost all human cell lines 
tested express ETV5 at varying levels229. 
 
In contrast, ETV1 and ETV4 show a more restricted mRNA expression pattern in 
human and mouse229,248,272. In human tissues, ETV1 mRNA is highly expressed in 
brain, testis, lung and heart, moderately in spleen, small intestine, pancreas and 
colon, weakly in liver, prostate and thymus, very weakly in skeletal muscle, kidney 
and ovary and not in placenta and peripheral blood leukocytes. Human ETV1 protein 
was found in the nucleus using immunocytochemistry. Analysis of human solid or 
hematopoietic tumor cell lines showed that most of them did not express ETV1 
detectably228.  
 
The expression of ETV4 is mainly located in the adult mouse brain and male 
epididymis. Lower expression levels were detected in the mammary gland. ETV4 is 
expressed to various extents in fibroblastic and epithelial but not in hematopoietic cell 
lines248. 
 
All ETV4 subgroup members are expressed in developing mouse embryos. 
Interestingly ETV4 and ETV5 show overlapping expression patterns in early 
development stages, suggesting a redundancy in these phases273,274. Later the 
embryogenetic expression patterns of ETV4 and ETV5 diverge. 
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ETV1 shows a completely different expression pattern compared to ETV4 and ETV5 
indicating a more divergent function during these stages273. 
The importance of the ETV4 subfamily to cell migration and invasion is currently 
discussed since expression of ETV4 and ETV5 was shown in numerous epithelial 
tissues that are often involved in branching morphogenesis (i.e. lung, salivary gland, 
mammary gland, kidney and the development of motor neurons) 231,273,275–279. 
 
1.3.1.5  Genetic ablation of ETV4 subfamily genes 
 
ETV1 knockout mice show postnatal lethality (3-5 weeks)280. ETV1 mutant mice 
exhibit a severe motor discoordination, but the specification of motor neurons and 
induction of muscle spindles occurs normally. The motor defect in ETV1 mutant mice 
results in a dramatic reduction in the formation of direct connections between 
proprioceptive afferents and motor neurons280.  
 
Although ETV4-deficient mice are viable, they show sexual dysfunctions. Male ETV4-
knockout mice are indeed morphologically normal and spermatogenesis yields 
functional sperm. However the mice are unable to ejaculate281. Female ETV4 
deficient mice do not show - as expected from the role of ETV4 in branching 
morphogenesis in breast and other organs - an impaired branching of the ductal tree 
but rather increased numbers of terminal end buds together with an increased 
proportion of proliferating cells in the postnatal mammary gland282. 
ETV4 mutant mice showed further that axons of specific motor neuron pools failed to 
branch normally within their target muscle and that the cell bodies of these motor 
neurons are mispositioned within the spinal cord278. 
 
ETV5-deficient mice have a defect in maintaining the spermatogonial stem cell self-
renewal without a block in normal spermatogenic differentiation and thus develop 
progressive germ-cell depletion, eventually leading to a Sertoli-cell-only syndrome271. 
This indicates that ETV5 loss has other effects besides lack of spermatogonial stem 
cells self-renewal that impair fertility283. Interestingly, microarray analysis of primary 
Sertoli cells from ETV5-deficient mice showed alterations in secreted factors known 
to regulate the hematopoietic stem cell niche271. Further it was shown that ETV5-
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deficiency causes an abnormal first wave of spermatogenesis, the production of 
specific Sertoli cells chemokines is impaired and defects in the formation of a blood-
testis-barrier are found284–286.  
Female ETV5-deficient mice showed a complex reproductive phenotype deficiency 
such as ovarian tissue architecture defects and decreased ovulation that rendered 
the mice infertile287. 
 
ETV4 and ETV5 are involved in branching morphogenesis of the developing mouse 
kidney and lung as well as in the limb outgrowth277,276,288. Of notice, in the kidney 
development overlapping expression of ETV4 and ETV5 in ureteric bud tip cells is 
positively regulated by glial cell line-derived neurotrophic factor (GDNF) and the 
receptor tyrosine kinase Ret signaling pathway. It could be shown that ETV4 and 
ETV5 are jointly needed for a successful kidney development, since mice lacking 
both ETV4 alleles and one ETV5 allele have a high frequency of renal agenesis 
(absence of the kidney) or hypodysplasia (severe malformation of the kidney) owing 
to branching defects, whereas mice completely deficient in ETV4 and ETV5 show a 
complete absence of kidney development277. 
 
1.3.1.6  Physiological and pathophysiological functions of the ETV4 
subfamily 
 
The role of the ETV4 subfamily members in normal tissue development and in 
the adult 
During chick and mouse development, ETV1 and other members of the ETV4 
subfamily are expressed in several embryonic tissues and exhibit combinatorial 
expression in specific regions of various organs273,274. Later during development, 
ETV1 is expressed in cortical layer V neurons, motor neuron pools, and subsets of 
muscle sensory neurons in the spinal cord289,280,290. ETV1 is expressed in a 
subpopulation of inferior olive neurons in the hindbrain which send their projections to 
the caudal cerebellum291. 
 
ETV4 is only expressed in the adult brain and epididymis248. However, in the 
developing organism ETV4 is expressed in various cell types especially those that 
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proliferate or migrate273. Frequently the expression of ETV4 overlaps in those cells 
with the expression of the other subfamily members, in particular with ETV5 273,274. 
In the developing mouse lung ETV4 and ETV5 are initially restricted to the distal 
buds. ETV5 is transcribed exclusively in the epithelium, while ETV4 is expressed in 
both epithelium and mesenchyme276. 
 
The phenotype of ETV4 knockout mice suggests that the sterility of male mice is due 
to a neurological impairment. Guidance of motor and sensory neurons might be 
damaged and innervations of penile smooth muscles are disrupted resulting in 
erectile dysfunction in adult ETV4-deficient mice. Livet et al. underlined in 2002 this 
hypothesis further, when they showed that ETV4 expression controls peripheral 
signals that are required to coordinate the central position and terminal arborization 
of specific sets of spinal motor neurons in mouse278. Induction of ETV4 expression 
through the glial cell line-derived neurotrophic factor (GDNF) is essential in two 
cervical motor neuron pools to control dendrite patterning and selectivity of 1a 
proprioceptive afferents292. Similar results were obtained in chicken developmental 
studies, where ETV1 and ETV4 are selectively expressed in motor neuronal pools 
that innervate specific muscles289. 
Further, the role of ETV4 in the branching morphology of the adult mammary gland, 
kidney and lung development, as well as the muscle regeneration through the 
proliferation and differentiation of satellite cells, involved in muscle repair, is 
discussed293,279,277,276. 
 
ETV5 protein is localized in granulose cells of the adult mouse ovary294. In cycling 
female mice, ETV5 mRNA is additionally detected in the corpora lutea295. 
 
The role of the ETV4 subfamily members in tumorigenesis and metastasis 
The overexpression of ETS genes, including members of the ETV4 subfamily, has 
been associated with breast cancer and prostate carcinomas. ETV4 subfamily 
members are expressed in human mammary epithelial cell lines and in the vast 
majority of human breast tumor cell lines, but also colon and prostate carcinomas 
and their cell lines296,238. The ETV4 subfamily proteins can cooperate with JUN, β-
catenin and T-cell factor/ lymphoid enhancer factor-1 (TCF/LEF-1) to increase the 
expression of the target gene MMP-7 (also known as matrilysin)238. Consecutively, 
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MMP-7 expression, like that of other MMPs, can lead to increased metastasis and 
tumor invasion. 
This was remarkably shown when the human nonmetastatic breast cancer cell line 
MCF-7 could be rendered invasive by the transfection of ETV4297. This was probably 
due to the ETV4-mediated induction of several matrix metalloproteinases (MMP-1, 
MMP-3, MMP-9) that are important for the extracellular matrix breakdown298,299,251.  
 
ETV4 is overexpressed in 76% of human tumor samples assessed through in situ 
hybridization300. In turn, especially ETV4 and its role in tumorigenesis and metastasis 
formation is discussed. ETV4 is known to be overexpressed in breast, ovarian and 
prostate cancer, oral squamous cell carcinoma, esophageal adenocarcinoma, 
colorectal cancer, non-small-cell lung cancer as well as in Ewing’s sarcoma300–310. 
Human epidermal growth factor receptor 2 (HER2/neu), also known as ErbB-2, is a 
receptor tyrosine kinase that is often linked to invasiveness and metastatic inclination 
in breast tumors which expression results in a poor prognosis for patients311. 
HER2/neu was shown to cause in a breast cancer induced mouse model elevated 
levels of ETV4 mRNA in mammary adenocarcinomas and originating lung 
metastases310.  
In human breast cancer patients ETV4 has been demonstrated to be overexpressed 
compared to healthy mammary epithelial cells, as shown by in situ hybridization300. 
Furthermore, it was found that in more than 90% of HER2/neu expressing tumors 
also ETV4 is overexpressed300. A positive feedback loop is suggested since ETV4 is 
able to activate its own transcription through its promoter and ETV4 is needed to 
efficiently mediate HER2/neu transcription via an ETV4 binding site249,250,300,312,313. 
This loop would keep ETV4 and HER2/neu expression elevated, maintaining the 
cancerous phenotype. 
In contrast, ETV4 has been demonstrated to repress the HER2 promoter in cell 
culture and to reduce the tumorigenic potential of HER2/neu in cell culture and 
immunodeficient mice314. This conflicts with most published data where ETV4 was 
shown to be a transcriptional activator and has been demonstrate to be 
overexpressed in HER2/neu-positive breast cancer in human and 
mouse300,315,248,238,310.  
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In line with those observations, RNAi-mediated transient knockdown of ETV4 
reduced invasiveness of squamous cell carcinoma-derived cell lines through the 
decreased expression of MMP-1, MMP-3 and MMP-9303.  
 
ETV5 is overexpressed in ovarian cancer and was confirmed to be important for cell 
adhesion regulation and thus enhancing cancer cell survival through the induced 
expression of adhesion molecules316. Interestingly, mouse mammary cancer cells 
tumorigenesis could be reduced upon siRNA- or shRNA-mediated inhibition of ETV4 
and ETV5317. 
 
Chromosomal rearrangements that result in high level expression of ETS gene family 
members are common events in human prostate cancer318. Fusion proteins involved 
in human prostate cancer often implicate ERG, ETV1, ETV4 and ETV5 that are 
highly expressed upon gene combination. The fusion partners are diverse, but are 
mostly androgen-activated genes318–320. ETS gene translocations represent an early 
event in prostate cancer but seem to be insufficient on their own to induce cancer 
formation318,320.  
In fact, the two ETS genes ERG and ETV1 are highly expressed in nearly all prostate 
tumors. ETV1, either truncated or full length, is expressed in ≈10% whereas gene 
fusions involving ETV4 and ETV5 have been reported to occur in 6% and <1% of 
prostate cancers, respectively. The idea is widely supported that ETS overexpression 
drives early stages of prostate cancer development269,318,319.  
The Ewing’s sarcoma and related cancer, an early documented translocation process 
in bone or soft tissue cancer entails a translocation between the EWS and an ETS 
gene, such as ETV1 and ETV4242,306,321–327. The translocations result in the formation 
of chimeric transcription factors: the N-terminus is often formed from the RNA-binding 
protein EWS that initiates transcription; the C-terminus is made from an ETS 
transcription factor supplying the ETS DNA-binding domain. Those mutant fusion 
proteins have been demonstrated to have a higher transcriptional activity than the 
wildtype proteins and might contribute to oncogenic development by altering the 
expression of target genes. 
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1.4  Aims of the thesis 
 
PHD2 is the most ubiquitous PHD family member and supposed to be the main 
cellular oxygen sensor in the body. So far, besides the activation by HIF-1 little is 
known about the regulation of the PHD2 gene in hypoxia328.  
 
1.4.1  Working hypotheses 
 
• Not only PHD2 enzyme activity but also expression levels are of importance 
for regulation of the hypoxic response. This regulation is predominantly linked 
to the conserved sequence and activity of the promoter region. 
• Being central to cellular oxygen homeostasis, it is conceivable that this 
feedback loop is regulated by transcription factors in addition to HIF.  
• The expression of such transcription factors might influence PHD2 expression 
levels and thus the HIF-PHD feedback loop. 
• Further understanding of the regulation of the cellular oxygen sensors might 
be of importance in therapeutic approaches in hypoxia-related conditions.  
 
1.4.2  Specific aims 
 
These hypotheses lead to the conceptual design and experimental confirmation of 
the following specific aims of this thesis: 
• to characterize the human PHD2 promoter in detail by serial truncations of the 
PHD2 promoter region thereby assessing the minimal and conserved PHD2 
promoter region  
• to set up a high throughput synthetic transcription factor screening for the 
identification of HIF-dependent and -independent co-activators involved into 
PHD2 gene transcription  
• to characterize these transcription factors and their implication in the overall 
transcriptional response to hypoxia 
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 hydroxylase domain 2 (PHD2) gene product 
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ABSTRACT 
Oxygen availability as well as insufficient oxygen supply regulate physiological 
adaptive processes and influence diseases such as cancer. The three human prolyl 
hydroxylase domain (PHD) proteins 1 to 3 are known as cellular oxygen sensors, 
acting via the degradation of hypoxia-inducible factor (HIF) α-subunits. Amongst the 
PHDs, PHD2 is most widely expressed whereas PHD1 and 3 show a more organ-
restricted expression pattern. The human PHD2 gene is driven by a promoter region 
located in a CpG island immediately upstream of the translational start site.  
We report that the transcriptional start site of the human PHD2 gene is located more 
than 318 nucleotides upstream of the translational start site. Hypoxic PHD2 
expression was shown on an endogenous level to be mediated through HIF-1. 
Additionally we identified and cloned 95 and 55 nucleotide long PHD2 promoter 
regions as highly conserved in several organisms. These regions encompassed a 
single HIF-binding site (HBS) and demonstrated strong hypoxia-inducibility. In this 
region, various putative transcription factor binding sites have been predicted. The 
ubiquitous transcription factor specificity protein 1 (SP1) was involved neither in 
normoxic nor hypoxia-induced expression of the PHD2 gene despite the prediction of 
numerous SP1-consensus motifs suggested so. Total abrogation of the hypoxic 
response was observed, when motifs located 5' or 3' to the HBS were mutated, but 
the binding of the HIF-1 complex was not affected. This suggests that the three-
dimensional structure of the HBS is determining HIF binding or that other 
transcription factors might contribute to hypoxic gene activation of the PHD2 
promoter, e.g. by stabilizing the HIF-DNA interaction or by serving as co-activators. 
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2.1  Introduction 
 
A disparity between oxygen transport and oxygen consumption inevitably leads to 
insufficient oxygenation and metabolic starvation of the affected tissue. Hypoxia-
inducible factors (HIFs) mediate the adaptation of hypoxic cells to these 
environmental conditions1. Three human prolyl-4-hydroxylase domain proteins, 
PHD1-3, are known as cellular oxygen sensors acting via the degradation of HIF 
(hypoxia-inducible factor) α-subunits2. Interestingly, two of the three PHD genes are 
inducible by HIFs, establishing a negative feedback loop3–8. We recently 
demonstrated that PHDs are capable of functionally regulating HIFα-subunits even 
under hypoxic conditions8. Thus, not only oxygen availability but also PHD 
abundance and activity regulate the HIF system8–12.  
Amongst the PHDs, PHD2 is most widely expressed, whereas PHD1 and PHD3 
show a more organ restricted expression pattern13,14. The human PHD2 gene is 
driven by a promoter region located in a CpG island immediately upstream of the 
translational start site3. Whereas the HIF effector system is well-studied, relatively 
little is known so far about the regulation of the PHD oxygen-sensing system. 
Regarding the numerous attempts to generate drugs affecting the PHD/HIF system, 
a better understanding of the mechanisms regulating PHD function and abundance 
will have important implications for basic science as well as for clinical application15–
22
. It is suggested that other important binding activities might contribute to hypoxic 
gene activation, e.g. by stabilizing the HIF-DNA interaction or recruitment of 
essential coactivators. Indeed, all three PHD genes have been shown to respond to 
certain upstream regulatory pathways involving estrogen stimulation, p53 activation, 
the proto-oncogene c-Jun, TGF-β – and hypoxia itself5–8.  
The PHD2 promoter region defined by Metzen et al. was recently shown to be active 
under basal and hypoxia-induced conditions and successfully used in a novel 
synthetic screening approach that involves site-specific transcription factor 
interplay3,23. The PHD2 promoter region has not yet been fully characterized as a 
result of an inaccurate description of the transcription start site. In an attempt to 
conclusively annotate the transcription start site of the PHD2 gene, we referred to 
the 5’-rapid amplification of complementary DNA ends (5’-RACE) technique, but 
failed to map the 5’-end of the promoter region (data not shown). We were not 
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successful to establish a reliable amplification reaction in this GC-rich region. The 
difficulty of this endeavor is underlined by a scarce literature on the PHD2 
transcriptional start site. The assembly of expression sequence tags (ESTs) equally 
was not elusive for the precise mapping of the transcription start site. Most of the 
ESTs were located in the very 3’-end of the gene which seems to be functionally 
irrelevant. Two transcription start sites based on the ESTs assembly were predicted 
in front of the first translated exon. One of them seems to rather be endorsed to an 
adjacent gene. The other predicted transcription start site presented a higher 
confidence score, but was not yet functionally proven. 
 
In this work, we aimed to study the PHD2 promoter architecture. Therefore, we 
narrowed down the transcriptional start site of the human PHD2 gene and found that 
motifs located 5' or 3' adjacent to the HIF-binding site (HBS) are highly important for 
hypoxia-induced PHD2 expression. This suggests a sterical involvement of the HBS-
adjacent regions in binding of HIF or other transcription factors in hypoxic gene 
activation of PHD2 expression. The gained information about the regulation of PHD2 
expression helped to understand the basics of the HIF-PHD2/3 feedback regulation 
and in a broader perspective the transcriptional regulation of hypoxic genes.  
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2.2  Results 
2.2.1  Narrowing of the transcriptional start site location in the PHD2 promoter 
 
Previously we have reported on a functional, single HBS located in the 5’-regulatory 
region of the human PHD2 gene3,23. Alignment of the PHD2 promoter region of 
various vertebrates revealed that the HBS surrounding region is conserved to 
approximately 66% (fig. 1A). Although, the predicted PHD2 promoter was confirmed 
to be functional, the transcriptional start site and with this the precise location of the 
PHD2 promoter remains unknown. In an attempt to map this important part of the 
promoter, 3’-truncated luciferase reporter gene constructs were generated. A region 
spanning from -1070/+3 (relative to the translation start site) showed maximal basal 
activity when transfected into U2OS (human osteosarcoma) and HeLa (human cervix 
carcinoma) cells23. The 3’ truncation, named P2P (-1070/-318), was cloned into a 
luciferase reporter gene vector, basal as well as hypoxic activation of the reporter 
were analyzed and compared to the P2P (-1070/+3) construct in U2OS and HeLa 
cells using a dual luciferase readout assay (fig. 1B). These reporter gene constructs 
harbour a translation start site for the reporter gene (luciferase), while transcriptional 
initiation by RNA polymerase II is mediated by the PHD2 promoter construct. If the 
transcription start site had been deleted, luciferase mRNA, protein and eventually 
reporter activity levels would be blunted to background levels. With the deletion of 
318 nucleotides upstream of the translational start site, luciferase expression still 
takes place, suggesting that the transcriptional start site is located further upstream 
of the eliminated 318 nucleotides (fig. 1C and D). Additionally, hypoxic induction was 
strictly dependent on a functional HBS, since point mutations of the binding site 
completely abolished the response to hypoxia in either cell line (fig. 1C and D).  
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Figure 1. The transcription start site of the human PHD2 gene is located more than 318 
nucleotides upstream of the translational start site.  
(A) Alignment of the PHD2 promoter region in various vertebrates revealed a conservation of the HBS 
surrounding region. (B) Illustration of the PHD2 promoter (P2P) 5’- and 3’- truncation and its cloning 
strategy. The functional HIF-binding site (HBS) is indicated by a black box. (C) Constructs as depicted 
in B. were transiently transfected into human osteosarcoma (U2OS) or the cervix carcinoma cell line 
HeLa (right panel), respectively. After 24 h of transfection, cells were incubated for further 24 h under 
20% O2 or 0.2% O2. Bars represent means ± S.E.M. of three independent experiments performed in 
quadruplicates. The HBS was mutated from CGTGC to ATAAT. Induction factors were calculated 
based on hypoxic reporter gene activation versus basal reporter activity at 20% O2. Data are given as 
mean ± S.D. 
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2.2.2  The PHD2 promoter is regulated by HIF-1 
 
The further characterization involved to typify the HIF-binding properties of the PHD2 
promoter. The core consensus motif 5’-RCGTG-3’ was defined by the analysis of 
about 70 HIF-target genes2. Such a HBS motif is also found in the PHD2 promoter 
and has been shown to be functional3. However, this motif does not allow 
discriminating if hypoxia-induced target gene expression is driven by HIF-1 or HIF-
224. Aprelikova et al. already gave indications by overexpression and silencing 
experiments that HIF-1, but not HIF-2 binding causes the hypoxia-induced PHD2 
expression25. We wanted to confirm this finding in two experimental settings.  
First, in Hif1a-deficient mouse embryonic fibroblasts (MEFs) (fig. 2A inlay) HIF-α 
expression was rescued by transfecting vectors overexpressing either HIF-1α or HIF-
2α or in control settings β-galactosidase. The PHD2 promoter construct pGL3 P2P (-
607/+3) - previously shown to have highest hypoxic induction while maintaining basal 
transcription levels23 - was additionally co-transfected. After treatment for 24 hours 
under normoxic or hypoxic conditions, luciferase reporter activity was analyzed. 
Forced expression of both HIF-1α and HIF-2α could induce normoxic PHD2 
expression concluding that PHD2 expression could be rescued. However, only 
overexpressed HIF-1α, but not HIF-2α, amplified the hypoxic PHD2 expression. In 
case of a mutated HBS, none of the HIF-α subunits could activate the promoter 
region (fig. 2A).  
To confirm the obtained result in an endogenous setting we used MCF7 cells in an 
second approach known to express functional HIF-1α and HIF-2α subunits (fig. 2B) 
for chromatin immunoprecipitation (ChIP) experiments using either anti-HIF-1α or 
anti-HIF-2α antibodies. Oxygen-dependent enrichment of the HRE-containing PHD2 
promoter region was mainly restricted to the HIF-1α precipitations (fig. 2C), providing 
further evidence for the preferential recruitment of HIF-1 over HIF-2 to the 
endogenous PHD2 locus. 
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Figure 2. The PHD2 promoter is regulated by HIF-1.  
(A) The HBS wt or mutated form of the truncated PHD2 promoter P2P(-607/+3) was transiently 
transfected into Hif1a - deficient mouse embryonic fibroblasts cells (MEF HIF1a -/-) along with either 
HIF-1α or HIF-2α expression vectors. The β-galactosidase (β-gal) control expression vector was 
cotransfected. After 24 h of transfection, cells were incubated under 20% or 0.2% O2 for another 24 h. 
Bars represent means ± S.E.M. for 3 independent experiments. (Inlay) Rescue of HIF-1α was 
confirmed by Western blotting. β-actin protein levels were used as loading control. (B) Analysis of 
HIF-1α and HIF-2α expression by Western blotting of MCF7 exposed to 24 h to normoxia or 0.2% O2 
hypoxic conditions. (C) Chromatin immunoprecipitation (ChIP) of normoxic or hypoxic MCF7 cells 
using antibodies directed against HIF-1α or HIF-2α, control serum (IgG) or 1:50 diluted input samples. 
The amount of co-precipitated chromatin derived from the human PHD2 promoter region containing 
the HBS was determined by PCR followed by agarose gel electrophoresis. 
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2.2.3  Conserved HBS-encompassing PHD2 promoter element and its effects 
on PHD2 expression 
 
Little is known about target gene regulation by HIF in cooperation with adjacent 
transcription factors. As the HBS is directly located within the promoter region, it is 
surrounded by multiple putative binding motifs for other transcriptional regulators. 
Computational analysis of murine and human PHD2 promoter regions only show few 
sequence similarities, but interestingly a stretch of 95 nucleotides (P2P(-465/-370) 
wt) encompassing a single HBS could be identified as highly conserved.  
The 5’-region of the conserved promoter element shows a strong accumulation of 
putative SP1-binding sites. In the 3’-end putative transcription factor binding sites 
were predicted in silico linked with two cell cycle-dependent factors (e.g. cell growth 
defect factor 1 (CDF-1); cyclin D binding myb-like transcription factor 1 (DMP1)).  
The conserved region of the PHD2 promoter, as well as a 5’ truncated 55 base pair 
long version - where most of the predicted SP1 binding sites were eliminated -named 
P2P(-425/-370) wt (depicted in fig. 3A) were cloned into luciferase reporter gene 
vectors. After transient transfection into U2OS and HeLa cells and incubation under 
20% O2 or 0.2% O2 for 24 hours, dual-luciferase activity was determined. 
Remarkably, those short regions were sufficient to confer highest hypoxic luciferase 
expression without any heterologous promoter in U2OS and HeLa cells (fig. 3B).  
In order to disrupt potential transcription factor binding sites, a selected subset of 
predicted binding sites was mutated by hexanucleotide mutations (mut) (5’-AAAAAA-
3’) within the conserved 55 nucleotide PHD2 promoter region and inserted into a 
dual luciferase readout system (fig. 3C). Two of these mutated constructs, namely 
those motifs located 5' or 3' adjacent to the HBS (mut A and B) completely lost 
hypoxic inducibility, even though the functional HBS, previously shown to be 
sufficient for HIF-1 binding, was preserved26. Mutation C (predicted binding site for 
SP1) and mutation D (predicted binding site for CDF-1) strongly reduced hypoxic 
reporter gene activation. Mutation E (predicted binding site for DMP1) shows, if at all, 
only a limited effect on PHD2 expression (fig 3D). Similar results were obtained 
when the experiment was repeated in HeLa cells (fig 3D). This suggests that other 
transcription factors might contribute to hypoxic gene activation, e.g. by stabilizing 
the HIF-DNA interaction or by serving as coactivators. 
BASAL AND INDUCIBLE REGULATION OF THE PHD2 GENE 
 
63 
However, neither Sp1-deficient MEFs nor basal or hypoxic PHD2 expression was 
affected when Sp1 expression was rescued. Mutation of the HBS completely 
abrogated hypoxic induction independently of SP1 (fig. 3E). 
 
 
 
Figure 3. Determination of regulatory elements in close vicinity to the HBS  
(A) Illustration of the conserved 95 bp and 55 bp long PHD2 promoter elements present in the 
constructs P2P(-465/-370)wt and P2P(-425/-370)wt, and its predicted transcription factor binding sites 
with consensus sequences: BNC – basonuclin 1; CDF-1 - cell growth defect factor 1; DMP1 - cyclin D 
binding myb-like transcription factor 1; HBS – HIF binding site; SP1 – specificity protein 1; WT-1 – 
Wilms tumor 1 (B) Luciferase reporter gene assays of P2P(-465/-370)wt, P2P(-425/-370)wt, P2P (-
607/+3) wt and mut. The constructs were transiently transfected into human U2OS and HeLa cells 
and 24 h after transfection, cells were incubated under 20% O2 or 0.2% O2 for another 24 h. (C) 
Scheme of hexanucleotide mutations (5’-aaaaaa-3’) and affected transcription factor binding sites 
within the PHD2 promoter element. (D) Luciferase reporter gene assays of P2P(-425/-370)wt and its 
binding site mutants A-E. Constructs as depicted in C. were transiently transfected as described in B. 
(E) Luciferase reporter gene assays of the wildtype or mutated form. The wt or mutated PHD2 gene 
regulatory region of P2P(-607/+3) (left graph) or P2P(-425/-370) (right graph) were transiently 
transfected into Sp1- deficient mouse embryonic fibroblasts (MEF Sp1 -/-) along with either SP1 (+) or 
β-gal (-) expression vectors. All bars represent means ± S.E.M. of 3 independent experiments 
performed in quadruplicates. 
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2.2.4  HIF binding to the PHD2 promoter stretch 
 
As the efficient abrogation of hypoxic reporter activation by mutation of the 
surrounding sequences might be due to impaired binding of HIF-1, we performed 
electromobility shift assay (EMSA) using nuclear extracts from HepG2 cells cultured 
at either 20% or 0.2% O2. In line with the dual-luciferase data EMSA revealed that 
mutations close to the HIF consensus sequence 5’-RCGTG-3’ do not impair the 
binding of HIF-1 (fig. 4A). While mutation of the HBS completely disrupted specific 
HIF-1 binding, oligonucleotides containing the flanking hexanucleotide mutations 
were still bound by HIF-1, albeit to a somewhat reduced extent. Interestingly, a 
hypoxia-inducible binding activity that was unaffected by mutation of the core HBS 
co-migrated with the HIF-1 complex (fig. 4A (i.)).  
To obtain a higher resolution, 2-nucleotide mutations to adenosines were introduced 
in the GC-rich HBS-flanking regions (fig. 4B). The oligonucleotides containing the 
flanking dinucleotide mutations of the conserved 55 nucleotides PHD2 promoter 
region were subsequently inserted into a luciferase reporter gene system. After 
transfection and treatment for 24 hours under normoxic or hypoxic conditions, 
luciferase activity was determined (fig. 4C). Interestingly, mutation 1 showed an 
increase in both normoxic and hypoxic levels, possibly through the mutation of a 
binding sequence of an inhibitory element. Mutations closer to the HBS reduced 
hypoxic inducibility and overall normoxic and hypoxic expression levels, although this 
reduction in PHD2 expression was not as pronounced as the complete abrogation 
through a mutation of the entire HBS. These findings suggest regions surrounding 
the HBS to influence PHD2 expression either for sterical reasons or through the 
interaction with other transcription factors binding adjacent to the HBS. The 
alignment of the HBS-region in the PHD2 promoter of various vertebrates showed 
certain conserved nucleotides 5’ and 3’ of the RCGTG motif (fig. 1A). In combination 
with the results obtained from dinucleotide mutations that suggest the additional 
importance of 2-3 nucleotides around the HBS we propose an enlarged core region 
of 5’-GTACGTGCX-3’. 
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Figure 4. Analysis of the PHD2 promoter region in close vicinity to the HBS  
(A) EMSA of nuclear extracts from HepG2 cells cultured at 20 or 0.2% O2 for 6 h. HIF binding to 
PHD2 promoter oligonucleotides (27 bp) (depicted in fig. 3C) encompassing the HBS surrounding 
sequence with or without indicated mutations. Specificity of the HIF-1 signal was demonstrated by 
supershift analysis with an anti-HIF-1α antibody.(i.) The arrowhead points to a band of a hypoxia-
inducible binding activity that is unaffected by mutation of the core HBS. (B) Scheme of dinucleotide 
mutations (5’-aa-3’) (bold) around the HBS within the 55 bp long GC-rich PHD2 promoter element 
P2P(-425/-370)wt. (C) The 55 nucleotides encompassing regulatory element of the human PHD2 
promoter was cloned into the promoterless pGL3basic luciferase reporter gene. Constructs as 
depicted in B. were transiently transfected into U2OS cells and treated as described in fig. 3B. Data 
are given as mean ± S.E.M. 
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2.3  Discussion 
 
The three human PHD proteins 1 to 3 are known as cellular oxygen sensors acting 
via the degradation of HIF-α subunits1,9,27–31. Amongst the PHDs, PHD2 is most 
widely expressed, whereas PHD1 and PHD3 show a more organ restricted 
expression pattern. However, little is known about the regulation of the PHD2 gene 
itself. Therefore we performed promoter analysis to study the transcriptional 
regulation of the PHD2 gene and to gain a better understanding of the underlying 
mechanisms in respect to hypoxia9,32. Interestingly, the PHD2 and PHD3 genes are 
inducible by HIFs themselves, establishing a negative feedback loop3–7,33. Thus, not 
only oxygen availability, but also PHD abundance regulates the hypoxic response33. 
We suggest that other transcription factors might contribute to hypoxic gene 
activation, e.g. by stabilizing the HIF-DNA interaction or by serving as co-activators. 
Therefore, we studied the promoter architecture and function in order to find further 
regulatory mechanisms of PHD2 gene expression.  
 
2.3.1  The transcription start site of the PHD2 gene 
 
The PHD2 gene has been mapped to chromosome 1 and consists of 5 exons34. In 
2005, Metzen et al. suggested through the identification of a CpG-island - a common 
genomic region for harboring a promoter - and various other prediction methods two 
different promoter sites upstream of the PHD2 coding sequence3. Transcription 
factor binding sites prediction revealed plenty of putative binding sites in the human 
and murine PHD2 gene hinting to a transcriptionally active genomic region. 
However, the promoter element predicted further upstream (approx. 3.5 kb 5’ of the 
translation start site) seemed to be transcriptionally silent in adult tissue and might 
be of relevance in early phases of embryonic development. This hypothesis, though, 
lacks experimental evidence to date. Thus, PHD2 gene expression seems to be 
solely driven by the functionally active promoter that is located immediately 5’ of the 
translation start site and contains a functional HBS (-412 bp to the translation start 
site)3,23. Although, EST assembly was performed the identification of the transcription 
start site was not successful3. The EST found most upstream in the UCSC genome 
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browser is located at the 3’-end of the first translated exon and misses the mRNA 
sequence of almost the complete first exon. The predicted transcription start sites 
that deviated from the EST sequence alignments were dispersed in the gene. A 
disadvantage of ESTs and EST-based transcription start site prediction is that they 
are derived from single sequencing reactions and might include erroneous runs. This 
misinformation lowers the reliability to obtain a correct sequence and might cause 
problems in assembling the accurate sequence. Some of the predicted transcription 
start sites for the PHD2 gene were settled in the very 3’-end which seems to be 
functionally questionable. Two other transcription start sites were predicted in front of 
the first exon. One of them has a low confidence score (21.0) and is located outside 
of the CpG-island. This transcription start site seems rather to be attributed to the 
adjacent gene (Disc1, encoded on the opposite strand and running in the opposite 
direction). The other predicted transcription start site with a higher confidence score 
(63.0) appears to be more potent. Although this sequence was absent in the PHD2 
promoter construct P2P (-1070/-318) the reporter was still transcriptionally active. 
This could mean that either the approach of deleting parts of the PHD2 promoter in a 
non-endogenous context is not appropriate or there is another, not yet predicted 
transcription start site present in the PHD2 promoter. Eventually, the transcription 
start can only be determined by experimental analysis of endogenous mRNA such 
as the establishment of 5’-RACE that did not succeed in our hands. 
 
2.3.2  The prevalence of HIF-1 for the hypoxia induced induction of PHD2 
 
The HIF-1α and HIF-2α subunits are structurally similar in their DNA binding and 
dimerization domains. However, they differ in their transactivation domains and have 
been shown to have assorted target genes. It was demonstrated that HIF-1α and 
HIF-2α regulate distinct target genes. HIF-1 has been reported to be primarily 
involved in the regulation of gene products of the glycolytic pathway, whereas HIF-2 
plays a role in stem cell pluripotency35,36. Since a binding preference of a HIF isoform 
is not deducible from the HBS motif alone the further characterization of the PHD2 
promoter included to analyze the prevalence of HIF-1 or HIF-2 trans-activation24. In a 
previous report the preference of HIF-1 for the PHD2 locus was indirectly proven by 
silencing or overexpressing either HIF-1α or HIF-2α. Hypoxia-induced PHD2 
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expression was affected neither way by HIF-2α25. We confirmed in two experimental 
settings that the hypoxic PHD2 promoter regulation is principally conducted through 
HIF-1α rather than HIF-2α. In a similar experiment to the above mentioned ones we 
rescued hypoxic PHD2 promoter activity through forced HIF-1α expression in MEF 
Hif1a-/
-
. However, the HIF-1/2α balance of a cell can be shifted by silencing or 
overexpressing one of the isoforms resulting in a potential compensation process37. 
Therefore, we aimed in a second experiment to demonstrate the dominance of HIF-1 
in hypoxic PHD2 expression on endogenous levels. We could show that endogenous 
HIF-1α is found on the PHD2 locus in hypoxia. However, MCF7 cells were reported 
to express a HIF-2α isoform having little transcriptional activity38. It was additionally 
reported that HIF-1α is decreasing in prolonged hypoxia while HIF-2α protein is 
increased37. The possibility is left that the preference for a particular HIF isoform to 
bind to the PHD2 promoter shifts in long-term hypoxia. Still, the preferred binding of 
HIF-1 at the PHD2 locus is in line with the observation of Schödel et al. who provided 
evidence that the majority of HIF-1 binding sites is located close to the promoter site, 
whereas HIF-2 binding sites are more often located in large distance to the 
influenced gene region24. As a matter of fact, the functional HBS is situated 412 bp 
upstream of the translation start site, within the promoter.  
 
2.3.3  The conservation of PHD2 HBS surrounding region 
 
As mentioned before, we found a conservation of the HBS and its surrounding 
sequence in human, mice and other vertebrates. We observed that the 95 bp and 55 
bp PHD2 promoter elements were sufficient to confer hypoxic inducibility, including 
in a murine tumor allograft model39. Interestingly, the regions located 5' or 3' adjacent 
to the HBS were shown to be highly important for hypoxia-induced PHD2 
expression, even though the functional HBS, previously shown to be sufficient for 
HIF-1 binding, was preserved26. The suggested enlarged HBS motif corresponds 
with the observed nucleotide sequence preferences of a high-resolution genome-
wide mapping of HBSs by ChIP24. In this unbiased approach an additional 
emphasize is put on the preference for a C/GT at the two positions before the HBS 
and a C after the RCGTG-motif. The same preference is found in the PHD2 HBS 
underlining the conservation and importance for hypoxia-induced regulation of the 
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oxygen sensor PHD2. Since roughly 50% of promoter sites are located in a CpG-
island, those regions show an accumulation of SP1-binding motifs (5’-GGGCGG-3’) 
simply because they are GC-rich. As well we predicted SP1-binding sites in the 
PHD2 region conserved amongst vertebrates that showed not to be functionally 
relevant and did not affect PHD2 expression either on basal or on hypoxic level.  
 
In summary, we confirmed on an endogenous level that hypoxic PHD2 expression is 
mediated through HIF-1. We identified a 95 bp-long PHD2 promoter region 
encompassing a single HBS as highly conserved in several organisms and 
demonstrate strong hypoxia-inducibility (even when the element was shortened to 55 
bp). Total abrogation of the hypoxic response, but not of the HIF-1 complex binding 
could be shown in dual-luciferase assay and EMSA experiments, when motifs 
located 5' or 3' adjacent to the HBS were mutated. Our findings shed light on the 
cellular events and networks connected to PHD expression.  
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2.4  Material and methods 
 
Plasmid constructs 
The 95 base pair conserved PHD2 promoter construct was previously published39 
and a 55 nucleotides truncated version of the regulatory element of the human PHD2 
promoter (P2P(-465/-370)wt and P2P(-425/-370)wt) was similarly generated. Both 
constructs were cloned by introducing synthetic oligonucleotides into the 
promoterless pGL3basic luciferase reporter gene backbone. Mutations were 
integrated by hexanucleotide (5’ -aaaaaa- 3’), dinucleotide (5’ -aa- 3’) or HBS 
mutations (5’-CGTGC-3’ to 5’-ataat-3’). PHD2 promoter (P2P) constructs containing 
the wildtype and mutated HBS in pGL3basic luciferase vector were published 
before3. These constructs were modified employing a 5’-truncation and a 3’-start 
codon fusion to the luciferase open reading frame by using standard restriction-
mediated cloning techniques. The PHD2 luciferase reporter plasmid  pGL3 P2P (-
607/+3) contained PHD2 promoter sequences extending from −607 to +3 (ATG start 
codon) and has been published previously40. Cloning of PHD2, PHD3, β-
galactosidase, HIF-1α, HIF-2α and SP1 expression vectors (pcDNA3.1) was carried 
out using Gateway technology (Invitrogen, Basel, Switzerland) as described 
previously10. 
 
Protein extraction and immunoblot analysis 
Cells were washed twice and scraped into ice-cold phosphate-buffered saline. 
Soluble cellular protein was extracted with a high salt buffer containing 0.1% Nonidet 
P-40 essentially as described before41. Protein concentrations were determined by 
the Bradford method using bovine serum albumin as a standard, and 50–80 µg of 
protein were subjected to immunoblot analysis. The following antibodies were used: 
mouse anti-human HIF-1α (Transduction Laboratories BD Biosciences), rabbit anti-
human HIF-2α (Novus Biologicals) and mouse anti-β-actin (Sigma) were detected 
with secondary polyclonal goat anti-mouse antibody coupled to horseradish 
peroxidase (HRP) (Pierce). Chemiluminescence detection was done using 
Supersignal West Dura (Pierce) and recorded with a CCD camera (Fuji, LAS 4000) 
followed by quantification with Quantity One software (Bio-Rad). 
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Cell culture and transfections 
Human cervix carcinoma (HeLa), human osteosarcoma (U2OS), human shPHD2 
breast cancer (MCF7), human hepatocellular carcinoma (HepG2) and mouse 
embryonic fibroblast (MEF) HIF1a-/- and Sp1-/- cells were grown in Dulbecco’s 
modified Eagle’s medium (Sigma) supplemented with 10% fetal calf serum (FCS) 
and antibiotics (penicillin 50 IU/ml and streptomycin 100 µg/ml, Invitrogen) (Gibco-
BRL) as described previously12. Hypoxic conditions were generated by incubation of 
cells in an InvivO2 400 hypoxic workstation (Ruskin Technologies). The oxygen 
concentration was maintained at 0.2-1%, with the residual gas being 94-94.8% 
nitrogen, and 5% carbon dioxide. Transfections were performed using 
polyethylenimine (Polysciences) as described previously8. 
 
Chromatin immunoprecipitation (ChIP)  
ChIP assays from parental MCF7 cells exposed to 20% or 1% O2 for 4 and 24 hours 
were performed essentially as described previously37. The following antibodies were 
used for immunoprecipitation: rabbit anti-HIF-1α (ab2185; Abcam), and rabbit 
polyclonal anti-HIF-2α IgG fraction (ab199; Abcam). Rabbit serum (011-000-001; 
Jackson ImmunoResearch) served as unspecific control. Enrichment of PHD2 
promoter chromatin was determined by PCR using the following primers: PHD2 
forward 5'-gtatgccctgcgctcctc-3', reverse 5'-gctgagagaatagggcctgtg-3'. 
 
Dual-luciferase assay  
Cells were cotransfected with 20 ng pRLSV40 Renilla luciferase reporter gene 
vector (Promega) and 3 µg reporter plasmid or 1.5 µg reporter and additionally 1.5 
µg expression plasmid, respectively. After 24 hours of normoxic and further 24 hours 
of hypoxic (0.2% O2) incubation cells were lysed in 20 µl passive lysis buffer 
(Promega). Luminescence was immediately analyzed with a microplate luminometer 
(Berthold) using the dual-luciferase reporter assay kit (Promega). 
 
Nuclear extract preparation and EMSA (electrophoretic mobility-shift assay) 
Nuclear extracts were prepared from HepG2 cells incubated in a 0.2% oxygen 
atmosphere for 4 hours as described earlier42. Oligonucleotides for gelshift assays 
were synthesized by MWG-Biotech (Microsynth, Switzerland). Sequences were 
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derived from the human PHD2 gene, containing the putative HBS (PHD2-HBS, nt 
2747, GenBank® accession no. AF229245) or a mutated HBS (PHD2-HBSmut): 
wildtype (wt: 5’-GCCGTGGTGTACGTGCAGAGCGCGCAG-3’),  
HBS mutant (HBS mut: 5’-GCCGTGGTGTAataatAGAGCGCGCAG-3’), 
mutant A (mut A: 5’-GCCGaaaaaaACGTGCAGAGCGCGCAG-3’), 
mutant B (mut B: 5’-GCCGTGGTGTACGTGaAaAaaGCGCAG-3’)  
 
The 5´-end 32P-labeling, annealing and binding reactions were performed as 
described previously42,3. Samples were resolved by electrophoresis on native 5% 
polyacrylamide gels at room temperature. Gels were dried and analyzed by 
phosphoimaging (BAS 1000; Fuji, Düsseldorf, Germany). Specificity was tested by 
supershift experiments. For this purpose, 1 µl of undiluted monoclonal anti-HIF-1α 
antibody (BD Biosciences, Heidelberg, Germany) was added to the nuclear extract 
60 min before the gel was run. 
 
Alignment 
Promoter region prediction and analysis of putative transcription factor binding sites 
in the human and murine PHD2 genes were performed with ALGGEN Promo 3.0 
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3). 
Sequence alignments were performed as described before using ClustalX3. 
 
Statistical analysis 
If not otherwise indicated, results are presented as mean values ± standard error of 
the mean (S.E.M.) of at least three independent experiments. P-values were 
obtained by unpaired t-tests (*P<0.05, **P<0.01, ***P<0.001). 
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ABSTRACT  
The human prolyl-4-hydroxylase domain (PHD) proteins 1 to 3 are known as cellular 
oxygen sensors, acting via the degradation of hypoxia-inducible factor (HIF) α-
subunits. PHD2 and PHD3 genes are inducible by HIFs themselves, suggesting a 
negative feedback loop that involves PHD abundance. To identify novel regulators of 
the PHD2 gene, an expression array of 704 transcription factors was screened by a 
method that allows to distinguish between HIF-dependent and HIF-independent 
promoter regulation. Amongst others, the E-twenty six (ETS) transcription factor 
ETV4 was found to contribute to PHD2 gene expression particularly under hypoxic 
conditions. Mechanistically, complex formation between ETV4 and HIF-1/2α was 
observed by mammalian two-hybrid and FRET analysis. HIF-1α domain mapping, 
CITED2 overexpression and FIH depletion experiments provided evidence for 
cooperation between HIF-1α and p300/CBP in ETV4 binding. Chromatin 
immunoprecipitation confirmed ETV4 and HIF-1α co-recruitment to the PHD2 
promoter. Of 608 hypoxically induced transcripts found by genome-wide expression 
profiling, 7.7% required ETV4 for efficient hypoxic induction, suggesting a broad role 
of ETV4 in hypoxic gene regulation. Endogenous ETV4 highly correlated with PHD2, 
HIF-1/2α and several established markers of tissue hypoxia in 282 human breast 
cancer tissue samples, corroborating a functional interplay between the ETV4 and 
HIF pathways.  
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3.1  Introduction 
 
Cellular adaptation to a shortage of oxygen is mainly governed by transcriptional 
regulation. Hypoxia-inducible factors (HIFs) are key players in the hypoxic cell and 
orchestrate the expression of hundreds of downstream target genes, adapting the 
cellular metabolism to a low oxygen environment1. Heterodimeric HIFs consist of a 
tightly O2-regulated α-subunit (HIF-1α, HIF-2α or HIF-3α) and a constitutively 
expressed β-subunit (HIF-1β). At oxic conditions HIF α-subunits are continuously 
marked for proteasomal degradation through hydroxylation of two key prolyl-residues 
by prolyl-4-hydroxylase domain (PHD) oxygen sensor proteins2. PHD hydroxylation 
activity fades as a direct function of oxygen, thus reciprocally controlling the nuclear 
accumulation of HIFαs. Stabilized HIF-complexes bind to a cis-acting HIF binding 
site (HBS) conformed by a highly conserved core 5‘-RCGTG-’3 motif present in all 
direct target genes1,3,4. In analogy to de-stabilizing proline hydroxylation, the 
transcriptional activity of HIF is tuned by factor inhibiting HIF (FIH) which 
hydroxylates a distinct asparagine residue within the HIFα carboxy terminus and 
consequently hinders its association with the transcriptional 300-kilodalton co-
activator protein (p300) and CREB binding protein (CBP)5–7. 
 
Amongst the three characterized HIF prolyl-4-hydroxylases, PHD2 is widely 
accepted as the most crucial isoform controlling basal activity of the HIF pathway in 
oxic cells8. Underlining its dominant role, disruption of the Egln1 locus, encoding 
mouse PHD2, results in prenatal lethality, while PHD1 and PHD3 knockout mice are 
born normally9. Broad-spectrum conditional deletions of all three PHDs in mice 
revealed a global hyperproliferative vascular phenotype uniquely when targeting 
PHD2, demonstrating an absolute requirement for PHD2 which is not confined to 
embryonic development10. Accordingly, PHD2 abundance is considered as a critical 
factor in tumor angiogenesis, though divergent roles of stromal and tumor cell 
derived PHD2 have been discussed11–13. As PHD2 protein is strikingly stable and the 
de novo translated enzyme outlasts a period of transient hypoxia by more than 48 
hours, transcriptional regulation of the PHD2 locus must be considered as the main 
process defining cellular levels of PHD214,15. Expression of PHD2 itself is delicately 
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influenced by HIF transcriptional activity, forming a negative feedback loop which 
facilitates dynamic oxygen sensing16–18. 
In order to identify upstream regulatory pathways affecting PHD2 gene expression in 
an unbiased system, we developed a screening approach that allows the 
identification of transcriptional interactions with DNA-bound HIF complexes and HIF-
independent promoter regulation at the same time. The herein described synthetic 
transactivation screening led to the identification of several members of the E-twenty 
six (ETS) and FOS families of transcription factors as novel activators of the human 
PHD2 promoter. Amongst those, ETS translocation variant 4 (ETV4; also known as 
E1A enhancer binding protein, E1AF; or polyoma enhancing activator 3, PEA3), was 
found to be a potent co-activator of HIF-1-dependent transcription.  
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3.2  Results 
3.2.1  A single HIF DNA-binding site (HBS) is sufficient for hypoxic induction 
of the human PHD2 promoter but dispensable for basal promoter activity 
 
Previously, we have reported on a functional, single HIF-binding site located in the 
5'-regulatory region of the human PHD2 gene16. By using a series of 5'-truncated 
luciferase reporter genes (schematically depicted in fig. 1A), the minimal hypoxia-
responsive region of the PHD2 promoter was further mapped to an element 
spanning nucleotides -424 to +3 relative to the translational start site. While pGL-
P2P(-424/+3) still revealed high hypoxic inducibility when transiently transfected into 
U2OS or HeLa cells, normoxic promoter activity of this region was largely lost when 
compared to the longer promoter variants, regardless of whether the HBS was 
wildtype or mutant (fig. 1B). Elongation of the promoter by at least 183 nucleotides 
(construct pGL-P2P(-607/+3)) showed robust normoxic activity in both cell lines (fig. 
1B). Since basal induction of HBS-lacking constructs was observed between 
nucleotides -424 and -607 without any further effects upstream, the existence of 
transcriptionally active elements required for oxic expression of the PHD2 gene in 
this particular region is suggested (fig. 1B). Of note, the fold of hypoxic activation of 
pGL-P2P(-607/+3) resembled the oxygen-dependent induction factors of 
endogenous PHD2 mRNA and protein in both cell lines (fig. 1C). 
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Figure 1. Identification of the minimal human PHD2 promoter.  
(A) Schematic representation of PHD2 promoter (P2P) 5'-truncations and their cloning strategy as 
used in this study. The translational start site is designated "+1". (B) Regulatory DNA regions of the 
human PHD2 gene were cloned into luciferase reporter vectors that were transiently transfected into 
human U2OS osteosarcoma cells. One day after transfection, cells were incubated for 24 hours at 
20% or 0.2% O2. Hypoxic induction factors (mean values ± S.D.) of relative luciferase activities were 
calculated from three independent experiments performed in triplicates. Mutation of a single HIF 
binding site (HBS, black rectangles in A) completely abrogated hypoxic inducibility of all constructs. 
(C) Hela and U2OS cells were incubated at 20% or 0.2% O2 for 4-24 hours and protein levels of HIF-
1α, PHD2 and β-actin were analyzed by immunoblotting. Total RNA was isolated from cultures 
treated as in B and mRNA levels of PHD2 and carbonic anhydrase 9 (CA9) were determined by RT-
qPCR. Transcript levels of CA9 served as positive control to confirm continuous hypoxic responses. 
Gene expression levels were expressed in relation to ribosomal L28 mRNA (rel. levels) calculated 
from 3 independent experiments (±S.D.). 
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3.2.2  A differential screening approach to identify site-specific transcription 
factor interplay 
Multiplexed transfection of firefly and renilla reporter genes controlled by either 
wildtype or HBS-mutant PHD2 promoters, respectively, allows to classify any 
reporter-modulating event as HIF-dependent or self-sufficient. Moreover, the dual 
reporter system provides a read-out that permits to screen under HIF-stabilizing 
conditions (e.g. hypoxia) while simultaneously assessing the non-induced 
background levels (simulated “normoxia”) in the very same cells, thereby reducing 
intra-assay variabilities and screening complexity. Nucleotides -607 to +3 of the 
PHD2 promoter containing either the wildtype or mutant HBS were used to drive 
transcription of firefly or renilla luciferase cDNAs, respectively. The two luciferase 
reporter genes showed identical hypoxic responses in the respective reporter vectors 
(fig. 2A). As a proof of principle, this system was tested by co-expressing mIpas, 
encoding an inhibitory isoform of HIF-α, with the two reporter plasmids as described 
above19. Indeed, a marked downregulation of hypoxic firefly versus renilla luciferase 
activity was observed when compared to co-transfection with the empty vector or an 
unrelated transcription factor (mHes-1). As expected, forced expression of PHD2 or 
PHD3 strongly attenuated the hypoxic activation of the reporter system, confirming 
that also post-translational mechanisms impairing the activation state of the HIF-
pathway can be assessed by this method (fig. 2B)17.  
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Figure 2. Synthetic transactivation screening allows to discriminate HBS-dependent and 
independent promoter activation.  
(A) P2P(-607/+3) driven firefly (blue) and renilla (red) luciferase reporter genes transfected into U2OS 
cells show similar hypoxic activation (0.2% O2 for 24 hours, black bars) when compared to normoxic 
(20% O2, open bars) cultures. HBS mutation completely abrogated hypoxic induction of both 
constructs. (B) Co-expression of transcription factors (mIpas, mHes-1) or PHD enzymes with P2P(-
607/+3)wt HBS driven firefly and P2P(-607/+3)mut HBS driven renilla luciferase reporters, 
respectively. Dual luciferase activities were determined after 24 hours of hypoxic exposure (0.2% O2) 
and expressed as relative luciferase activity normalized to controls receiving the empty expression 
vector. (C) Schematic overview of the PHD2 promoter-luciferase constructs used for synthetic 
transactivation screening. Expected readouts for HBS-dependent (firefly reporter activation only, blue 
circle) and independent reporter gene activation (simultaneous activation of firefly and renilla reporter 
genes indicated by blue and red circles, respectively) are illustrated by a cross table. (D) Workflow of 
synthetic transactivation screening analyzing a commercial transcription factor expression library. (E) 
Z-scores of two independent screening experiments were plotted for both reporters. Thresholds for z 
> 2 are indicated by dotted lines. (F) Paired values for individual co-expressed cDNAs for firefly (blue) 
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and renilla (red) read-outs are depicted. A fold of induction greater than 2 was considered as lead for 
a re-screening. Positions of HIF-1α and seven new transcription factors positively re-evaluated at a 
secondary screening level are indicated. Data are given as the mean of two independent screening 
experiments. For calculations and full gene names refer to the text. 
 
3.2.3  Members of the FOS and ETS transcription factor families transactivate 
the human PHD2 promoter 
 
An array of 704 cDNA expression vectors representing all commonly known 
transcription factor families was screened using the HBS-specific synthetic 
transactivation readout. Possible HIF co-regulators alter firefly but not renilla 
luciferase expression, whereas HIF-independent factors interfere with both reporters 
(schematically depicted in fig. 2C). A work flow of the transfection and screening 
procedure is given in figure 2D. Two independent screens were performed and 
reproducibility was visualized by plotting z-scores (fig. 2E). Solid correlations were 
observed for the vast majority of the co-expressed transcription factors, confirming 
that no significant deviation between the two experiments occurred. Reporter gene 
inductions by each co-expressed transcription factor were calculated as multiples of 
the respective 96-well plate median individually for firefly and renilla activities, 
averaged over the two experiments, and ranked according to the induction factors of 
the HBS-mutant renilla reporter (fig. 2F). The cut-off was defined as an increase in 
luciferase activity by a factor of at least 2, tolerating a deviation of 0.05. Factors that 
showed a reproducible increase in either firefly luminescence (supplementary table 
S1A) or firefly and renilla luminescence together (supplementary table S1B) were 
considered as leads. Underlining the validity of this approach, the only known 
transcriptional activator of PHD2 expression, namely HIF-1α, was amongst the 
cDNAs identified (fig. 2E and F). For re-evaluation, the cDNAs of 43 leads were 
retrieved and partially sequenced to verify their identities. Seven of these cDNAs, 
namely ETS-variant 4 (ETV4), Spi-C transcription factor (SPIC), ETS homologous 
factor (EHF), the proto-oncogenes JUN and FOSB, v-crk sarcoma virus CT10 
oncogene homolog (CRK) and Jumonji domain-containing protein 2A (JMJD2A), 
resulted in a reproducible HBS-dependent regulation of the PHD2 promoter. Most of 
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these factors can be attributed to two major groups: the ETS (ETV4, EHF, SPIC) and 
the FOS (JUN, FOSB) families. 
3.2.4  ETV4 activates PHD2 and transferrin promoters synergistically with HIF-
1 
Expression vectors of the seven newly identified factors were co-transfected together 
with pGL-P2P(-607/+3) HBS wildtype or mutant reporter genes, cloned into identical 
backbones to exclude false positive effects which may have resulted from the two 
different luciferase cDNAs in the original screen. In the presence of a functional 
HBS, co-expression of ETV4 resulted in a striking super-induction of the PHD2 
promoter under hypoxic conditions only (fig. 3A, left panel) which was fully lost with 
the mutant construct (fig. 3A, right panel). Since ETV4 was the strongest hit 
identified, subsequent work focused on the role of this transcription factor as a 
putative transactivator of PHD2. Of note, the PHD2 promoter region used in this 
screen lacks a consensus 5'-A/CGGAAGT-3' ETV4 binding site20. Thus, direct binding 
of ETV4 to the PHD2 promoter appears unlikely, though not fully excluded regarding 
the small residual stimulation of constitutive PHD2 promoter activity following HBS 
mutation. However, the complete lack of hypoxic PHD2 promoter stimulation by 
ETV4 suggests that HIF-1 might actually recruit ETV4 to enhance hypoxic induction. 
Accordingly, knockdown of HIF-1α by RNA interference in U2OS cells abrogated 
hypoxia and ETV4 mediated induction of the wildtype PHD2 promoter (fig. 3B, right 
panel), while an unrelated control siRNA had no effect (fig. 3B, left panel). A 
heterologous reporter construct driven by the minimal SV40 promoter in conjunction 
with either a wildtype (fig. 3C, left panel) or mutant (fig. 3C, right panel) hypoxia 
response element derived from the human Transferrin gene recapitulated the strong 
hypoxic superinduction by exogenous ETV4, proposing a more general model of 
synergistic interaction between ETV4 and HIF-121. In line with our screening data, 
overexpressed ETV4 significantly up-regulated endogenous PHD2 mRNA and 
protein levels in hypoxic U2OS cells, while PHD1 mRNA levels remained unaffected 
(fig. 3D and E). 
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Figure 3. Hypoxic transactivation of the PHD2 promoter by ETV4 requires HIF-1α activity.  
(A) Standard dual luciferase reporter gene assays of seven re-evaluated hits from the transcription 
factor overexpression array. Wildtype (left panel) or HBS mutant (right panel) PHD2 promoter regions 
controlling firefly luciferase reporter plasmids were co-transfected into U2OS cells together with 
expression constructs of the aforementioned factors. Transfection of an empty expression vector 
(empty) served as negative control and differences in transfection efficiency were controlled by co-
transfecting SV40 promoter driven renilla luciferase. Cells were cultured at 20% or 0.2% oxygen for 
24 hours before dual luciferase activities were determined. (B) Transient RNAi mediated knockdown 
of HIF-1α fully abrogated hypoxic activation of the PHD2 promoter by ETV4. U2OS cells were 
transiently transfected with siRNA oligonucleotides targeting HIF-1α (siHIF1α, right panel) or a control 
sequence having no human target (siControl, left panel). Reporter gene experiments using the P2P 
reporter construct with only wildtype HBS were performed as described in A. The inset shows an 
immunoblot confirming the robust knockdown of HIF-1α in U2OS cells. (C) ETV4 and HIF-1 
synergism in hypoxic gene activation is not restricted to the PHD2 promoter. A heterologous hypoxia 
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responsive reporter gene containing two functional HBS from the human Transferrin hypoxia 
response element (pGL-TfHRE wt) was tested in luciferase reporter assays as described in A. 
Mutation of both HBS (pGL-TfHRE mut) caused an abrogation of the signal as seen in A. (D, E) 
Forced expression of ETV4 in U2OS cells upregulates endogenous PHD2 protein and transcript 
levels. (D) Whole cell lysates were prepared from cells exposed for 16 hours to 20% or 0.2% oxygen 
and analyzed for HIF-1α, ETV4, PHD2 and β-actin levels by immunoblotting. (E) Total RNA was 
extracted of similarly treated cells and mRNA levels of PHD1, PHD2 and L28 were quantified by RT-
qPCR. Data are shown in relation to ribosomal L28 mRNA (rel. levels) calculated from 3 independent 
experiments (**p<0.01, paired Student's t-test).  
 
3.2.5  ETV4 interaction with the carboxy-terminal transactivation domain of 
HIF-1α depends on co-recruitment of p300 
 
Intrigued by the HIF-dependent ETV4 effects, we aimed for the characterization of a 
putative physical interaction between ETV4 and HIF-1α. Utilizing a mammalian two-
hybrid system, expression plasmids encoding for ETV4 fused to the activation 
domain (AD) of viral protein 16 (VP16-ETV4) were co-transfected with HIF-1α 
oxygen regulatory domains fused to a Gal4-DNA binding domain (DBD, see fig. 
4A)22,23. Due to its intrinsic transactivation activity, constructs containing the carboxy-
terminal activation domain (CAD) of HIF-1α (amino acids 775-826) were sufficient to 
activate the Gal4-responsive promoter (fig. 4B)23. Co-expression of ETV4 strikingly 
superinduced GH1α740-826 and GH1α786-826, particularly under hypoxic 
conditions, suggesting that HIF-1α CAD and ETV4 co-operate to transactivate target 
genes (fig. 4B). ETV4 effects on the amino-terminal activation domain (NAD; HIF-1α 
amino acids 549-582) were negligible23. Both, HIF-1α and ETV4 have been 
demonstrated to interact with the ubiquitous transcriptional co-activators 
p300/CBP24,25. To address the question whether the two factors directly interact or 
whether a ternary complex between HIF-1, p300/CBP and ETV4 is formed 
(schematically depicted in fig. 4C), binding of HIF-1α CAD to p300 was disrupted by 
forced overexpression of CBP/p300-interacting transactivator 2 (CITED2), known to 
negatively regulate HIF function26. Structural analyses revealed that CITED2 and 
HIF-1α share an overlapping binding interface in the p300 cysteine-histidine-rich 1 
(CH1) domain and competition assays showed a 33-fold higher affinity of CITED2 for 
ETV4 IS A BROAD CO-ACTIVATOR OF HIF-SIGNALING 
 
87 
binding to p300 CH1 than a corresponding HIF-1α CAD peptide, indicating that 
CITED2 is a dominant inhibitor of HIF-1α:p300/CBP complex formation27. HIF-1α 
CAD:ETV4 interplay was totally abrogated by CITED2 in mammalian two-hybrid 
experiments (fig. 4D), underscoring the assumption that ETV4 co-activation of HIF-1 
requires functional interaction of the latter with p300/CBP.  
 
While transient knockdown of p300 slightly reduced the intrinsic transactivation 
activity of GH1α786-826 in mammalian two-hybrid experiments, robust 
superinduction of this construct occurred when VP16-ETV4 was co-transfected, 
irrespective of the presence of p300 (fig. 4E). Thus, we assume that both p300 and 
CBP can function as bridging molecules for HIF-1α CAD:ETV4 interplay. Underlining 
the essential requirement of p300/CBP for HIF-1α:ETV4 interaction, normoxic 
transactivation activity of co-transfected GH1α786-826 and VP16-ETV4 was similar 
to hypoxic activation levels in U2OS cells transiently depleted of FIH (fig. 4F). FIH 
has been described previously as oxygen-dependent negative regulator of HIF-
α:p300/CBP interaction7. Chromatin immunoprecipitation (ChIP) experiments using 
either anti-HIF-1α or anti-ETV4 antibodies revealed oxygen-dependent enrichment of 
the HRE-containing PHD2 (EGLN1) promoter region in both precipitations (fig. 4G), 
providing further evidence for co-recruitment of the two transcription factors to the 
endogenous PHD2 locus. 
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Figure 4. Transcriptional cooperation between ETV4 and HIF-1 is disrupted by CITED2.  
(A) Schematic representation of HIF-1α and ETV4 domain structure and fusion constructs used in 
mammalian two-hybrid assays. PAS, PER-ARNT-SIM; bHLH, basic helix-loop-helix domain; ODD, 
oxygen-dependent degradation domain; NRR, negative regulatory region; NAD and CAD, amino- and 
carboxy-terminal activation domains, respectively. A GAL4-DNA binding domain (DBD) was fused to 
regions encompassing the HIF-1α NAD and CAD. Full-length ETV4 bearing two activation domains 
(AD, acidic domain; Ct, carboxy-terminal tail) flanking a central ETS domain was fused to a VP16 
activation domain (VP16-AD). Numbers indicate the amino acids present in the respective constructs. 
(B) U2OS cells were co-transfected with a Gal4-responsive reporter plasmid and Gal4-HIF-1α (GH1α) 
constructs alone or in combination with VP16-ETV4. The GH1α fusion constructs are specified by the 
amino-terminal starting amino acid of the truncated HIF-1α regions (530, 740 and 786, respectively). 
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Following transfection, cells were evenly split and incubated at 20% or 0.2% O2 before luciferase 
activities were determined 24 hours later. Non-interacting Gal4 DBD-p53 and VP16-AD-CP1 served 
as negative control (neg. ctrl.), while the interactions between Gal4 DBD-PHD2 and VP16-AD-HIF-
2α(ODD) or VP16-AD-FKBP38 were used as positive controls (pos. ctrl. 1 and pos. ctrl. 2, 
respectively). (C) Scheme of the potential interactions between HIF-1, p300/CBP and ETV4 as 
assessed by mammalian two-hybrid assays. Both CITED2 and FIH can block the interaction between 
HIF-1α and p300/CBP. (D) Co-transfection of the indicated amounts of a CITED2 expression 
construct together with the mammalian two-hybrid expression vectors followed by hypoxic exposure 
and luciferase activity determination as described for B. (E) Co-transfection of siRNA directed against 
p300 together with the mammalian two-hybrid expression vectors followed by hypoxic exposure and 
luciferase activity determination as described for B. The p300 knockdown efficiency of different siP300 
oligonucleotides was analyzed by immunoblotting (upper panel) and siP300#1 was chosen for further 
experiments. (F) Co-transfection of siRNA directed against FIH together with the mammalian two-
hybrid expression vectors followed by hypoxic exposure and luciferase activity determination as 
described for B. The efficiency of the siFIH mediated FIH knockdown was confirmed by 
immunoblotting as shown in the inset. (G) Chromatin immunoprecipitation (ChIP) of normoxic or 
hypoxic PC3 cells using antibodies directed against HIF-1α or ETV4, or control serum. The amount of 
co-precipitated chromatin derived from the human PHD2 promoter region (encoded by EGLN1) 
containing the HBS was determined by PCR followed by agarose gel electrophoresis. 
 
3.2.6  Both HIF-α isoforms are capable of forming a complex with ETV4 
 
Fluorescence resonance energy transfer (FRET) analyses of co-expressed ETV4 
and HIF-1α marked with cyan or yellow fluorescent protein tags (CFP and YFP, 
respectively) resulted in a robust energy transfer between both factors. Similar FRET 
efficiencies were observed when YFP-labeled HIF-2α was used together with CFP-
ETV4 (fig. 5A and B). The intracellular distance of the two nuclear proteins was 
calculated to be 5.6-5.7 nm and did not differ in oxygenated or hypoxic cells, which 
might be explained by saturation of the HIF-α degradation pathways by exogenous 
overexpression of the transcription factors. Notably, efficient energy transfer between 
HIF-1α and p300 at ambient oxygen tensions has been reported previously28. 
 
ETV4 IS A BROAD CO-ACTIVATOR OF HIF-SIGNALING 
 
90 
 
 
Figure 5. Both HIF-1α and HIF-2α co-localize with ETV4 to the nucleus within molecular 
proximity.  
U2OS cells were transiently transfected with the indicated CFP or YFP plasmids, and FRET analysis 
was performed at 20% O2 or 1% O2 24 - 48 hours post transfection. (A) Microscopic images showing 
the subcellular localization of the exogenous proteins. Fluorescence intensity of FRET signals is 
visualized by false colors on a color bar from low (blue) to high (white) intensity. (B) FRET efficiencies 
for CFP-ETV4 and YFP-HIF-1α (upper panel) or YFP-HIF-2α (lower panel) fusion protein pairs were 
calculated from 20 - 40 randomly selected cells which displayed various fluorescent acceptor/donor 
ratios. Scatter plots were fit to a single-site binding model. FRET efficiencies are given as the 
percentage of transferred energy relative to the energy absorbed by the donor. 
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3.2.7  A broad role for ETV4 in hypoxic gene expression  
 
Recent work reported high ETV4 expression levels in the human prostate cancer cell 
line PC3 that lacks the constitutive photomorphogenic protein COP1 acting as E3 
ubiquitin ligase for a variety of ETS proteins29,30. Since endogenous ETV4 
expression levels in U2OS cells was close to the detection limit, the PC3 cell model 
was chosen to study the involvement of ETV4 in the hypoxic response by applying a 
genome-wide expression array screening. PC3 cells lentivirally infected with shRNA 
expression constructs targeting ETV4 (shETV4) revealed a robust knockdown of 
mRNA and protein levels, while a non-target control shRNA (shNTC) did not affect 
ETV4 expression (fig. 6A and B). ETV4 depleted PC3 cells showed robustly 
reduced mRNA levels of the known ETV4 target gene cyclooxygenase-2 (COX2), 
confirming loss of ETV4 function in these cells (fig. 6B)25,31. Total RNA was isolated 
from PC3 shETV4 and shNTC control cells exposed to 20 or 0.2% oxygen for 24 
hours and samples from three independent experiments were labeled for microarray 
analysis. When compared to normoxic control cells, 977 mRNAs and large intergenic 
non-coding RNAs (lincRNAs) were more than 2-fold downregulated (p<0.05) in 
normoxic PC3 cells lacking ETV4 (fig. 6C; green). Hypoxia alone upregulated 608 
mRNAs/lincRNAs more than 2-fold (p<0.05) (fig. 6C; red). Interestingly, 450 
mRNAs/lincRNAs showed a more than 2-fold reduction (p<0.05) of the hypoxic 
expression levels in cells lacking ETV4 when compared to hypoxic control cells (fig. 
6C; blue) out of which a group of 47 mRNAs/lincRNAs was found to be 
simultaneously hypoxia-inducible. Individual expression levels of these 47 transcripts 
centered on the mean of the three normoxic control samples (PC3 shNTC) are 
depicted in a heatmap in figure 6D. Array data were validated by RT-qPCR of four 
randomly chosen transcripts (fig. 6E). 
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Figure 6. Genome-wide microarray expression analysis reveals a broad role for ETV4 in HIF 
mediated hypoxic gene regulation.  
(A) Efficient knockdown of ETV4 in human PC3 prostate cancer cells. PC3 cells were stably 
transduced with lentiviral shRNA expression vectors encoding either a non-target control (shNTC) or 
shETV4. Following 24 hours of exposure to 20% O2 or 0.2% O2, ETV4, HIF-1α, PHD2 and β-actin 
protein levels were analyzed by immunoblotting. (B) Total RNA was isolated from cultures treated as 
in A and mRNA levels of ETV4 and its target gene COX2 were determined by RT-qPCR. Gene 
expression levels were expressed in relation to ribosomal L28 mRNA (rel. levels) calculated from 3 
independent experiments. (C) Venn diagram showing the number of transcripts regulated by either an 
at least two-fold induction by hypoxia alone (red), an at least two-fold reduction in normoxic cells by 
the knockdown of ETV4 (green), or an at least two-fold reduction in hypoxic cells by the knockdown of 
ETV4 (blue), respectively. (D) Heatmap of the individual expression levels of the 47 transcripts that 
required ETV4 for efficient hypoxic induction. (E) Expression levels of four randomly chosen 
transcripts shown in D were confirmed by RT-qPCR as described for B. 
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3.2.8  HIF target genes divide into two groups, either ETV4 co-activated or 
independent  
 
Because hypoxically upregulated gene sets are highly variable between different 
cellular models, we next focussed on a pre-defined gene set of 61 hypoxia-inducible 
transcripts. This gene set has previously been reported based on established HIF 
target genes32. In line with this publication, the majority of these genes was found to 
be hypoxically upregulated in PC3 shNTC control cells (green dots in fig. 7A, left 
panel). Comparing hypoxic expression levels of the same genes in PC3 shETV4 
knockdown with shNTC control cells, the group of established HIF target genes 
roughly clustered into two halves, representing transcripts which either remained 
unaffected or which did not respond to hypoxia anymore in the absence of ETV4 
(fig. 7A, right panel). Interestingly, following ranking of the HIF target genes 
according to their requirement for ETV4, the HIF-dependent PHD3 oxygen sensor 
(encoded by EGLN3) showed the highest ETV4 sensitivity for hypoxic induction in 
PC3 cells (fig. 7B and C), demonstrating that ETV4 plays a major role in the 
feedback control of mammalian oxygen sensing. However, a number of established 
HIF-responsive genes was only slightly affected (e.g. PAI1, encoded by SERPINE1) 
or completely resistant (e.g. GLUT1, encoded by SLC2A1) to ETV4 depletion (fig. 
7B and C), suggesting that the HIF pathway can be divided into two branches 
according to the requirement for ETV4. 
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Figure 7. Role of ETV4 in the regulation of established HIF target genes in vitro and in vivo.  
(A) Dot plots showing the correlation between transcripts in normoxic vs. hypoxic control cells (left 
panel) or in hypoxic control vs. hypoxic ETV4 knockdown cells (right panel) as derived from the gene 
array data (grey dots). Red dots refer to internal controls and the blue dot shows ETV4 which is 
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downregulated in shETV4 cells. Green dots indicate the positions of a pre-defined set of 61 well-
established HIF target genes. (B) Heat map of the 61 HIF target genes ranked by the magnitude of 
ETV4 requirement for hypoxic induction according to differences in hypoxic expression levels with 
∆hyp = log2(shNTC_hypoxia) - log2(shETV4_hypoxia) and mean hypoxic expression levels centered 
to the mean of normoxic control cells. (C) Exemplary mRNA levels of HIF target genes which either 
require ETV4 for efficient hypoxic induction (PHD3 and CA9) or which remain unaffected by the ETV4 
knockdown (GLUT1 and PAI1). mRNA was quantified as described for Figure 6B. (D, E) Correlation 
between ETV4 and established markers for tissue hypoxia in human breast cancer. (D) Independent 
specimens (spec.) of immunohistochemical evaluation of ETV4 expression in primary mammary 
carcinoma with high (upper panel) or low (lower panel) ETV4 expression levels. (E) Rank-order 
correlations (Spearman's rho) for ETV4 and PHD2 as well as known markers reflecting tissue hypoxia 
(HIF-1α, HIF-2α, PAI1, GLUT1 and CA9) are summarized in a cross table. The number of cases 
where both of the correlated markers could be assessed is displayed in parentheses. Asterisks 
indicate statistical significance with *p<0.05 and **p<0.01.  
 
3.2.9  ETV4 expression levels correlate with HIF-α accumulation in human 
breast cancer  
 
Elevated ETV4 transcript levels have been reported in a variety of human neoplastic 
diseases including breast cancer33. Moreover, the onset of spontaneous mammary 
tumor development has been shown to be profoundly delayed in MMTV-neu 
transgenic mice which express a dominant negative variant of the mouse homologue 
of ETV4, suggesting that ETV4 may possess tumor promoting effects34. We recently 
characterized protein levels of a variety of hypoxic marker genes, including HIF-1α, 
in tumor samples of 282 patients diagnosed with primary breast carcinoma13,35. 
When the same entities were immunostained for ETV4 protein levels, a strong and 
highly significant correlation between ETV4 and PHD2 was observed in samples 
where both factors were assessed (p<0.01, Spearmans’s rho, N=243). Consistent 
with our model of synthetic action of ETV4 and HIF-α, a solid association was also 
observed between these transcription factors and three well described target genes 
(PAI1; GLUT1; CA9) of the HIF pathway. Correlation coefficients between ETV4, 
PHD2 and HIF-1α and HIF-2α were considerably higher than those observed 
amongst both HIF-αs and the three markers for tissue hypoxia (fig. 7D and E), 
demonstrating a putative role for ETV4 in the regulation of PHD2 expression also in 
vivo. 
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3.3  Discussion 
 
Unique responsiveness to altered oxygen environments and broad conservation of 
all components of the PHD/HIF oxygen sensing pathway in multicellular life clearly 
indicate the central role of HIFs as literally hypoxia-inducible transcription factors36. 
Eukaryotic gene expression, however, is a multi-step process requiring the complex 
transcription machinery to interact with promoter DNA and initiate transcription37. Not 
surprisingly, numerous studies have identified other nuclear regulators that 
contribute to the full spectrum of transcriptional changes in response to hypoxia. Yet, 
general patterns of direct interplay amongst HIFs and other transcriptional regulators 
are largely unknown and interactions were often found to rely on specific cell 
models38. Here, we report on a novel screening approach that, in combination with 
overexpression of arrayed transcription factors, aimed for the systematic analysis of 
HBS-specific transcription factor interplay. The core PHD2 promoter was employed 
as a paradigm for HIF-dependent gene regulation, since it embeds a single HBS 
conferring hypoxic activation and because the endogenous locus is ubiquitously 
expressed.  
We identified various members of the activating protein-1 (AP-1) family as novel 
activators of the PHD2 gene, though JUN/FOS have been found to enhance hypoxic 
gene expression previously38. However, to the best of our knowledge our study is the 
first to link ETV4 with HIF-dependent transcription. As shown by the use of different 
reporter genes, ETV4 function as facilitator of HIF-1 transactivation activity is not 
restricted to the PHD2 promoter. While nuclear distances between ETV4 and HIF-
1/2α, as calculated by FRET experiments, support a close interaction, our data favor 
a model where p300/CBP serves as essential bridging molecule between the two 
factors. This conclusion is based on the following features of the interaction between 
ETV4 and HIF-1α: i. oxygen sensitivity in the absence of the oxygen-dependent 
degradation domain; ii. mapping to the C-terminal activation domain; iii. competition 
by CITED2; and iv. requirement of FIH for oxygen sensitivity. Such a ternary 
complex is still in line with the FRET data, as previous findings suggest binding of 
HIF-1α to both CH1 and CH3 domains of p30039. ETV4 is known to interact with 
p300 at its CH3 domain and thus might well get into close or even physical contact to 
HIF-1α40. Interestingly, out of the 371 known interactors of human p300/CBP, 101 
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(27.2%) were present in the synthetic transactivation screen, but only 10 (9.9%) of 
them met the criteria to be considered as reproducible activators of the PHD2 
promoter41. Apparently, there is no simple redundancy amongst the p300/CBP 
interactors to serve as transcriptional co-activators, and the target gene context is 
thought to play an important role in p300/CBP complex formation41. The latter is of 
particular importance, as it provides some reliability regarding the specificity of our 
screening approach, underlining its general applicability. 
 
Based on literature searches, ETV4 and HIF pathways share several common target 
genes, including matrix metalloproteases (MMP) 1, MMP-3, MMP-7, MMP-9, iNOS 
and COX-242–45. Hence, one might speculate that the two factors directly cooperate 
at regulatory elements of these genes, jointly boosting invasive properties of 
malignant cells. Notably, ETV4 and its close relatives ETV1 and ETV5 are frequently 
overexpressed in prostate cancer due to gene fusion with androgen-responsive gene 
loci46. Similarly, loss of the tumor suppressor PTEN causes high normoxic 
expression levels of HIF-1α, a key feature of invasive prostate cancers47. Recent 
studies employing animal models propose a mutational sequence, where early loss 
of PTEN and overactivation of ETS target genes collectively promote prostatic 
cancer progression30,48. Thus, it will be highly interesting to explore a putative 
synthetic HIF-1/ETV4 role in these pathologies. 
 
Due to its high endogenous expression levels in the PC3 prostate cancer cell line, 
gene array analyses in ETV4 wildtype and knockdown PC3 cells were undertaken to 
explore the general role of ETV4 in hypoxic gene regulation. Remarkably, 47 of 608 
hypoxically induced transcripts depend on ETV4 for efficient upregulation. Further 
analysis concentrating on a set of 61 established HIF target genes revealed 14 
genes whose hypoxic induction was at least two-fold higher in the presence of ETV4 
than in its absence. For example, hypoxic induction of carbonic anhydrase 9 (CA9) 
was strongly dependent on the presence of ETV4, as it was largely absent in ETV4 
knockdown cells. This finding further explains the unusually strong hypoxic 
inducibility of CA9 which has previously been attributed to the cooperation between 
HIF and ATF-4, another transcription factor that we found to be involved in oxygen 
signaling49,50. Somewhat unexpected, PHD2 did not fulfill, at least in PC3 cells, our 
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stringency criteria for ETV4-dependent hypoxically induced genes. Individual 
inspection revealed a 2.7-fold hypoxic induction that was only reduced by 16% in the 
absence of ETV4. Low hypoxic inducibility in this cell type was also seen on the 
protein level (fig 6A) and might explain the rather weak response of this gene to 
ETV4 depletion, despite the fact that forced expression of ETV4 strongly induced the 
PHD2 promoter in the U2OS cell model. However, out of the 61 established HIF 
target genes, PHD3 was most sensitive to ETV4 depletion, suggesting that in PC3 
cells PHD3 rather than PHD2 might represent the primary oxygen sensor targeted by 
ETV4. 
 
In vivo, ETV4 has been implicated in kidney branching morphogenesis, 
differentiation of spinal motor neurons and mammary gland development51–54. 
Importantly, ETV1 (ER81), ETV4 (PEA3/E1AF) and ETV5 (ERM) are highly similar 
and constitute the PEA3 sub-family among the ETS-domain family of transcription 
factors55. ETV4 and ETV5 are functionally highly redundant and a double knockout 
was required to reveal the role of ETV4 in kidney development51,52. Thus, we tested 
the ability of these additional sub-family members to induce the PHD2 promoter. 
Whereas ETV1 did not have any effect, ETV4 and ETV5 similarly super-induced the 
hypoxic PHD2 and transferrin promoters in a HBS-dependent manner, suggesting 
functional redundancy of these two sub-family members in hypoxic gene regulation 
(suppl. fig. S1). Since the DNA-binding/ETS domain is highly conserved between all 
three PEA3 sub-family members, we further conclude that the interaction with HIFα 
takes place outside of the ETS domain of ETV4. 
 
Because these developmental processes often occur in tissues with low 
oxygenation, our data point to a role of tissue hypoxia in physiological ETV4/ETV5 
function. Likewise, high expression levels of ETV4 have been linked to metastasis or 
bad prognosis in a variety of human cancers56. These clinical features are well 
known for hypoxic tumors expressing high levels of HIF-157. Supporting our 
screening results, we found a strikingly good correlation between ETV4 and PHD2 
protein levels in breast cancer tissues, in line with a potentially relevant function of 
ETV4 in hypoxic tissues in vivo. 
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In summary, synthetic transactivation screening as exemplarily demonstrated for 
HIF-dependent gene expression proved to be a powerful tool to unravel novel 
interactions amongst common signaling pathways. The general setup of this method 
may be easily adapted to study other transcriptional pathways. A multiplexed single-
well readout system predestines this approach for extensive screening projects, 
including small molecule library analyses and genome-wide gene silencing 
approaches, where inter-well variances are technically difficult to control. 
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3.4  Supplementary Data 
 
Figure S1. Co-activation of HIF-dependent promoters by the ETS-domain PEA3 sub-family 
members ETV1, ETV4 and ETV5.  
(A) Schematic representation of the SV40 promoter driven firefly luciferase reporter gene control 
constructs containing five PEA3 wildtype (left panel) or mutant (right panel) consensus DNA-binding 
motifs. (B) The pGL-5xPEA3wt-SV40 or pGL-5xPEA3mut-SV40 control constructs were co-expressed 
together with HA-tagged ETV1, ETV4 or ETV5 expression constructs and a renilla luciferase control 
vector in U2OS cells. After transfection, cells were incubated for 16 hours under 20% or 0.2% O2 
before luciferase activities were determined. Shown are ratios of firefly to renilla luciferase activities of 
three indpendent experiments performed in triplicates (mean values ± S.D.). All three PEA3-family 
members activate the wildtype but not the mutant PEA3 consensus motif in a largely oxygen-
independent manner. (C) Firefly luciferase expression vectors driven by the PHD2 promoter (pGL-
P2P(-607/+3); upper panel) or the heterologous SV40 promoter containing two HBS from the human 
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Transferrin gene (pGL-TfHRE; lower panel) were co-transfected into U2OS cells together with 
expression constructs for β-galactosidase or HA-tagged ETV1, ETV4 or ETV5, and a renilla luciferase 
control vector. Hypoxic exposure and luciferase determination was as described in B. ETV4 and to a 
somewhat lesser extent ETV5 but not ETV1 superinduced both reporter gene constructs in a HBS-
dependent manner. 
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Table S1A. Candidate factors activating the human PHD2 promoter in a HBS-dependent 
manner.  
The table summarizes all leads derived from the primary synthetic transactivation screening with gene 
products inducing preferentially pGL-P2P(-607/+3)wt. Induction factors for firefly (FF) and renilla (RL) 
luciferase values were expressed relative to the respective plate median. Data represent the mean of 
two independent screening experiments and are ranked according to their ability to activate pGL-
P2P(-607/+3)wt by a factor of at least 1.95. 
 
Symbol 
fold of 
median 
FF 
fold of 
median 
RL 
Accesion 
number 
Description 
     
CRK 4.38 1.66 NM_005206 
v-crk sarcoma virus CT10 oncogene homolog 
(avian), transcript variant I 
ZNF447 3.16 1.71 NM_023926 
zinc finger and SCAN domain containing 18 
(ZSCAN18) 
LHX4 3.15 1.57 NM_033343 LIM homeobox 4 
JMJD2A 2.94 1.35 NM_014663 jumonji domain containing 2A 
TERF2IP 2.58 1.10 NM_018975 
telomeric repeat binding factor 2, interacting 
protein 
SSRP1 2.50 1.18 NM_003146 structure specific recognition protein 1 
PBX2 2.50 1.19 NM_002586 pre-B-cell leukemia homeobox 2 
FOSL2 2.49 1.85 NM_005253 FOS-like antigen 2 
NONO 2.38 1.13 NM_007363 non-POU domain containing, octamer-binding 
ZNF323 2.29 1.11 NM_030899 zinc finger protein 323, transcript variant 1 
FOXM1 2.24 1.57 NM_021953 forkhead box M1, transcript variant 2 
ZNF558 2.23 1.26 NM_144693 zinc finger protein 558 
TFEB 2.21 1.25 NM_007162 transcription factor EB 
SPIC 2.19 1.15 NM_152323 Spi-C transcription factor (Spi-1/PU.1 related) 
FUSIP1 2.15 1.86 NM_006625 
FUS interacting protein (serine/arginine-rich) 1, 
transcript variant 1 
FOS 2.11 1.06 NM_005252 
v-fos FBJ murine osteosarcoma viral oncogene 
homolog 
HIF1A 2.09 1.35 NM_001530 
hypoxia-inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor), transcript 
variant 1 
EHF 2.08 1.07 NM_012153 ets homologous factor 
ZNF398 2.06 1.70 NM_020781 zinc finger protein 398, transcript variant 2 
ETV4 2.05 0.65 NM_001986 
ets variant gene 4 (E1A enhancer binding 
protein, E1AF), transcript variant 1 
SFPQ 2.03 1.21 NM_005066 
splicing factor proline/glutamine-rich 
(polypyrimidine tract binding protein associated) 
MGC41917 2.02 1.33 NM_153231 zinc finger protein 550 
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ZNF200 2.00 0.96 NM_003454 zinc finger protein 200, transcript variant 1 
ZNF282 2.00 1.65 NM_003575 zinc finger protein 282 
NEUROD1 1.99 1.10 NM_002500 neurogenic differentiation 1 
GTF2B 1.99 1.49 NM_001514 general transcription factor IIB 
TBPL1 1.97 1.87 NM_004865 TBP-like 1 
ZNF606 1.96 1.03 NM_025027 zinc finger protein 606 
ZNF43 1.96 1.65 NM_003423 zinc finger protein 43 
GABPA 1.95 1.47 NM_002040 
GA binding protein transcription factor, alpha 
subunit 60kDa  
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Table S1B. Candidate factors activating the human PHD2 promoter in the absence of a 
functional HBS.  
The table summarizes all leads derived from the primary synthetic transactivation screen with gene 
products inducing preferentially pGL-P2P(-607/+3)mut. Induction factors for firefly (FF) and renilla 
(RL) luciferase values were expressed relative to the respective plate median. Data represent the 
mean of two independent screening experiments and are ranked according to their ability to activate 
pGL-P2P(-607/+3)mut. 
 
Symbol 
fold of 
median 
FF 
fold of 
median 
RL 
Accesion 
number 
Description 
     
JUN 2.84 4.06 NM_002228 jun oncogene 
EBF1 3.41 3.71 NM_024007 early B-cell factor 1 
ZNF655 3.70 3.20 NM_138494 zinc finger protein 655, transcript variant 1 
TCEB3 2.19 2.91 NM_003198 
transcription elongation factor B (SIII),  polypeptide 3 
(110kDa, elongin A) 
FOSB 2.89 2.81 NM_006732 
FBJ murine osteosarcoma viral oncogene homolog B, 
transcript variant 1 
TFDP1 3.21 2.76 NM_007111 transcription factor Dp-1 
NR0B2 2.34 2.74 NM_021969 nuclear receptor subfamily 0, group B, member 2 
CEBPB 2.21 2.59 NM_005194 CCAAT/enhancer binding protein (C/EBP), beta 
SF1 2.81 2.39 NM_201998 splicing factor 1, transcript variant 3 
C1orf83 2.19 2.32 NM_153035 chromosome 1 open reading frame 83 
TBX5 2.47 2.10 NM_000192 T-box 5, transcript variant 1 
MORF4L2 2.43 1.99 NM_012286 mortality factor 4 like 2 
ZNF508 2.71 1.96 NM_014913 ADNP homeobox 2 
          
 
 
  
ETV4 IS A BROAD CO-ACTIVATOR OF HIF-SIGNALING 
 
105 
ACKNOWLEDGEMENTS 
We would like to thank N. Sang, L. Poellinger and J.-L. Baert for providing 
expression plasmids; S. Behnke and M. Storz for assistance with TMA analyses; S. 
Hafen-Wirth for the labeling of the microarray samples; and P. Spielmann for general 
technical assistance. 
 
FUNDING 
This work was supported by the Deutsche Forschungsgemeinschaft Grants 
FA225/22 (to U.B.-P. and J.F.) and GRK1431/2 (to J.F.); the Hartmann Müller-
Stiftung (to D.P.S.); the Forschungskredit of the University of Zürich (to D.P.S.); and 
the Swiss National Science Foundation Grant 31003A_129962/1 (to R.H.W. and 
D.P.S.). 
 
Conflict of interest statement. None declared. 
 
ETV4 IS A BROAD CO-ACTIVATOR OF HIF-SIGNALING 
 
106 
3.5  Unpublished supplementary data 
 
 
Figure S2. Role of ETV4 in the regulation of established HIF target genes in vitro.  
(A) A panel of exemplary mRNA levels of HIF target genes which either show tendency to require 
ETV4 for efficient hypoxic induction (VEGF) or which remain unaffected by the ETV4 knockdown 
(NDRG1 etc.). mRNA was quantified as described for Figure 6B. Measured from three independent 
experiments except for PHD1 and VEGF that was measured from two independent experiments. 
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3.6  Materials and methods 
 
Cell culture 
Human HeLa cervix carcinoma and U2OS osteosarcoma cells were grown in 
Dulbecco's modified Eagle's medium (DMEM, Sigma). Human PC3 prostate cancer 
cells were cultured in Roswell Park Memorial Institute medium (RPMI-1640, Sigma). 
Media were supplemented with 10% fetal calf serum (FCS) and antibiotics (penicillin 
50 IU/ml and streptomycin 100 µg/ml; Gibco-BRL). Hypoxic cell culture was carried 
out at 0.2% O2 (if not indicated differently) using a gas-controlled InvivO2 400 
workstation (Ruskinn Technologies). Transfections were performed using 
polyethylenimine (Polysciences) as described before17. 
 
PHD2 promoter constructs 
PHD2 promoter (P2P) constructs containing the wildtype and mutant HBS in the 
pGL3basic luciferase vector (Promega) were generated in earlier work16. Serial 5’-
truncations of P2P and a start codon fusion to the luciferase open reading frame 
(ORF) were employed for both promoter versions using standard cloning techniques. 
Within the scope of the screening approach, the firefly reporter gene of pGL-P2P(-
607/+3) variants was replaced with the renilla luciferase ORF cloned into NcoI and 
XbaI sites. 
 
Transfection and synthetic transactivation screening 
Reverse transfection and screening was carried out by using an arrayed expression 
library containing 704 transcriptionally relevant human full-length cDNAs from the 
Origene collection (FTCW 19603, GFC-Transfection Array in a 96-well format)58. An 
annotated list of all genes covered by this array is provided online by the 
manufacturer. Dried DNA (100 ng) of a distinct expression construct spotted per well 
was reconstituted at room temperature with 20 µl of serum-free medium containing a 
mixture of pGL-P2P(-607/+3) HBSwt firefly and pGL-P2P(-607/+3) HBSmut renilla 
reporter plasmids (100 ng DNA/each). Subsequently, 20 µl of diluted TransIT-LT1 
transfection reagent (3:1, µg DNA/ µl TransIT-LT1; Mirus Bio LLC) were added and 
complex formation was allowed for 30 minutes at room temperature before 60 µl of a 
cell suspension containing 1x104 U2OS cells in DMEM supplemented with 10% FCS 
ETV4 IS A BROAD CO-ACTIVATOR OF HIF-SIGNALING 
 
108 
were plated in each well. Plates were incubated at 20% O2 for 24 hours before being 
subjected to the screening conditions of 0.2% O2 for an additional 24 hours. Cultures 
were lysed in 20 µl of passive lysis buffer (Promega) and luminescence was 
immediately analyzed with a microplate luminometer (Berthold) using a standard 
dual luciferase reporter assay system (Promega). Luciferase activities were 
normalized to the median calculated individually for each plate and luminescence 
source and expressed as induction factors (IF) according to ( ) with Ni = 
individual luciferase activity value of each well of plate i and mediani = median of 
luciferase activities of all 96-wells on plate i. To compare the distribution of replicate 
assays a standard z-score evaluation was performed following ( ) with  
= plate mean of respective luminescence values and σi = S.D. of plate mean of 
luminescence values. 
 
Reporter gene assays and mammalian two-hybrid analyses 
Construction of pGLTfHRE wt and pGLTfHRE mut reporter plasmids carrying a 
hypoxia-responsive enhancer element derived from the human Transferrin gene was 
described previously21. Transfections for standard reporter gene experiments were 
carried out on 100 mm culture plates essentially as described earlier17. In brief, 
U2OS cells were co-transfected with 3 µg reporter plasmid or a mix of 1.5 µg 
reporter and 1.5 µg expression plasmids, respectively. Transfection efficiency was 
controlled by co-transfection of 20 ng pRLSV40 renilla luciferase reporter vector 
(Promega). RNA-interference (RNAi) mediated knockdown of HIF-1α, FIH-1 or p300 
was achieved by transiently transfecting once (HIF-1α, p300) or twice (FIH-1) U2OS 
cells with 100 nM stealth RNAi duplexes (HIF-1α, 5'-caggacaguacaggaugcuugccaa-
3'; FIH-1, 5'-gaaacauugagaagaugcuuggaga-3'; p300, 5'-
ggauucgucugugauggcuguuuaa-3'; control, 5'-gcuccggagaacuaccagaguauua-3'; 
sense strands) using Lipofectamine 2000 according to the manufacturer's 
instructions (Invitrogen). Combined knockdown and reporter gene analyses were 
performed by sequentially transfecting cells with stealth RNAi duplexes 24 hours 
before subjecting them to PEI-mediated DNA transfection. 
i
i
median
N
IF =
i
iiNZ
σ
)( X−
= iX
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Mammalian two-hybrid analyses were performed using the mammalian Matchmaker 
system (Clontech) as described previously14. Expression vectors of HIF-1α NAD and 
CAD fused to Gal4 DBD were a kind gift of Dr. Sang (Drexel University, Philadelphia, 
U.S.A.)22. U2OS cells were transiently co-transfected with 1.5 µg of Gal4 DBD and 
1.5 µg of VP16 AD fusion protein vectors together with 500 ng of firefly luciferase 
reporter vector pGRE5xE1b and 20 ng of pRL-SV40. Total transfected DNA amounts 
were equalized in each experiment using the corresponding empty vector. Luciferase 
reporter gene activities were determined using the dual-luciferase reporter assay 
system (Promega). 
 
Fluorescence resonance energy transfer (FRET) 
The full length ORF of human ETV4 was cloned into pENTR4 and subsequently 
recombined with pECFP-C1-DEST to obtain the expression vector for a cyan 
fluorescent ETV4 fusion protein15. U2OS cells were transiently transfected with the 
pECFP-ETV4 and pEYFP-HIF1 or pEYFP-HIF2 plasmids as recently described59. 
FRET was monitored under normoxic or hypoxic conditions (1% O2 for 4 hours) 24-
48 hours post-transfection.  
 
Protein extraction and immunoblot analysis 
Cells were washed twice and scraped into ice-cold phosphate-buffered saline. 
Soluble cellular protein was extracted with a high salt extraction buffer containing 0.4 
M NaCl, 0.1% Nonidet P-40, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM 
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 1× protease inhibitor cocktail 
(Sigma). Protein concentrations were determined by the Bradford method and 50-80 
µg of cellular protein were subjected to immunoblot analysis using the following 
antibodies: mouse monoclonal antibody (mAb) anti-human HIF-1α (clone 54/HIF-1α; 
BD Transduction Laboratories), mAb anti-ETV4 (PEA3(16); Santa Cruz 
Biotechnology) and rabbit anti-ETV4 (sdix20580002; Novus Biologicals), rabbit anti-
human PHD2 (NB100-137; Novus Biologicals), mAb anti-FIH-1 (NBP1-30333; Novus 
Biologicals), mAb anti-p300 (554215; BD Pharmingen), and mAb anti-β-actin (clone 
AC-74; Sigma). Primary antibodies were detected with respective polyclonal anti-
mouse or anti-rabbit sera conjugated to horseradish peroxidase (HRP; Pierce). 
Chemiluminescence signals were developed using Supersignal West Dura substrate 
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(Pierce) and images were acquired with a digital light imaging system (LAS 4000; 
Fuji). 
 
mRNA quantification 
Complementary DNA was generated by reverse transcription (RT) of 1-5 µg of total 
RNA using AffinityScript reverse transcriptase (Agilent). Transcript levels were 
determined by real-time quantitative (q) PCR using a SybrGreen qPCR reagent kit 
(Sigma) in combination with the MX3000P light cycler (Agilent). All RT-qPCR data 
are presented as ratios relative to ribosomal protein L28 mRNA values. Primer sets 
for human PHD2, CA9 and L28 have been described earlier17,60. 
 
Tissue microarray analysis 
Clinico-pathological characterization and immunohistochemical analyses of selected 
components of the HIF-pathway utilizing a tissue microarray (TMA) consisting of 282 
invasive breast cancer cases diagnosed at the Institute of Surgical Pathology 
(University Hospital, Zürich, Switzerland) have been described recently13. Sections of 
the same TMA were stained with a rabbit polyclonal anti-ETV4 antibody 
(HPA005768, Sigma) in a 1:100 dilution using an automated immunohistochemistry 
platform (Ventana BenchMark, Roche). An immunoreactive score (IRS) for ETV4 
staining was calculated by multiplication of staining intensity (graded between 0 and 
3) and the percentage of positive cells (graded between 0 and 4 with 0, nil; 1, <10%; 
2, 10-50%; 3, 51-80%; 4, >80%) as quantified by a senior pathologist (G.K.). 
Nonparametric correlations between ETV4 expression and HIF-1/2α or HIF target 
genes were analyzed by calculating Spearman's rank correlation coefficient using 
PASW (IBM SPSS Statistics 18) software. 
 
shRNA constructs and lentiviral infections 
Expression vectors encoding shRNA sequences targeting human ETV4 and a non-
coding control driven by the U6 promoter in a pLKO.1-puro plasmid were purchased 
from Sigma. Viral particles were produced in HEK293T cells using the ViraPower 
lentiviral expression system according to the manufacturer's instructions (Invitrogen). 
Infected PC3 cells were cultured in RPMI-1640 supplemented with 0.5 µg/ml 
puromycin. 
ETV4 IS A BROAD CO-ACTIVATOR OF HIF-SIGNALING 
 
111 
Chromatin immunoprecipitation (ChIP)  
ChIP assays from parental PC3 cells exposed to 20% or 0.2% O2 for 4 and 24 hours 
were performed essentially as described previously35. The following antibodies were 
used for immunoprecipitation: rabbit anti-HIF-1α (ab2185; Abcam), and rabbit anti-
ETV4 (sdix20580002; Novus Biologicals). Rabbit serum (011-000-001; Jackson 
ImmunoResearch) served as unspecific control. Enrichment of PHD2 promoter 
chromatin was determined by PCR using the following oligonucleotides: PHD2 
forward 5'-gtatgccctgcgctcctc-3', reverse 5'-gctgagagaatagggcctgtg-3'. 
 
Gene array analysis  
Total RNA was extracted from pools of shRNA expressing PC3 clones with RNeasy 
(Qiagen). RNA integrity was evaluated using the Agilent 2100 Bioanalyzer. Genome-
wide RNA levels were quantified using the human gene expression ShurePrint GE3 
(8×60K) microarray according to the manufacturer's instructions (Agilent). All data 
were deposited in NCBI's Gene Expression Omnibus (GEO) and are publicly 
accessible through GEO accession number GSE32385 
(http://www.ncbi.nlm.nih.gov/geo/). 
 
Statistical analysis 
If not otherwise indicated, results are presented as mean values ± standard error of 
the mean (S.E.M.) of at least three independent experiments. Column statistics 
applying paired Student's t-tests were calculated using GraphPad Prism version 4.0 
(GraphPad Software).  
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4  The ETS-transcription factor ETV4 is oxygen regulated and 
 interacts indirectly with PHD2 
 
 Kristin Wollenick, Jun Hu, Utta Berchner-Pfannschmidt, Joachim Fandrey, 
 Roland H. Wenger and Daniel P. Stiehl 
 
 
ABSTRACT 
Oxygen homeostasis is a key mechanisms in cells and tissue that when disturbed 
eventually leads to the activation of the transcription factor family hypoxia inducible 
factors (HIF) which orchestrates the hypoxic response of the tissue by initiation of 
angiogenesis and erythropoiesis supporting gene products. The stability of HIF is 
oxygen-dependently regulated through HIF-prolyl-4-hydroxylase domain proteins 
(PHD). Since the two PHD genes, PHD2 and PHD3 are also inducible by HIF, a 
negative feedback loop is established. The ETS-transcription factor ETS 
translocation variant 4 (ETV4) was recently found to interact with HIFs to promote 
PHD2 transcription in hypoxia. Here we show that increased ETV4 levels positively 
correlate with PHD2 mRNA levels in various cancer cell lines. Furthermore, ETV4 
potentially increase the hypoxic activation of promoters that contain a distinct 
sequence architecture surrounding the HIF-binding site (HBS). Hence, next to PHD2 
promoter activity other promoters such as CA9 are shown to have an increased 
activity in the presence of ETV4. Additionally, ETV4 protein is more abundant in 
hypoxia, in PHD2 knockdown cells, and in cells treated with a PHD-inhibitor. 
Mammalian-2-hybrid experiments suggest a possible interaction between ETV4 and 
PHD2.  
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4.1  Introduction 
 
Recently, we reported a new level of interplay between the ETS- and HIF-pathways 
in cellular adaptation to low oxygen environments1. A member of the large ETS-
transcription factor family, ETS variant 4 (ETV4, also known as PEA3 or E1AF), was 
found to contribute to hypoxic PHD2 gene expression1. ETV4 was demonstrated to 
affect not only PHD2 expression, but also the transferrin regulatory region in an HIF-
DNA-binding site dependent manner. Similarly, we observed an increase in hypoxic 
PHD2 promoter activity with the overexpression of the structurally similar family 
members ETV5, but not ETV1. Further, we showed that CAIX and PHD3 expression 
are highly ETV4-dependent, too. The question remains why certain hypoxia-induced 
genes are super-induced by ETV4 whereas others remain unaffected. It is widely 
accepted that the HBS adjacent regions are of high importance for the full functional 
power of HIF2,3. This was equally shown to be true for the HBS located in the PHD2 
promoter (cf. 2.2.3 et seqq.). The consensus binding sequence of the ETV4 family 
members was defined as 5'-A/CGGAAGT-3' and is located in different promoters of 
pro-metastatic matrix metalloproteases (MMPs), like MMP-1 and MMP-9 as well as 
human stromelysin-1, matrilysin, collagenases type I and IV, leading to tissue 
rearrangement - a common event in metastatic processes4–11. A link between ETS-
transcription factors and the HIF-pathway was described previously1,12–14. In line with 
the observation promoter analysis revealed putative ETS binding sites in HIF-2α 
dependent genes that were located in 90% of the cases even in proximity to the 
putative HREs15. However, the specific common binding motif of the ETV4 family 
members is not found in the neighboring sequence of the PHD2 HBS. ETV4, ETV5 
and ETV1 have been shown to be involved in the development of branching tissue as 
well as the migration and invasion of various cancers16–22. The ETVs are degraded 
via the ubiquitin-proteasomal pathway. When the degradation pathway is disturbed 
an accumulation of ETVs leads to the expression of gene products (MMPs etc.) that 
support the invasive features of cancer cells, i.e. prostate cancer23–25. For example, 
recent reports showed that deficiency in constitutive photomorphogenesis protein 1 
homolog (COP1), an E3-ubiquitin ligase, results in the accumulation of ETVs and 
produces increased cell proliferation, hyperplasia, and early prostate intraepithelial 
neoplasia being a pre-stage of prostate adenocarcinomas23,24. 
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We aimed for the investigation of the interaction between HIF and ETV4 signalling. 
We report that ETV4 is intimately involved in the HIF-pathway by a positive regulation 
in hypoxia. Here, we hypothesize an interaction with PHD2. The data suggests that 
the transcription factor ETV4 is similar in hypoxic activation and stability to the HIF-α 
subunits and needs to be further analyzed to understand its role in hypoxia-mediated 
transcription.  
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4.2  Results 
4.2.1  High ETV4 mRNA levels correlate with high PHD2 mRNA levels in 
various cancer cell lines 
 
The ETS-transcription factor ETV4 was recently shown to enhance PHD2 promoter 
activity by co-activation of the hypoxia inducible factors (HIFs), suggesting that the 
oncogene ETV4 plays a role in solid tumor progression of hypoxic cancers1. We 
hence tested a range of different human cancer cell lines reported to express ETV4, 
such as human fibrosarcoma (HT1080), osteosarcoma (U2OS), hepatocellular liver 
carcinoma (HepG2), colorectal cancer (HCT116) and breast cancer (MDA-MB-231), 
for their ETV4 and PHD2 mRNA levels in normoxic and hypoxic conditions. As 
reported previously, ETV4 mRNA levels remain unchanged following hypoxic 
treatment of the cells, whereas PHD2 levels are induced in hypoxia. In line with the 
observation that ETV4 is super-inducing the PHD2 promoter, PHD2 mRNA levels are 
highest in cell lines that most strongly express ETV4 (HepG2 and U2OS) (fig. 1). This 
suggests that ETV4 and PHD2 expression levels positively correlate in various 
cancer types and that ETV4 expression might influence the hypoxic phenotype of a 
cancer. 
 
.  
Figure 1. ETV4 and PHD2 mRNA levels positively correlate with each other in various human 
cancer cell lines.  
The indicated human cancer cell lines reported to express ETV4 were tested for their ETV4 and PHD2 
mRNA levels in normoxic (24 h) and hypoxic conditions. Total RNA was extracted 8 h and 24 h 
respectively after hypoxic incubation and mRNA levels of ETV4, PHD2 and L28 were quantified by 
reverse transcription qPCR.  
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4.2.2  The transcription factor ETV4 shows strong, hypoxically inducible 
activation of those HBSs that are structurally similar in 5’- and 3’- architecture 
 
ETV4 not only superinduces the activity of the PHD2 promoter, but also of the 
transferrin promoter in a HIF-dependent manner1. Therefore, we compared 107 
known HIF target genes, all of them sharing the consensus sequence 5’-RCGTG-3’, 
for similarities in the 5’- and 3’- sequences surrounding the HBS (fig. 2A). 
Interestingly, the 5’- and 3’- area of the PHD2 promoter HBS seems to be similar to 
the transferrin promoter, indicating a structural relationship needed for an ETV4-HIF 
cooperation to increase the activity of the HBS. This conservation - especially of the 
5’-region - was found in several further HBSs. We therefore transfected the 
corresponding reporter gene constructs together with ETV4. ETV4 mostly enhanced 
the reporter activity, when a structural similarity of the 5’-region existed, such as the 
HBS of carbonic anhydrase IX (CA9) (fig. 2B). This finding is in line with our previous 
report where we could demonstrate a strong ETV4-dependency of the CA9 locus1. 
When the HBS-flanking regions were different, e.g. in the lysyl oxidase (LOX) and 
erythropoietin (EPO) HBSs, no superinduction was achieved. Thus, the specificity of 
those target genes that are superinduced through the collaboration of ETV4 and HIF 
might be determined by the expanded consensus sequence 5’- GTGTACGTGCA-3’. 
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Figure 2. ETV4 enhances the transcriptional activity of HBS that show a similar PHD2 HBS 
surrounding architecture.  
(A) The upper panel shows an overview of HBSs of 107 validated HIF-1α target genes that were 
examined for the commonly occurring motif 5’-RCGTG-3’ using the Gibbs Motif Sampler of 
CisGenome. The lower panel represents only sequences similar to the HBS in the PHD2 promoter 
region. Therefore, the other HBS-regions were compared to the PHD2 HBS which served as a 
standard template. The height of each letter is proportionate to its occurrence frequency, with the most 
frequent at the top. The height of each stack is then normalized to reflect the information content of the 
sequence at the respective position (measured in bits). Interestingly, the 5’-region and to the same 
extent the 3’-region surrounding the HBS seem to be conserved, too, extending the consensus 
sequence to 5’-GTGTRCGTGCA-3’. A selection of HBS motifs is shown on the upper right panel 
highlighting those positions of nucleotides that are conserved. (B) Luciferase reporter gene assay of 4 
different HBS-containing regions: C-X-C chemokine receptor type 4 (CXCR4), lysyl oxidase (LOX), 
carbonic anhydrase 9 (CA9), erythropoietin (EPO) and their empty vector controls. Following co-
transfection without (left) or with (right) ETV4 expression constructs in U2OS cells, for 24 h cells were 
incubated overnight under 20% O2 (normoxia) or 0.2% O2 (hypoxia). ETV4 could enhance the reporter 
activity of the CA9 promoter, but none of the other promoters, suggesting that ETV4 specifically 
superinduces transcriptional activity of certain HBSs similar to the PHD2 promoter. Bars represent 
means ± S.E.M. of 3 independent experiments. 
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4.2.3  Stable knock down of ETV4 in U2OS cells does not affect hypoxia-
induced HIF target genes 
 
In order to analyze the effects of ETV4-depletion in U2OS cells we established a 
stable shRNA-mediated ETV4-knockdown pool (fig. 3A). By testing several target 
genes that were reported in literature to be dependent on ETV4 expression 
(cyclooxygenase2 (COX2)26,27, MMPs (MMP-2)5,6, osteopontin (OPN)28, plasminogen 
activator-urokinase (PLAU)29,30 or hypoxia-induced (PHD231, PHD332, vascular 
endothelial growth factor a33 (VEGFa)) we aimed at elucidating if ETV4 silencing also 
affects the hypoxic response. Some of these genes have been reported to be both, 
ETV4 target genes and simultaneously involved in the cellular response to hypoxia 
such as COX230,34 and VEGF35,33,36. ETV4 target genes like COX2, MMP-2, OPN and 
PLAU were downregulated in these cells, whereas other genes remained unaffected. 
However, some genes such as PHD2 as well as other proven hypoxia-induced target 
genes (i.e. PHD3, VEGFa, transferrin receptor) did not reveal any ETV4-dependency, 
although genome-wide microarray data from PC3 cells suggested so1.  
U2OS cells stably knocked down for ETV4 were transfected with the PHD2 promoter 
region (P2P (-607/+3)) and exposed to hypoxia. The knockdown of ETV4 did not 
differ from wildtype cells with respect to hypoxic inducibility of the reporter construct 
(fig. 3B). A possible explanation for this unexpected finding is that ETV4 is most 
probably not sufficiently expressed in U2OS cells since ETV4 protein levels were 
close to their detection limit. Given that ETV4 is an oncogene driving tumor 
development when overexpressed, the knockdown in a cell line that does not 
express high levels of this protein appears to be the wrong approach. Therefore, 
ETV4 silencing should be applied rather in a cancer cell line that naturally expresses 
more ETV4.  
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Figure 3. Role of ETV4 in the regulation of established ETV4 and HIF target genes in vitro.  
(A) In a stable pool of ETV4-knockdown U2OS cells, mRNA levels of a panel of in literature primarily 
reported HIF- (yellow background; PHD237, PHD332, VEGFa38, TFRC39, NDRG140, BNIP341, 
RTP80142, CXCR443, DITT3, COX234) and ETV4-dependent (pink background; Her244, PLAU30, 
PLAUR45, OPN28, MMP2 and MMP946, IL847) target genes which either show tendency to require 
ETV4 for efficient induction (COX2, RTP801) or that remain unaffected by the ETV4 knock-down 
(NDRG1 etc.) were mRNA was quantified by RT-qPCR. Measured from three independent 
experiments except for Cox-2, MMP-2, MMP-9, OPN, CXCR4 and PHD2 that were determined from a 
single experiment. (B) Stable shETV4 knockdown U2OS clones were transiently transfected with the 
PHD2 promoter driven reporter gene plasmid pGL3 P2P(-607/+3) in its HBS wildtype or mutant form. 
24 h after transfection, cells were incubated overnight under 20% O2 (normoxia) or 0.2% O2 (hypoxia). 
Mutation of the HBS leads to the abrogation of hypoxic inducibility. Bars represent means ± S.E.M. for 
3 independent experiments. 
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4.2.4  ETV4 protein is increased in hypoxia 
 
Since ETV4 overexpression was demonstrated to induce PHD2 expression levels in 
hypoxia1, we examined if a transient silencing rather than a stable ETV4-
downregulation in U2OS cells would affect PHD2 expression (cf. 4.2.3). Therefore, 
we carried out a transient siRNA-mediated knockdown of ETV4. We expected to 
decrease hypoxia-induced PHD2 expression since ETV4 as a HIF co-activator is 
missing. As observed for the stable ETV4 knockdown, the transient silencing equally 
did not change PHD2 mRNA or protein expression levels in U2OS cells underlining 
the importance of an adequate cell model with sufficient ETV4 expression (fig. 4A 
and B). While ETV4 mRNA levels remained unaffected by hypoxia (fig. 4A), 
excluding ETV4 as HIF target gene, ETV4 protein levels significantly increased (fig. 
4B, quantification). This observation suggests that hypoxia regulates ETV4 protein. 
The negative feedback loop of HIF-α and PHD2/PHD3 is most prominent and 
balances the cellular hypoxic response. When this negative regulation process is 
disturbed by a silencing of the main cellular oxygen sensor PHD2, HIF-α subunits 
accumulate in normoxia. As ETV4 protein levels seem to be similarly regulated by 
hypoxia as HIF-α subunits we performed a transient PHD2 knockdown. Interestingly, 
a transient silencing of PHD2 resulted in increased ETV4 protein levels in normoxic 
conditions similar to HIF-1α (fig. 4B). This could hint to a hydroxylation-dependent 
regulation of ETV4 through PHDs that is inhibited when the O2-concentration is low 
or when PHDs are silenced. 
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Figure 4. ETV4 protein is increased in hypoxia and shows high levels in normoxic conditions 
when PHD2 is knocked-down.  
(A and B) Transient knockdown by siRNA of ETV4 or PHD2, respectively. U2OS cells were cultured 
under normoxic (20% O2) or hypoxic (0.2% O2) conditions for 8 h. (A) Total RNA was extracted after 8 
h of normoxic or hypoxic incubation, and mRNA levels of ETV4, PHD2 and ribosomal protein L28 were 
quantified by RT-qPCR. (B) Cellular proteins were extracted and endogenous ETV4, PHD2, HIF-1α, 
CAIX and β-actin levels were analyzed by immunoblotting. The lower graph represents the 
immunoblot quantification of ETV4 of 4 independent experiments. P-values were obtained by unpaired 
Student t-tests (*P<0.05, ***P<0.001). 
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4.2.5  ETV4 shows rapid protein accumulation when treated with DMOG or with 
proteasomal inhibition by MG132 
 
In order to confirm a possible hydroxylation-dependent regulation of ETV4 we applied 
in a time dependent manner the PHD-inhibitor dimethyloxalylglycine (DMOG) to 
U2OS cells and analyzed ETV4 protein levels. We could demonstrate that like 
hypoxia, the PHD inhibitor DMOG also induced ETV4 protein levels in U2OS cells 
(fig. 5A). ETV4 protein levels peaked already after one hour, whereas HIF-1α 
induction started only after 2 hours of treatment. As a conclusion the observed ETV4 
protein accumulation in hypoxia is not HIF-dependent since ETV4 predates HIF-1α 
stabilization.  
Furthermore, both ETV4 and HIF were induced by proteasomal inhibitor MG132 (fig. 
5B). Interestingly, also here ETV4 induction preceded HIF-1α induction. ETV4 and 
HIF-1α accumulated after 30 min and 4 hours, respectively. Consequently, this result 
hints at a shorter half-life of the ETV4 protein as compared to HIF-1α. 
 
 
 
Figure 5. ETV4 shows rapid protein accumulation when U2OS cells were treated with the PHD-
inhibitor DMOG or proteasomal inhibition by MG132.  
(A and B) Immunoblot detection of ETV4, PHD2, HIF-1α and β-actin. U2OS cells were incubated for 
the indicated time in the presence of solvent control, 2 mM DMOG (A) or 5 µM MG132 (B).  
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4.2.6  Interaction of ETV4 with PHD2 under hypoxic conditions? 
 
To assess the possible interaction between ETV4 and PHD2, we carried out 
fluorescence resonance energy transfer (FRET) analysis as well as mammalian-2-
hybrid assays. The FRET data showed no interaction between ETV4 and PHD2 
under normoxic conditions (fig. 6A and B). This finding could be supported in the 
mammalian-2-hybrid approach, where the two proteins are coupled either to a VP-16 
activation domain (AD) or to a GAL-4 DNA-binding domain (DBD), respectively. If the 
two proteins interacted, they would activate the GAL4 response element-driven firefly 
luciferase reporter construct. However, under hypoxic conditions a weak interaction 
could be detected between PHD2 and ETV4 in a HIF-1α dependent manner (fig. 6C 
and D).  
A possible explanation could be that ETV4 is a hydroxylation target of PHD2. 
Sequence analysis of the ETV4 revealed a large number of proline residues that 
could potentially be hydroxylated by PHDs. However, the known HIF-1α 
hydroxylation sequence site LxxLAP was not found in the ETV4 protein, but two 
close, although not proven to be functional sites - LxxLxAP- were found in the C-
terminal end of the ETV4 protein (fig. 6E). 
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Figure 6. ETV4 does not interact in normoxia with PHD2 in FRET analysis. ETV4-PHD2 
interaction is regulated by oxygen.  
(A) U2OS cells were transiently transfected with the indicated CFP or YFP plasmids, and FRET 
analysis was performed at 20% O2 or 1% O2 24 h post transfection. FRET efficiencies for CFP-ETV4 
and YFP-PHD2 fusion protein pairs were calculated from 20 - 40 randomly selected cells which 
displayed various fluorescent acceptor/donor ratios. Scatter plots were fit to a single-site binding 
model. FRET efficiencies are given as the percentage of transferred energy relative to the energy 
absorbed by the donor. The FRET signal (red dots) is below the negative control curve of none-
interacting proteins (blue). (B) Microscopic images showing the subcellular localization of the 
exogenous proteins. Inlay shows single cell expression of pECFP-Dest-C1-ETV4 and pEYFP-Dest-
C1-PHD2. (C and D) Transient knockdown U2OS cells were generated for non target control (C) or 
HIF-1α (D) via siRNA. Subsequently, those cells were transiently transfected with GAL4-DBD and 
VP16-AD fusion protein vectors and a GAL4-response element-driven firefly luciferase reporter gene, 
as well as a renilla luciferase control vector. The interaction between AD-HIF2α ODD and DBD-PHD2 
was used as positive control and AD-CP1 / DBD-p53 functioned as negative control. Following 
transfection, the cells were incubated under normoxic (20% O2) or hypoxic (0.2% O2) conditions, and 
luciferase reporter gene activities were determined 24 h later. Firefly / renilla luciferase activity ratios 
were normalized to the normoxic positive control DBD-PHD2 /HIF-2α ODD-AD co-transfection, which 
was arbitrarily defined as 1. (Inlay) To confirm siRNA-efficiency HIF-1α and β-actin levels were 
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analyzed by immunoblotting. (E) The ETV4 protein sequence contains a multitude of proline residues 
(bold red). The prolyl-hydroxylation consensus sequence site LxxLAP found in the HIF-1α subunit is 
not incorporated in the ETV4 protein sequence. However, two putative sequences, although not 
absolutely identical to those motifs described in HIF-1α, are found in the C-terminus of the protein 
(LxxLAxP; underscored).  
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4.3  Discussion 
 
In this study, we compared the ETV4-transcription factor pathway with the hypoxic 
PHDs-HIF-1α pathways in human cancer cells, such as U2OS, PC3 and HepG2. 
Hypoxia is known to regulate the stability and activity of the HIF-α subunits and thus 
target gene expression. Our data propose that the mRNA levels of ETV4 and PHD2 
positively correlate in various cancer cell lines suggesting that the degree of ETV4 
expression might have an influence on the hypoxic phenotype and malignantly on a 
cancer. However, for a broader and statistically relevant correlation it would be of 
interest to enlarge this analysis by including a bigger range of cancer cell lines and 
primary cells. ETV4 family members share a high degree of sequence similarity. The 
ETS-domain, responsible for the DNA-interaction shares 95% of similarity and the 
transactivation domains still roughly 85%. Recently, we have reported that ETV4 is 
able to increase the transcriptional activity of the PHD2 promoter as well as of a 
transferrin reporter construct in a HBS-dependent manner1. Although we showed that 
ETV5 is also capable to compensate for ETV4 action, ETV4 has more physiological 
relevance since in various tissues it is more widely expressed than ETV5. Functional 
redundancy might explain why neither transient RNAi-mediated nor lentiviral-
mediated stable knockdown of ETV4 affected PHD2 expression levels or PHD2 
promoter activity in U2OS cells. However, most probably the osteosarcoma cell line 
U2OS is a mediocre cell model for investigating the effects of PHD2 expression, 
since ETV4 mRNA and protein expression levels are not sufficiently abundant in 
those cells.  
 
In this study, we report that the reason of an ETV4-mediated super-induction of 
specific hypoxia-induced target genes maybe lie in the common architecture of the 5’- 
and 3’-regions adjacent to the HBS. This structure seems to be required for the 
increased trans-activation by ETV4. This hypothesis is underlined by the observation 
that the carbonic anhydrase 9 (CA9) promoter - that is similar to the PHD2 HBS 
region - also was showing a super-induction under hypoxic conditions in the 
presence of ETV4. In contrast, when the HBS-flanking region is dissimilar to the 
PHD2 HBS, the super-induction does not take place. This observation would argue 
for the synergistic interplay between ETV4 and HIF when distinct sequence 
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architectures are given. A highly informative and unbiased approach to support this 
hypothesis would be the genome-wide measurements of protein-DNA interaction by 
chromatin immunoprecipitation (ChIP) followed by quantitative measurements and 
high-throughput sequencing of the transcriptome. These combined techniques could 
be used to determine the common features of hypoxia-induced and ETV4-dependent 
target genes. However, the interaction of the ETS-DNA-binding domain with the DNA 
appears rather unlikely in this combination, since despite the strong conservation of 
ETV4 family members in their DNA-binding domain (5% of dissimilarity), ETV1 did 
not super-induce the PHD2 or transferrin promoter. Additionally, the characteristic 
consensus sequence 5'-A/CGGAAGT-3' is not found in HBS-adjacent regions. We 
therefore propose a model in which ETV4/5 adopt a particular conformation by 
binding to p300/CBP and HIF. This conformation supports the interaction of other 
ETV4/5 domains (absent or different in the ETV1 protein) to interact with the HBS-
adjacent DNA-regions to super-induce specific hypoxia-induced target genes.  
 
DNA binding and co-activatory features of ETV4 in hypoxic gene expression might be 
additionally linked to the finding that ETV4 is regulated in U2OS cells by hypoxia. 
This would lead to the discovery of a new oxygen-dependent transcription factor and 
implies physiological importance of the hypoxic super-induction of distinct genes in 
special cell types. Strikingly, ETV4, as well as HIF-1α shows an accumulation of 
protein under hypoxia, through the treatment with the PHD-inhibitor DMOG or 
proteasomal inhibition by MG13248. The very high turnover of ETV4 could speak for 
the high transcriptional power of ETV4 and the importance to eliminate this (co-) 
transcription factor from the cell when not needed. Similarly the HIF-α subunits are 
strictly regulated and lead, when unregulated, to cancer development. PHDs regulate 
the stability of HIF-α subunits through the hydroxylation of distinct proline residues49–
53
. The ETV4 subfamily, similar to HIF-1α, also undergoes posttranslational 
modification as phosphorylation or sumoylation and might also include 
hydroxylation23,25,54–67. An indication could be the multiple bands of ETV4 in SDS-
PAGEs. Additionally, PHDs were reported to hydroxylate other proteins68. We 
suggest that the hypoxic regulation takes place on a posttranslational level possibly 
through the prolyl hydroxylation of ETV4 by PHDs. This is evidenced by the 
accumulation of ETV4 under hypoxia, through the treatment with the PHD-inhibitor 
DMOG or the transient silencing of PHD2, although regulatory mechanisms based on 
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translational levels still need to be examined. It is conceivable that, as the HIF-α 
subunit is no longer ubiquitinylated by the von-Hippel-Lindau ubiquitin ligase, COP1 
is no longer able to mark ETVs under hypoxia for degradation. No hypoxic regulation 
of ETV4 is observed In PC3 cells1. Generally, PC3 cells express high levels of ETVs 
due to the deficiency in the E3-ubiquitin ligase COP1 that leads to constant ETV 
accumulation. We suggest that in COP1-expressing cells the hydroxylation of ETV4 
prolyl residues by PHDs inhibit the interaction between Cop1 and ETV4. As a result 
this leads to an accumulation of ETV4 protein. In PC3 cells the degradation process 
is impaired and it triggers an oxygen-independent accumulation of ETV4. Especially 
the increased normoxic ETV4 protein levels in PHD2 silenced cells hint to the 
conjecture that PHD2 is possibly involved in the regulation of ETV4 degradation. It 
would be of further interest if also the knockdowns of PHD1/3 have the same effects 
on ETV4 protein levels. That PHDs are capable to hydroxylate other target proteins 
than the HIF-α subunit was indirectly shown with several other proteins, such as 
RbpI, the large subunit of RNA polymerase II, activating transcription factor-4 (ATF4) 
or pyruvate kinase M2 (PKM2)68–71. However, we did not pursue if hydroxylated 
prolines are detectable in ETV4 by mass spectroscopy, since the proline-rich nature 
of the protein is hindering the analysis72.  
Since PHD2 and PHD3 are HIF target genes on their own, their induction in hypoxia 
partially compensates for the decreased enzymatic activity in oxygen-deprivation by 
an increased amount of proteins and consequently recovers basal proteasomal 
degradation of HIF-1α73. ETV4 downregulation decreased PHD3 mRNA induction in 
hypoxia, suggesting that ETV4 is also a positive transcriptional regulator of PHD3 
expression and might thereby indirectly influence the degradation of HIF-1α1. 
Furthermore, our results show that ETV4 and HIF-1α exhibit a similar response to 
modulators of PHD activity, but that they are differently fine-tuned during the hypoxia-
mimicking DMOG time course. ETV4 levels are high in very early hypoxia, whereas 
HIF-1α is induced later during acute hypoxia, but both factors are degraded in 
prolonged hypoxia-mimicking conditions. This proposes that HIF and ETV4 have 
different roles in the hypoxic cellular response, underlined by the tendency of ETV4 
to super-activate especially those target genes that are responsible in both, acute 
and chronic hypoxia74.  
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In summary, we could show that the ETV4 and hypoxia pathways seemed to be 
interlinked at the level of PHD2/3 expression regulation and protein-protein 
interactions1. ETV4 protein was demonstrated to be more abundant in hypoxia, in 
PHD2 knockdown cells, and in cells treated with a PHD-inhibitor. Additionally, a 
possible interaction between ETV4 and PHD2 is suggested by mammalian-2-hybrid 
experiments. The common feature for the synergistic interplay of ETV4 and HIF 
might be a specific sequence architecture surrounding the HBS. 
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4.4  Materials and methods 
 
Plasmid constructs 
PHD2 promoter (P2P) containing the wildtype and mutated HBS in pGL3basic 
luciferase vector were obtained from DP Stiehl37. These constructs were modified 
employing a 5’- truncation and a 3’- start codon fusion to the luciferase open reading 
frame by using standard restriction-mediated cloning techniques1. The PHD2 
luciferase reporter plasmid contained PHD2 promoter sequences extending from 
−607 to +3(ATG start codon) (transcriptional start site unknown) and has been 
published previously75 Cloning of pM-PHD2-Gal4 DNA binding domain (DBD) and 
ETV4-VP16 activation domain (AD) expression vector (pcDNA3.1) plasmids was 
carried out using Gateway technology (Invitrogen, Basel, Switzerland) as described 
previously76. The ETV4 family member plasmids pSV-ETV1, pSV-PEA3 (ETV4) and 
pSV-ERM (ETV5) were kindly provided by J-L Baert (France)59. The human CXCR4 
promoter and the intronic region cloned into pGL2b (Promega) was a kind gift of W 
Krek43. Erythropoietin (EPO) 3' hypoxia response element was kindly provided by RH 
Wenger77. 
 
Protein extraction and immunoblot analysis 
Cells were washed twice and scraped into ice-cold phosphate-buffered saline. 
Soluble cellular protein was extracted with a high salt extraction buffer containing 
0.1% Nonidet P-40 essentially as described before78. Protein concentrations were 
determined by Bradford method using bovine serum albumin as a standard, and 50 –
80 µg of protein were subjected to immunoblot analysis. According to standard 
procedures using PVDF membranes (Roth)76. The following antibodies were used: 
mouse anti-human HIF-1α (Transduction Laboratories BD Biosciences), rabbit anti-
human PHD2 (Novus Biologicals), mouse anti-β-actin (Sigma), mouse anti-ETV4 
(Santa Cruz Biotechnology) and mAb anti-CA09 (M75, kindly provided by S. 
Pastorekova), were detected with secondary polyclonal goat anti-mouse and anti-
rabbit antibodies coupled to horseradish peroxidase (HRP) (Pierce). 
Chemiluminescence detection was done using Supersignal West Dura (Pierce) and 
quantified with a CCD camera based light imaging system (Fuji, LAS 4000) followed 
by quantification with Quantity One software (Bio-Rad). 
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Cell culture and transfections 
Human human fibrosarcoma cell line (HT1080), osteosarcoma cell line (U2OS), 
hepatocellular liver carcinoma cell line (HepG2), colorectal cancer cells (HCT116) 
and breast cancer cell line (MDA-MB-231) were grown in Dulbecco’s modified 
Eagle’s medium (Sigma) supplemented with 10% fetal calf serum (FCS) and 
antibiotics (penicillin 50 IU/ml and streptomycin 100 µg/ml, Invitrogen) (Gibco-BRL) 
as described previously79. Hypoxic conditions were generated by incubation of cells 
in an InvivO2 400 hypoxic workstation (Ruskin Technologies). The oxygen 
concentration was maintained at 0.2-1%, with the residual gas being 94-94.8% 
nitrogen, and 5% carbon dioxide. Transfections were performed using 
polyethylenimine (Polysciences) as described previously73. 
 
Dual-luciferase assay  
Cells were cotransfected with 20 ng pRLSV40 renilla-luciferase reporter vector 
(Promega) and 3 µg reporter plasmid or 1.5 µg reporter and additionally 1.5 µg 
expression plasmid, respectively. After 24 hours of normoxic and further 24 h of 
hypoxic (0.2% O2) incubation cells were lysed in 15 µl of passive lysis buffer 
(Promega). Luminescence was immediately analyzed with a microplate luminometer 
(Berthold) using dual-luciferase reporter assay system (Promega). 
Mammalian two-hybrid analyses were performed using the mammalian Matchmaker 
system (Clontech) as described previously76. U2OS cells were transiently co-
transfected with 1.5 µg of Gal4 DBD and 1.5 µg of VP16 AD fusion protein vectors 
together with 500 ng of firefly luciferase reporter vector pGRE5xE1b and 20 ng of 
pRL-SV40. Total transfected DNA amounts were equalized in each experiment using 
the corresponding empty vector. Luciferase reporter gene activities were determined 
using the dual-luciferase reporter assay system (Promega). 
 
Fluorescence resonance energy transfer (FRET) 
The full length open reading frame of human ETV4 was cloned into pENTR4 and 
subsequently recombined with pECFP-C1- DEST to obtain the expression vector for 
a cyan fluorescent ETV4 fusion protein80. U2OS cells were transiently transfected 
with the pECFP-ETV4 and pEYFPHIF1 plasmids as recently described (22), and 
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FRET was monitored under normoxic or hypoxic conditions (1% O2 for 4 hours) 48 
hours post transfection. 
 
mRNA quantification 
Total RNA was obtained as described previously76. Complementary strand DNA 
synthesis was performed with 1–5 µg total RNA using reverse transcriptase 
(AffinityScript, Stratagene). Complementary DNA / mRNA levels were determined by 
reverse-transcription (RT) quantitative (q) -PCR using SybrGreen qPCR reagent kit 
(Sigma) and the MX3000P light cycler (Stratagene). Ribosomal protein L28 mRNA 
was assessed to equal input levels. All qPCR data are presented as ratios relative to 
L28 values. Primers were as follows: hL28 forward, 5'-gcaattccttccgctacaac-3'; hL28 
reverse, 5'-tgttcttgcggatcatgtgt-3'; hPHD2 forward, 5'-gaaagccatggttgcttgtt-3'; hPHD2 
reverse, 5'-ttgccttctggaaaaattcg-3'; hETV4 forward, 5’-acggacttcgcctacgactca-3’; 
hETV4 reverse, 5’-cctggcgacctcctcaggct-3’. 
 
RNA interference 
U2OS cells were transfected with 100 nM siRNA duplex oligonucleotides using 
Lipofectamine 2000 (Invitrogen). The following RNA interference sequences 
(Invitrogen) were used:  
control siRNA, forward 5′-gcuccggagaacuaccagaguauua-3′;  
ETV4_oligo 2 siRNA, forward 5′-ggguggugaucaaacaggaacagac-3′; 
ETV4_oligo 3 siRNA, forward 5′-ugacaucugagucguaggcgaaguc-3′; 
PHD2 siRNA, forward 5’-uaacaagcaaccauggcuuucgucc-3’. 
 
shRNA constructs and lentiviral infections 
Expression vectors encoding shRNA sequences targeting human PHD2 and ETV4 
driven by the U6 promoter in a pLKO.1-puro plasmid were purchased from Sigma. 
Viral particles were produced in HEK293T cells using the ViraPower lentiviral 
expression system according to the manufacturer's instructions (Invitrogen). 
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Statistical analysis 
If not differently indicated, results are presented as mean values ± standard error of 
the mean (S.E.M.) of at least three independent experiments. P-values were obtained 
by unpaired t-tests (*P<0.05, **P<0.01, ***P<0.001). 
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5  Discussion 
5.1  The key players in hypoxia  
 
An imbalance between oxygen delivery and consumption leads to a restricted 
oxygenation of tissues. Such an undersupply of oxygen is involved in a variety of 
pathologies like ischemia, stroke, inflammation and cancer. The unique 
responsiveness to altered oxygen environments together with the striking 
conservation of the PHD-HIF-system in metazoans indicates the central role of HIFs - 
literally the hypoxia-inducible transcription factors1.  
As a result of the negative HIF-PHD2/3 feedback loop we consider the 
transcriptionally hypoxic regulation of the PHD2 gene as important since the PHD2 
enzyme abundance influence its enzymatic capacity2,3. For a profound understanding 
of the transcriptional regulation we thoroughly studied the PHD2 promoter 
architecture and aimed to find indications on further regulatory mechanisms of its 
gene expression.  
 
To date, HIF is the only known transcription factor influencing the PHD2 gene 
transcription. Since eukaryotic gene expression is a multi-step process requiring the 
complex transcription machinery to interact with promoter DNA and initiate 
transcription, it is not surprising that several studies have identified other nuclear 
regulators that contribute to the full spectrum of transcriptional changes in response 
to hypoxia4. The finding of general interaction patterns between HIFs and other 
transcription factors is restricted to specific experimental paradigms such as specific 
cell models5.  
 
5.2  Biological relevance of the work 
5.2.1  Architecture and regulation of the PHD2 (EGLN1) gene 
 
The PHD2 gene is located on chromosome 1 and consists of 5 exons6. In 2005 two 
different promoter sites upstream of the PHD2 coding sequence were identified7. 
While the promoter element situated further upstream seemed to be dormant in adult 
tissue, the PHD2 gene appears to be solely transcribed by the functionally active 
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downstream promoter. This latter promoter is reported to be embedded in a CpG 
island immediately 5´ of the translational start site and contains one functional HBS (-
412 bp to the translational start site).  
 
Although Metzen et al. initiated important work in light of the PHD2 promoter analysis 
the transcriptional start site of the PHD2 gene is still unknown. Then as now the 
analysis of ESTs was performed for the identification of the transcription start site, but 
did not succeed7. The ESTs listed in the UCSC genome browser were mostly located 
on the very 3’-end of the mRNA. The EST found most upstream is located at the 3’-
end of the first exon and misses the mRNA sequence of almost the complete first 
translated exon. Thus, transcription start site prediction based on ESTs resulted 
mostly in functional questionable locations. The inbuilt disadvantage of this 
transcription start prediction method is the origin of ESTs itself. The single 
sequencing reactions might be erroneous and the first roughly 20 bases are often not 
reliable due to the polymerase / primer establishment that impairs the sequencing in 
the beginning of the reaction. However, these first bases are of importance when 
ESTs are used for transcription start prediction as they represent the very beginning 
of a transcribed sequence. As a consequence, these flaws lower the reliability of the 
results obtained. However, one potential transcription start site was found with the 
additional help of the detection of clusters of predicted transcription factor binding 
sites. This putative transcription start site lies in front of the first exon. This sequence 
was absent in the 3’ truncated PHD2 promoter construct P2P (-1070/-318). But the 
reporter was still transcriptionally active. This could mean that either the approach of 
deleting parts of the PHD2 promoter in a reporter assay context is not appropriate or 
there is another, not yet predicted transcription start site present in the PHD2 
promoter. Eventually, a successful establishment of 5’-RACE is needed to confirm by 
experimental analysis the transcriptional start site.  
 
This work provides evidence on an endogenous level that the PHD2 promoter is 
hypoxically regulated primarily through HIF-1α rather than HIF-2α. This might be 
constrained to an intermediate time of acute hypoxia, since it is to date widely 
accepted that HIF-1α levels decrease with prolonged hypoxia while HIF-2α 
stabilization increases8. Thus, HIF-2α might take a more dominant role in PHD2 
expression under specific conditions. Additionally, this work was performed in MCF7 
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cells that were reported to express a HIF-2α isoform with little transcriptional activity 
and influencing by this the recruitment to an endogenous transcriptionally active 
locus9. However, the finding is still in line with various other reports where by indirect 
means the prevalence of HIF-1 was proven to hypoxially induce PHD2 expression10. 
Further supportive data are given by the location of the HBS that is found close to the 
gene. This is a circumstance that statistically favors HIF-1 over HIF-2 binding11,12.  
 
Interestingly, we found a 55-95 bp encompassing stretch around the PHD2 HBS 
conserved in humans, mice and other organisms. Despite the shortness of these 
regions they were able to confer hypoxic inducibility. When motifs located 5'- or 3'- 
adjacent to the HBS were disrupted by introducing a subset of mutations, hypoxic 
inducibility was completely lost, even though the functional HBS, previously shown to 
be sufficient for HIF-1 binding, was preserved13. The conserved PHD2 promoter 
region also encompasses several consensus binding sequences for the ubiquitous 
transcription factor specificity protein 1 (Sp1) that assures transcription of many 
genes involved in early development of organisms. In Sp1-deficient cells PHD2 
expression was not affected either on basal or on hypoxic levels, concluding that an 
accumulation of SP1-binding sites (5’-GGGCGG-3’) only was due to the fact that the 
PHD2 promoter is embedded in a GC-rich region. If not for SP1 other (co-) 
transcription factors might have functional relevance to PHD2 transcriptional 
regulation. For instance, we showed that the ETS-transcription factor ETS-transcript 
variant (ETV) 4 and its structurally close subfamily member ETV5 are able to 
enhance the PHD2 promoter activity in a HBS-dependent manner upon 
overexpression. Nonetheless, the increase of promoter activity is most probably not 
due to direct binding of those ETS-factors to the DNA-elements but rather owned to 
complex formation with HIF14.  
 
5.2.2  Applicability of the synthetic transactivation screening approach  
 
The identification of HIF1/2α interaction partners was diverse in the past. Especially, 
yeast-two-hybrid (Y2H) screens were favored for long due to their low dependency 
on the physiological abundance or half-life of the interacting candidate protein. A Y2H 
screening in our research group lead to the identification of FKBP3815, Cdr216 and 
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HELZ17 as specific PHD interactors determining PHD2 protein stability, attenuating 
the hypoxic response in the cell or influencing general translational or proliferative 
activities. However, the discovered interactor HELZ notably was not linked to any 
cellular processes in hypoxia17. Another disadvantage of Y2H screenings is the 
circumstance that some interactions are based on post-translational modifications of 
the potential candidate protein. For example, the HIF-α-VHL interaction needs the 
hydroxylation of specific prolyl-residues in the HIF-α subunit. However, these post-
translational modifications cannot be introduced by yeast and consequently prevent 
the detection of interacting proteins. Additionally, proteins formed from subunits might 
not be represented in their native confirmation causing misleading interaction of false 
positive proteins.  
In comparison, proteomics strategies relying on affinity purification formats, such as 
immunoprecipitation followed by mass spectroscopy, to identify candidate proteins 
are freed from those drawbacks18. However, they come with other inbuilt 
disadvantages. First, the possible low abundance of target proteins is limiting the list 
of detectable interacting proteins. Second, the short half-life of candidate proteins in 
mammalian cells, such as HIF-α, is hindering the discovery of new interaction 
partners by proteomic approaches.  
Another high-throughput screening is the use of genome-wide RNAi-mediated array 
experiments. They allow a loss-of-function screening, but miss to find the potential 
interaction of oncogenes that are usually overexpressed. Besides, the cost to perform 
such an assay are very high. 
This work strived to identify interaction partners of HIFs that act in a broad trans-
activating range. Therefore, we designed a cost-efficient, novel screening approach 
through the combination of overexpressing arrayed transcription factors together with 
the core PHD2 promoter. We aimed to overcome the above mentioned 
disadvantages of a Y2H approach and the limitation of proteomics by allowing 
expression and post-translational modification in mammalian cells. Further, the 
screening was designed in such a way that we detect for a gain-of-function and not 
for the loss-of-function. With this approach we were able to identify HBS-specific 
transcription factor interplays. In this screening approach comprising 704 different 
transcription factors we found several members of the activating protein-1 (AP-1) 
family such as the proto-oncogenes JUN and FOSB as novel activators of the PHD2 
gene, which beforehand have only been reported to generally enhance hypoxic gene 
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expression5. Additionally, three ETS-family members were shown to increase PHD2 
promoter activity. Amongst them, ETV4 showed most striking effects on HBS-
dependent transcription not only on the PHD2, but also on the transferrin promoter. 
This work demonstrates for the first time that ETV4 is interlinked with HIF-dependent 
transcription.  
The previously described synthetic transactivation screening proved to be a powerful 
tool for HIF-dependent gene expression studies. It could be demonstrated that novel 
interactions amongst common signaling pathways were discovered and could be 
suggested for further use in areas like small molecule library analyses and genome-
wide gene silencing approaches. Especially, the possible involved post-translational 
modification and the very short half-life of ETV4, seen in proteasome-inhibited or 
DMOG-treated cells, would have made the detection by Y2H or proteomics difficult. 
Most probably these are the reasons why ETV4 was not earlier found to be an 
interaction partner of HIF. By in silico comparison of the human p300/CBP 
interactome with the synthetic transcription factor overexpression array we found no 
simple redundancy of p300/CBP interactors with reproducible activators of the PHD2 
promoter. This could be due to a need for distinct target gene architectures that have 
been reported central for p300/CBP complex formation19. The lack of mere 
redundancy between the p300/CBP interactome and our screening results is of 
particular importance with regards to our screening design, as it provides some 
reliability regarding the specificity and its general applicability. Since ETV4 mRNA 
levels remain unchanged in hypoxic treatment, it could not be detected by genome-
wide expression analyses which relies on comparative profiling of target mRNA 
expression levels. As a consequence, the link to a hypoxically regulated ETV4 family 
remained undiscovered until our development of the synthetic transactivation 
screening. The setup of this method facilitates easy adaptation in order to study other 
transcriptional pathways while combining a multiplexed single-well readout system 
with minimized inter-well variances that are usually difficult to control. 
 
5.2.3  ETV4’s hypoxia-induced target genes 
 
It could be shown in gene array analyses that ETV4 facilitates HIF transactivation 
activity of 7.7% (47 out of 608 genes) of all hypoxically induced genes in PC3 human 
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prostate cancer cells - a cell line that shows high endogenous ETV4. Moreover, out 
of 61 established HIF target genes previously published the hypoxic induction of 14 
genes was at least two-fold higher in the presence of ETV4 than in its absence20. 
These findings suggest a broad, but specific role of ETV4 which was so far 
unrecognized in the literature.  
Interestingly, carbonic anhydrase 9 (CA9) was found to be strongly ETV4-dependent. 
The strong hypoxic inducibility of CA9 might be interlinked with the additional 
presence of ETV4 in cooperation with HIF and ATF-421,22. Intriguingly, the 
architecture of the CA9 HBS with the 5’ and 3’ adjacent region is similar to the ones 
of the PHD2 or transferrin promoter. We could also demonstrate a super-induction of 
the CA9 promoter by ETV4 overexpression, whereas this effect was abrogated when 
using HBSs with dissimilar flanking regions to the PHD2 HBS. We therefore 
hypothesize that HBS-architecture is a strong driver of ETV4-HIF synergism. 
However, direct interactions of ETV4 with HBS neighboring DNA sequences seem to 
be unlikely out of two reasons. First, the commonly known consensus sequence of 
the ETV4 subfamily is AT-rich and is not found in the GC-rich vicinity of the HBS. 
Secondly, although the ETV4 family members are highly similar in DNA-binding 
domain structure ETV1 was demonstrated not to potentiate the PHD2 or transferrin 
promoter activity. Suggesting that rather sterical reasons - possibly generated by a 
specific DNA-sequence - determine ETV4-dependent hypoxia-induced genes from 
ETV4-independent ones.  
 
Our findings showed activation of the PHD2 promoter in the U2OS cell model when 
ETV4 was overexpressed. However, an ETV4 knockdown did not influence PHD2 
expression levels in U2OS cells. It seems that the osteosarcoma cell line U2OS is not 
an adequate cell model for investigating the effects of PHD2 expression, since ETV4 
mRNA and protein expression levels are very low in those cells. In addition, it is well 
possible that the overlapping features of the ETV4-subfamily compensate for the 
transient or stable knockdown of ETV4 and thus, do not affect PHD2 promoter 
activity or expression levels in U2OS cells. To verify a putative compensation we 
tested ETV1 and ETV5 mRNA levels in the U2OS knockdown cells. ETV5 is more 
expressed than ETV1, but if ETV5 protein is sufficiently expressed for compensating 
ETV4 remains unknown. An ETV4 knockdown in a cell line such as PC3 that 
expresses substantially higher levels of ETV4 surprisingly also did not show the 
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expected decrease in hypoxic PHD2 expression, but rather in PHD3 expression 
levels. Individual inspection of the genome-wide expression analysis revealed a 2.7-
fold hypoxic induction of PHD2 that was only reduced by 16% in the absence of 
ETV4. This indicates that PHD3 rather than PHD2 is the main molecular oxygen 
sensor in this prostate cancer cell type. To further understand the function of ETV4 in 
hypoxic tissue it would be interesting to study, if PHD3 levels correlate with ETV4 
expression in prostate cancer tissue sections. 
 
5.2.4  The trimeric HIF:p300/CBP:ETV4 complex 
 
Intrigued by the HIF-dependency of ETV4 effects, we characterized the biochemical 
interaction between ETV4 and HIF-α. In a mammalian two-hybrid approach we found 
that ETV4 co-operates with the C-terminal activation domain of HIF-1α to 
transactivate target genes. This interaction is still sensitive to oxygen although the 
oxygen-dependent degradation domain of HIF-1α is missing. A very close interaction 
between ETV4 and HIF-1/2α of approximately 5.6-5.7 nm by FRET experiments 
suggests per se direct interaction between ETV4 and HIFs. Despite this very close 
proximity, it is still possible that another protein might be involved.  
We rather suggest a ternary complex formation between ETV4 and HIF-α via 
p300/CBP. Based on the following results: first, we could show that the interaction 
between ETV4 and HIF-1α could be competed by the co-transfection of CBP/p300-
interacting transactivator 2 (CITED2), known to negatively regulate HIF function23,24. 
Structural analyses revealed that CITED2 and HIF-1α share an overlapping binding 
interface on the 300-kilodalton co-activator protein (p300) cysteine-histidine-rich 1 
(CH1) domain and competition assays showed a 33-fold higher affinity of CITED2 for 
binding to p300 CH1 than a corresponding HIF-1α CAD peptide, indicating that 
CITED2 is a dominant inhibitor of HIF-1α:p300/CBP complex formation25. We could 
further underscore our model by the knockdown of p300 or FIH. Through a transient 
knockdown of p300 though, we found only a slight reduction of the intrinsic 
transactivation activity that was mediated by the C-terminal activation domain 
accompanied by a robust superinduction through ETV4. We therefore hypothesized 
that ETV4 activation occurs independent of the presence of p300. Mechanistically, 
this could be explained by compensatory action of CREB binding protein CBP protein 
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that substitutes for the loss of p300. FIH is an oxygen-dependent negative regulator 
of HIF transcriptional activity as it hydroxylates a distinct asparagine residue within 
the HIF-α carboxy terminus in normoxic conditions. The hydroxylated HIF-α carboxy 
terminus is no longer able to associate with p300/CBP. A transient depletion of factor 
inhibiting HIF (FIH) resulted in the steady association of HIF with p300/CBP. The FIH 
knockdown interrupted the oxygen sensitivity of the ETV4-HIF-1α cooperation and 
adds to the hypothesis that the HIF-ETV4 interaction is influenced by another protein, 
namely p300/CBP26. 
In conclusion, although FRET data propose a direct interaction of HIF and ETV4, our 
findings suggest a ternary complex formation with HIF-1α binding to both p300 
domains: CH1 and CH327. ETV4 has been reported to interact with p300 at its CH3 
domain and could come by this into close contact with HIF-α28.  
 
 
Figure 1. Transcriptional cooperation between ETV4 and HIF-1 is disrupted by CITED2 or FIH. 
(A) Scheme of the potential interactions between HIF-1, p300/CBP and ETV4 as assessed by 
mammalian two-hybrid assays. (B) Both CBP/p300-interacting transactivator 2 (CITED2), known to 
negatively regulate HIF function and factor inhibiting HIF (FIH) can block the interaction between HIF-
1α and p300/CBP and as a result limit the synergistically driven transcription of HIF:ETV4 downstream 
target genes (EGLN3, CA9, etc.).  
 
5.2.5  HIF and ETV4 – a toxic duet in cancer 
 
The HIF and ETV4 pathways interleave partially with each other. For example, 
various matrix metalloproteases (MMP) like MMP-1, MMP-3, MMP-7 and MMP-9, as 
well as the chemokine receptor CXCR4, the NO-synthetase iNOS and the 
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cyclooxygenase COX-2 are common target genes29–39. As a consequence, the 
malignant properties of several cancer cells could be due to the detrimental 
cooperation of HIF and ETV4 on regulatory regions of the aforementioned genes. 
Importantly, not only ETV4 but also its structurally-close relatives ETV1 and ETV5 
are reported to be frequently overexpressed in prostate cancer due to their 
translocation and fusion to androgen-responsive genes40–42. For example, the loss of 
the important tumor suppressor phosphatase and tensin homolge (PTEN) was 
observed to cause an accumulation of HIF-1α also in normoxia – a phenomenon 
often observed in invasive prostate cancers43. In recent animal studies, the early loss 
of PTEN combined with a simultaneous overactivation of ETS-factors lead to a gross 
activation of target genes necessary for prostatic cancer development44,45. From a 
therapeutic view point, it would be highly informative to elucidate the role of 
HIF/ETV4 interaction in these pathologies. We therefore suggest to extend tissue 
microarray analyses from breast cancer samples14, to other clinical specimens such 
as prostate cancer tissue. This would not only shed light on the HIF/ETV4 interaction 
in additional cancer types, but also allow a systematic analysis of the coincidence of 
elevated HIF and ETV4 levels in the nuclei of these cells. 
 
5.2.6  Developmental aspects of the HIF and ETV4 collaboration 
 
In developmental aspects, ETV4 has been involved in branching morphogenesis of 
kidney and liver as well as in spinal motor neuronal differentiation46–50. Notably, the 
ETS-domain responsible for DNA-interaction shares 95% of similarity and the 
transactivation domains still roughly 85% amongst all ETV4-subamily members51–55. 
The structural similarities of ETV4 family members ETV1 (ER81) and ETV5 (ERM) 
raised the question if these factors have overlapping functions in tissue development 
and cancer progression55. ETV4 and ETV5 show indeed strongly compensatory 
functions in kidney development that were only revealed when both transcription 
factors had been knocked out46,47.  
 
This familiarity led us to test the additional sub-family members of ETV4. Notably, we 
could show that not only ETV4, but also ETV5 super-induced the hypoxic PHD2 and 
transferrin promoters in an HBS-dependent manner, whereas ETV1 did not. This 
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suggests a putative functional overlap of the two subfamily members in the hypoxic 
gene regulation. As not all ETV4-subfamily members show superinducibility with HIF, 
it is probable that the interface of HIF-α interaction rather lies outside of the ETS-
DNA-binding domain. As tissue hypoxia often occurs in developmental processes, 
our findings suggest a physiological role of ETV4/ETV5 in low oxygenated tissues or 
organs at the beginning of vascularisation. In line with the observations that ETV4 is 
highly expressed in various forms of cancer and that hypoxic tumors show high HIF-1 
expression levels, we found an impressively good correlation between ETV4 and 
PHD2 protein levels in breast cancer tissues51,56. This hints to a potentially relevant 
function of ETV4 in hypoxic tissues in vivo. In contrast to ETV1 and ETV5, ETV4 is 
more widely expressed in most tissues (such as the kidneys, mamma and prostate) 
and makes it an interesting target for further studies on EPO-producing cells or 
hypoxic breast or prostate cancer. Even though a group effect of the entire subfamily 
on hypoxic gene regulation would be supportive, the lack of high affinity and 
specificity antibodies momentarily inhibits further investigations. 
 
5.2.7  ETV4 is oxygen regulated and interacts indirectly with PHD2 
 
In line with the ETV4-PHD2 correlation in arrayed tissue samples, our data also 
suggest a positive correlation between ETV4 and PHD2 mRNA expression levels in 
various cancer cell lines, such as U2OS and HepG2. However, mRNA levels may 
differ from protein data - as shown in the prostate cancer cell line PC3. This cell line 
was reported to express only intermediate levels of ETV4 mRNA, but ETV protein 
levels are elevated due to an impaired degradation process via ubiquitin ligase 
COP144.  
 
We found in U2OS osteosarcoma cells that ETV4 protein levels are up-regulated in 
hypoxia, but mRNA levels remain unchanged suggesting translational stability 
changes on the protein level. The ETV4 and HIF pathways show an interesting 
pattern of overlap: as HIF-1α, ETV4 shows an accumulation of protein by 
proteasomal inhibition with MG132, after the treatment with the PHD-inhibitor 
dimethyloxalylglycine (DMOG) or in hypoxia57. However, differences are: ETV4 levels 
are high at the beginning of hypoxia-mimicking DMOG treatment, whereas HIF-1α is 
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induced slightly later. Eventually both factors degrade in prolonged hypoxia-
mimicking conditions. Since PHD2 and PHD3 are part of the negative HIF-feedback 
loop, their increased expression in hypoxia partially compensates the decreased 
enzymatic activity during oxygen-deprivation and consequently ensures basal 
proteasomal degradation of HIF-1α58 
It is widely accepted that PHDs regulate the stability of HIF-α subunits through the 
hydroxylation of distinct proline residues59–63. The PEA3 subfamily, similar to HIF-α, 
has also been reported to undergo diverse posttranslational modifications such as 
phosphorylation or SUMOylation and might also include hydroxylation64–79. ETV4 
migrates as multiple distsinct bands in SDS-PAGE could reflect posttranslational 
modifications of the same protein. Additionally, PHDs were reported to putatively 
hydroxylate other proteins than HIF-α, such as RbpI, the large subunit of RNA 
polymerase II, activating transcription factor-4 (ATF-4) or pyruvate kinase M2 
(PKM2)22,80–82. This list could be enlarged to comprise ETV4 and might explain the 
hypoxic accumulation of ETV4. We could demonstrate that ETV4 indirectly interacts 
with PHD2 in hypoxia and potentially in normoxia in a mammalian-2-hybrid approach. 
In line with this speculation, the application of a PHD-inhibitor (DMOG) or the 
knockdown of the main cellular oxygen sensor PHD2 lead to increased ETV4 protein 
levels in oxic U2OS cells.  
In PC3 cells ETV4 downregulation decreased PHD3 mRNA induction in hypoxia, 
suggesting that ETV4 also positively regulates PHD3 expression. It could be 
hypothesized that COP1 - similar to the von-Hippel-Lindau protein - is not able to 
degrade ETVs in hypoxic conditions due to the missing hydroxylation of distinct 
prolines. This would suggest the implication of PHDs in the regulation of ETV4 
degradation. The study of a group effect, namely the knockdown of PHD1 and PHD3 
in U2OS cells could reveal if other PHDs are equally involved in ETV4 regulation. 
The enzymatic PHD effect on the surrogate substrate protein ETV4 is hindered by 
the proline-rich nature of the protein that would probably mask the detection of 
hydroxylated prolines by mass spectroscopy83. Finally, we cannot exclude that the 
increased ETV4 protein levels could also be due to translation-enhancing 
mechanisms that influence the ETV4 turnover. 
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5.3  Outlook 
 
Since ETV4 and its family members just entered the large field of hypoxic 
transcriptional regulation a detailed mechanistic insight of their interaction with HIF 
and possibly PHDs premains elusive. More work is required to investigate how the 
ETV4-subfamily members play a role in influencing the hypoxic pathway. Most 
urgently, the origin of the potential hypoxic regulation of ETV4 and its concise 
mechanism needs to be elucidated. More insight could be gained through the use of 
other hypoxia-mimicking agents such as cobalt chloride or desferrioxamine that need 
to be applied to pin down the origin and regulatory mechanisms of an ETV4-HIF 
synergism. Importantly, we aim to find out what common features are needed for 
driving ETV4 to be a co-factor of HIFs. This could be done in models for breast or 
prostate cancer, without neglecting developmental questions where the ETV4-
subfamily is known to be crucially involved. As a matter of fact, the implications of 
development in the kidney and liver are most intriguing as they represent important 
set points of physiological hypoxia sensing and response. An exciting approach 
would be the exposure of ETV4-null mice to normobaric hypoxic conditions 
accompanied by a tight monitoring of transcriptional and metabolic changes (i.e. 
EPO-production) in organs and other tissues, e.g. kidney, liver, lung as well as breast 
tissue and the prostate gland since ETVs and HIFs showed here to play a crucial role 
in tumor development.  
Furthermore, the analysis of the synthetic transactivation screening could be 
enlarged from activators to inhibitors. So far, only activators were analyzed whereas 
potential repressors of PHD2 expression had been neglected in this screening 
approach. This could open a completely new level of regulatory transcription 
mechanisms in the hypoxic cascade, since HIF is only known to activate but not to 
directly repress gene transcription.  
Finally, the adaptation of the established screening approach could be applied to 
small molecules or siRNA-mediated library screenings where downstream targets of 
HIF are analyzed in detail. 
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